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We have learned that nothing is simple and rational 
Except for what we ourselves have invented; 
That God thinks in terms neither of Euclid nor Riemann; 
That science has “explained” nothing; 
That the more we know the more fantastic the world 
becomes; 
And the profounder the surrounding darkness. 
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The worldwide incidence of autoimmune diseases is rising, especially in industrialized countries. 
Apart from alleviating symptoms, the aim of any treatment is to regain a balance between 
tolerance and immunity. As T cells play a central role in both processes, the pathways leading to 
their activation are attractive targets for immunosuppressant drugs. The search for new inhibitors 
in recent years, however, was mostly focused on biologicals like monoclonal antibodies or fusion 
proteins. This improved the treatment of autoimmune conditions significantly, but administration 
and immunogenicity limit their application. Thus, there is a need for new small molecule 
immunosuppressant drugs with new modes of action. 
To pursue new lead compounds, we mined the chemical space contained in a library of extracts 
from plants used in Traditional Chinese Medicine (TCM). This pre-selection was done to focus on 
plants used over a long period of time with some evidence for bioactivities. To identify extracts 
and compounds that inhibit the proliferation of activated primary T lymphocytes isolated from 
human blood, we used an in vitro assay. Through FACS analysis, the assay also allowed for the 
direct identification of cytotoxic or necrosis inducing effects. 
We screened 435 extracts from plants used in TCM at a concentration of 30 µg/mL. From these, 
around 40 extracts showed T cell proliferation inhibition and 6 plants in total were selected for 
further investigations based on the absence of cytotoxicity, availability, batch to batch 
reproducibility, and a literature survey. Seven extracts from these plants were subjected to HPLC 
activity profiling, which allowed the identification of regions of activity in four of the extracts. The 
compounds in these active regions were the focus of subsequent isolation of compounds from 
these plant extracts. The work on two plants, Artemisia argyi and Toddalia asiatica, resulted in the 
publication of three peer reviewed publications. The work on two other extracts is still ongoing. 
The first extract was an ethyl acetate extract from the aerial parts of A. argyi. From this extract, 18 
compounds, including 5 new sesquiterpene lactones were isolated. A series of four isomeric 
sesquiterpene lactones, two diastereomeric seco-tanapartholides and two diastereomers of canin, 
showed activity at micromolar concentrations (IC50 values between 1.0 and 3.7 µM). Published 
data on the series of canin-diastereomers gave only unsatisfactory information on their identities 
and absolute configurations. Thus, their absolute configurations were determined independently 
using ECD and VCD. The relative configurations of seco-tanapartholides A and B were only known 
in part and interestingly, ECD gave almost enantiomeric spectra. Therefore, the absolute 
configuration was solved by VCD. Visual and computational methods were used for evaluation of 
the spectra. The knowledge of their absolute configurations can now be used as the basis for 
possible development as immunosuppressant lead compounds. These results are published in 
the Journal of Natural Products (Vol. 82, 2019). 
Next, we investigated the mode of action of the isolated compounds and the ethyl acetate extract 
from A. argyi. To identify the affected transcription factors, reporter cell lines for AP-1, NFAT, and 
NF-κB were used. The target of the A. argyi extract and the tested sesquiterpene lactones was 
thereby found to be located upstream of NFAT and NF-κB. We further investigated the effects of 
both, the extract and the sesquiterpene lactones, on calcium signaling involved in the NFAT 
pathway. Although some of the compounds had an effect on calcium signaling, none of them, nor 
a combination of all, inhibited calcium influx into the cell or from the ER as effectively as the extract 
itself. These results were published in Frontiers in Pharmacology (Vol. 11, 2020). 
The second extract we investigated in the course of this work was the MeOH extract from the 
roots of T. asiatica. Here, the alkaloid nitidine was identified as a highly active constituent with an 
IC50 value of 0.37 µM. Another, less active (IC50 6.72 µM), alkaloid was identified along with other 
inactive alkaloids, lignans and coumarins, some of them glycosylated. A combination of ECD, OR, 
GCMS analysis of hydrolyzed sugars, enantioselective HPLC analysis of hydrolyzed aglycones 
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and NMR in the presence of the chiral shift reagent Eu(hbc)3 was used to identify the absolute 
configurations of these compounds. Three of the compounds were new natural products. The 
results are published in the Journal of Natural Products (Vol. 83, 2020). 
From identifying several compounds with significant activity in inhibiting T cell proliferation, we 
found the CFSE assay to be useful for the identification of new lead compounds with relevant 
activities. As many of the natural products found did not have well described absolute 
configurations, we used a broad array of methods to fill this gap and publish the results for use by 
future researchers. The combination of ECD (as a sensitive method) with complementary 
techniques like VCD, chromatography of hydrolyzed compounds, or the use of shift reagents in 
NMR proved to be very effective. It enabled us to solve challenging cases like seco-





Die weltweite Inzidenz von Autoimmunerkrankungen hat in den letzten Jahren, vor allem in 
Industrieländern, zugenommen. Für die Behandlung ist es wichtig, abgesehen von der 
Symptommilderung, die Balance zwischen Toleranz und Immunität wiederherzustellen. Da T 
Zellen in beiden Prozessen eine zentrale Rolle spielen, sind die T Zell aktivierenden Signalwege 
über AP-1, NFAT und NF-κB attraktive Ziele für immunsuppressive Medikamente. Die Entwicklung 
von neuen Inhibitoren ist aktuell primär auf Biopharmazeutika wie monoklonale Antikörper oder 
Fusionsproteine fokussiert. Das hat zwar die Therapie von Autoimmunerkrankungen deutlich 
verbessert, allerdings ist deren Anwendung durch Darreichungsform und Immunogenizität 
limitiert. Dadurch entsteht in der Therapie ein Bedarf für neue kleine Moleküle mit neuen 
Wirkmechanismen.  
Um neue Leitstrukturen zu finden, nutzten wir die chemische Diversität in einer Bibliothek von 
Extrakten aus Pflanzen, die in der traditionellen Chinesischen Medizin (TCM) Verwendung finden. 
Diese Auswahl sollte den Fokus auf Pflanzen lenken, die bereits über lange Zeit genutzt werden 
und damit zumindest über eine begrenzte Evidenz für biologische Aktivität verfügen. Für die 
Identifizierung von Extrakten oder Stoffen, die die Proliferation von primären, aus menschlichem 
Blut isolierten T Zellen hemmen, wurde ein in vitro Test verwendet. Durch die Analyse mit 
Fluoreszenz aktivierter Zellsortierung (FACS) wurden dabei auch zytotoxische oder 
nekroseinduzierende Effekte identifiziert. 
Wir testeten 435 Extrakte von Pflanzen aus der TCM bei einer Konzentration von 30 µg/mL. Bei 
etwa 40 Extrakten stellten wir eine Hemmung der T Zell Proliferation fest. Insgesamt sechs 
Pflanzen wurden, basierend auf Zytotoxizität, Verfügbarkeit, Reproduzierbarkeit und bekannter 
Literatur, für weitere Untersuchungen ausgewählt. Für sieben Extrakte dieser Pflanzen wurde ein 
HPLC Aktivitätsprofil erstellt, welches in vier Extrakten aktive Regionen aufzeigte. Die Stoffe in 
den aktiven Regionen standen demnach im Fokus der Isolierung. Die Arbeit an zwei der Pflanzen, 
Artemisia argyi und Toddalia asiatica, führte zu drei im Peer-Review Verfahren begutachteten 
Publikationen. Die Arbeit an zwei anderen Extrakten ist noch im Gange. 
Der erste Extrakt war ein Ethylacetatextrakt der überirdischen Teile von A. argyi. Aus diesem 
Extrakt wurden 18 Stoffe isoliert, darunter fünf neue Sesquiterpenlaktone. Eine Reihe von 
isomeren Sesquiterpenlaktonen, zwei Diastereomere seco-Tanapartholide und zwei 
Diastereomere von Canin, zeigten Aktivität bei mikromolaren Konzentrationen (IC50 Werte 
zwischen 1.0 und 3.7 µM). Die Daten in der Literatur zu Identität und absoluter Konfiguration 
reichten nicht für eine eindeutige Identifizierung dieser Stoffe. Daher wurden die absoluten 
Konfigurationen unabhängig mit ECD und VCD bestimmt. Die relativen Konfigurationen der seco-
Tanapartholide A und B waren nur zum Teil bekannt und im ECD wurden quasi-enantiomere 
Spektren gemessen. Daher wurden die absolute Konfiguration final mit VCD bestimmt. Für die 
Auswertung der Spektren wurden sowohl visuelle als auch rechnerische Methoden verwendet. 
Die jetzt bestätigten absoluten Konfigurationen der isolierten Stoffe können nun als Basis für eine 
mögliche weitere Entwicklung als immunsuppressive Leitstruktur dienen. Die Ergebnisse wurden 
im Journal of Natural Products veröffentlicht (Vol. 82, 2019). 
Als nächstes haben wir die Wirkmechanismen des A. argyi Extrakts sowie die der isolierten Stoffe 
untersucht. Um die inhibierten Transkriptionsfaktoren zu identifizieren wurden Reporterzelllinien 
für AP-1, NFAT und NF-κB verwendet. Die Angriffsziele von sowohl Extrakts als auch der 
isolierten Sesquiterpenlaktone wurden dadurch in der Signaltransduktion oberhalb von NFAT und 
NF-κB lokalisiert. Der Einfluss des Extrakts sowie den Sesquiterpenlaktonen auf die 
Kalziumsignaltransduktion im NFAT Signalweg wurde im Detail untersucht. Dabei wurde sowohl 
der Einfluss auf den Kalziumeinstrom in die Zelle als auch aus dem ER ins Zytosol gemessen. In 
beidem haben weder die einzelnen isolierten Sesquiterpenlaktone noch eine Mischung aus Allen 
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eine annähernd starke inhibierende Wirkung auf den Kalziumfluss gezeigt wie der A. argyi Extrakt. 
Die Ergebnisse wurden in Frontiers of Pharmacology publiziert (Vol. 11, 2020). 
Der zweite Extrakt, den wir untersuchten, war ein Methanolextrakt der Wurzeln von T. asiatica. 
Darin wurde das Alkaloid Nitidin mit einem IC50 Wert von 0.37 µM als hochaktiver Bestandteil 
identifiziert. Ein weniger aktives Alkaloid (IC50 6.72 µM) wurde zusammen mit einer Reihe von 
inaktiven, zum Teil glykosylierten, Alkaloiden, Lignanen und Coumarinen isoliert. Eine 
Kombination aus ECD, OR, GCMS Analyse der hydrolysierten Zucker, enantioselektiver HPLC 
der hydrolysierten Aglykone und NMR in Gegenwart des Shift-Reagenzes Eu(hbc)3 wurde zur 
Identifizierung der absoluten Konfigurationen der isolierten Stoffe verwendet. Zwei der isolierten 
Stoffe waren neu und ein Stoff wurde als erstes überzeugend beschrieben. Die Ergebnisse 
wurden im Journal of Natural Products veröffentlicht (Vol. 83, 2020). 
Die Isolierung von mehreren Stoffen mit signifikanter T Zell Inhibition zeigt den Nutzen des CFSE 
Assays für die Identifizierung von neuen Leitstrukturen mit relevanter Aktivität. Für viele der 
isolierten Stoffe waren keine gut beschriebenen absoluten Konfigurationen publiziert. Daher 
haben wir ein breites Spektrum an Methoden verwendet, um diese Lücke zu füllen und die 
Ergebnisse für zukünftige Forschung zu publizieren. Die Kombination von ECD (als sensitiver 
Methode) mit komplementären Techniken wie VCD, Chromatografie der hydrolysierten Stoffe und 
der Verwendung von Shift-Reagenzien im NMR hat sich dabei als effektiv erwiesen. So wurden 
auch anspruchsvolle Fälle wie die seco-Tanapartholide A und B aus A. argyi und die glykosylierten 
















Autoimmune diseases are a rising burden in industrialized countries. Regardless of the cause for 
this increase, the development of therapeutics is focused almost exclusively on biologics like 
antibodies and fusion proteins. As these are limited in their application by their possible 
immunogenicity and dosage forms, there is an increasing need for new small molecule drugs to 
treat this diverse group of diseases. None of the small molecule immunosuppressant drugs of 
natural product origin on the market originate, so far, from plants. Due to diversity and complexity 
of secondary metabolites present in plants, this lack was identified as a potential lead to address 
the need for new small molecule therapeutics. Thus, the aim of this work is the identification of 
new immunosuppressant lead structures from plant extracts. For this, an assay measuring the 
proliferation inhibition of human primary T lymphocytes in vitro is used to identify plant extracts 
and compounds with immunosuppressant properties. This assay mimics physiological activation 
of T cells, which is relevant to many autoimmune diseases, where a constant activation of 
autoreactive T cells leads to their proliferation and subsequent attack on healthy tissues. As this 
assay is done in a medium throughput format, only a focused library of plant extracts can be 
screened with a reasonable effort. To prioritize extracts, the application of plants as traditional 
medicines, for example in traditional Chinese medicine (TCM), can be used. These culminate the 
experience of practical applications over thousands of years, which could increase the chance of 
finding pharmacologically active ones. Additionally, our library of extracts from plants used in TCM 
contains a broad spectrum of plant genera among the 435 extracts. This corresponds to the 
presence of a variety of scaffolds, which is an ideal prerequisite for finding new ones. Hit extracts 
are subjected to HPLC activity profiling, thereby guiding the isolation of possibly active 
compounds. Furthermore, the isolation of close derivatives can give hints at possible structure 
activity relationships. To this end, however, the absolute configurations need to be known. Thus, 
we aim to do an extensive characterization of the isolated compounds. This is done by the use of 
available technologies like microprobe NMR, ECD, VCD, OR, as well as advanced chemical and 
chromatographic methods. Once structures are sufficiently characterized, the biological data 
obtained from their testing can be used to reliably assess their prospect for further development. 
This enables the meaningful characterization of the mechanism of action for the isolated 
compounds and, for the extracts itself. In the end, the characterization of absolute configuration 















2.1. Autoimmune diseases 
The definition of an autoimmune disease can be given as “a clinical syndrome caused by the 
activation of T cells or B cells, or both, in the absence of an ongoing infection or other discernible 
cause”.1 As the immune responses of T cells, B cells, and other immune cells are highly 
interconnected, their understanding is essential to bringing new treatment options into the clinic. 
2.1.1. The immune response  
The primary protection of the human body from foreign structures is the skin and other epithelial 
tissues. These form strict physical and chemical barriers around it and as soon as the surface of 
the skin is breached by a pathogen, it is recognized by cells of the immune system residing in 
the skin. The following reaction is usually divided in two branches, the “inherited” (or innate) and 
the “acquired” (or adaptive) immune system. In a more modern view, this corresponds to a static 
(or inherited) set of receptors recognizing general signs of a pathogen and a flexible (or adaptive) 
repertoire of receptors responding to any other unknown structure.2  
 The innate immune system 
The innate immune system is the first response to any pathogen. It acts fast (minutes to hours) 
but unspecific, and uses, among other cell types, macrophages, dendritic cells, and natural killer 
(NK) cells. Its cells employ a range of pattern recognition receptors (PRRs) that recognize 
pathogen- and damage-associated molecular patterns (PAMPs and DAMPs). Bacterial 
lipopolysaccharides (LPS), for example, are recognized through Toll-like receptors (TLRs).3 This 
prompts the expression of antimicrobial proteins and pro-inflammatory cytokines.2 Cytokines are 
a class of proteins used for the signaling between cells. They form expression patterns that 
influence the reaction of immune cells by signaling either pro- or anti-inflammatory conditions. This 
influences, whether an immune response is started, or tolerance against an antigen is induced. 
The second important group of signal molecules are chemokines, which are chemoattractants to 
guide necessary immune cells to a site of inflammation.4  
Practically, when PRRs are activated in a tissue, a local inflammation reaction starts. This is 
characterized by pro-inflammatory cytokine patterns activating immune cells close by. They, in 
turn, emit chemokines, which attract macrophages and other supporting immune cells to get rid of 
the source of inflammation. Inflammation is clinically characterized by swelling, redness and 
increased temperature of the effected tissue. In many cases, this response already leads to the 
clearance of the pathogen, which is phagocytized by macrophages. Parts from these phagocytized 
pathogens are then presented on the cell surface as antigens. The recognition of presented 
antigens and future memory of this antigen is part of the adaptive immune response.  
 The adaptive immune system 
The adaptive immune system uses highly variable receptors on B and T cells to recognize 
unknown threats. Both, B and T cells, are derived from hematopoietic stem cells in the bone 
marrow. But, while B cells also mature in the bone marrow itself, T cells migrate into the thymus 
for maturation, hence the names. For this reason, both the bone marrow and the thymus are 
considered primary lymphoid tissues (PLT).5 The development of B and T cells each generates 
a diverse population of naïve cells with an individual receptor specificity of each individual cell. 
This repertoire of receptors differs between individuals.  
B cells recognize antigens directly through their B cell receptor (BCR) expressed on the cell. 
This receptor can also be expressed by B cells in a soluble form as antibodies (also called 
immunoglobulins or IG).6 After maturation, not yet activated B cells, also called naïve B cells, are 
12 
 
found in secondary lymphoid tissues (SLT) including lymph nodes, the spleen, and gut-associated 
lymphoid tissues (Peyer’s patches).7  
T cells express a T cell receptor (TCR), which only recognizes antigens presented by the Major 
Histocompatibility Complex (MHC) on Antigen Presenting Cells (APC).8 Mature naïve T cells 
circulate between the blood and different SLTs, in which they sample as many antigens presented 
as possible. When the TCR on a T cell recognizes its antigen on a MHC molecule, the T cell can 
in principle become activated. This leads to the excretion of interleukin 2 (IL-2), which stimulates 
T cell proliferation. Mature T cells can be defined by clusters of differentiation (CD) on their surface. 
Whether a T cell is CD8-positive (CD8+ T cell) or CD4 positive (CD4+ T cell) determines the class 
of MHC molecule, by which it is activated. 
The binding of MHC class I molecules to the TCR is mediated by CD8. Therefore, they are only 
recognized by CD8+ T cells.9 Induced by the presence of interferons (IFN α, β, and γ) during 
inflammation, MHC class I molecules can be expressed by any nucleated cell to present antigens 
from inside of the cell.10 This identifies cells with, for example, intracellular viruses to CD8+ T cells, 
which will then kill that cell to stop the infection. For this reason, CD8+ T cells are also called 
cytotoxic or killer T cells. 
MHC class II molecules present antigens only to CD4+ T cells, as the binding is mediated by 
CD4.11 MHC class II molecules are only expressed on the surface of immune cells, particularly B 
cells and dendritic cells.10 For example, an antigen is taken up by dendritic cells at the site of 
inflammation and is transported to the closest SLT, such as a lymph node, where it is presented 
to circulating CD4+ T cells. When a CD4+ T cell is activated, it will further differentiate into the main 
subsets TH1, TH2 or TH17, which tailor the cytokine response to the recognized pathogen 
(intracellular bacteria, helminth parasites, extracellular bacteria, fungi, etc.).12, 13 Independent of 
the subset, CD4+ T cells can either be follicular helper T cells (TFH) or effector T cells (Teff). 
Follicular helper T cells TFH associate with B cells in lymph nodes to form germinal centers. There, 
B cells undergo class switching to produce antibodies with a higher affinity to the pathogen. As 
effector T cells Teff, they coordinate the immune response through cytokine excretion. Additionally, 
in the contraction phase 1-2 weeks after infection, they can become memory T cells. Those can 
be reactivated, if the pathogen reoccurs, thereby shortening the reaction time of the immune 
system.14 This is the basis of immunity to a pathogen. 
 T and B cell receptors 
For B and T cell receptors to “anticipate” so far unknown structures, a huge arsenal of receptors 
is needed. This is achieved by variable regions in each receptor that form the antigen binding 
site.15 For structural integrity and functional signal transduction, constant regions make up the rest 
of the receptor. Multiple copies of the DNA sequences encoding for the variable regions are 
present in the germline cells.16 In the development of B or T cells, these copies get randomly 
combined into the gene used to express the T or B cell receptor in each cell. This process is called 
somatic or V(D)J recombination and generates a unique repertoire of receptors from up to 1015 
theoretically possible variants. Practically, in mice, a variety of 2 x 106 T cells with different TCR 
specificities are found, sufficient to recognize most foreign antigens.17 For T cells, this happens 
only after an initial proliferation of T cell progenitors in the thymus. 
Among this diversity of receptor specificities, there are inevitably ones that recognize antigens of 
the body itself. In a healthy individual, these are eliminated. A concept of how this works was 
introduced by Sir Frank Macfarlane Burnet as clonal selection.18 For predicting adaptive immunity, 
he was awarded the Nobel prize in 1960. Meanwhile, the concept has been refined, but is still 
valid in principle. T cells should only recognize foreign antigens presented to them on MHC 
molecules. 19 This is ensured by positive and negative clonal selection. 
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 Positive clonal selection 
Immature T cells in the thymus are double positive for CD4 and CD8 and can, in principle, 
interact with both classes of MHC molecules. Both classes are expressed in the thymic cortex. 
Whether a cell interacts with MHC class I or class II molecules decides, however, which of the co-
receptors will continue to be expressed.19 This determines the later functionality of the respective 
cell as CD4+ helper T cell or CD8+ killer T cell and is called positive selection. 4 out of 5 immature 
T cells do not interact with either class of MHC molecules and are eliminated.20  
 Negative clonal selection 
The second step in the thymus is negative selection of T cells that interact with autoantigens. To 
recognize those, self-peptides from other tissues are expressed in the thymus by the autoimmune 
regulator gene (AIRE).21 If T cells react strongly to the resulting self-peptide:self MHC complexes 
on thymic cortical, medullary epithelial, or thymic dendritic cells, they are eliminated. In the end of 
the T cell maturation process, only 3-5% of initial T cell progenitors become functional T 
lymphocytes.20  
Both, negative and positive selection are part of the central tolerance.22 This protects self-tissues 
from the attack by mature T lymphocytes during their circulation between the blood and SLTs.  
 
Figure 1. Graphic representation of interactions following TCR activation by the antigen (ag) presented by the 
antigen presenting cell (APC) on a MHC molecule. This ultimately leads to the activation of AP-1, NFκB, and 
NFAT. 
2.1.2. Activation of T cells 
Activated mature T cells can either neutralize recognized cells in case of CD8+ killer T cells or 
initiate a full immune response in case of CD4+ helper T cells. While they use different co-




 Signal transduction from the TCR 
First, the TCR matches with its corresponding antigen:MHC complex (Figure 1).The binding of its 
co-receptor CD8 or CD4 to the respective MHC molecule on the APC activates Lck (lymphocyte 
specific protein tyrosine kinase). Lck then phosphorylates the cytosolic region on the TCR called 
the immunoreceptor tyrosine based activation motif (ITAM).23, 24. The phosphorylation of ARAM 
leads to the recruitment of the kinase ZAP-70, which phosphorylates LAT (linker for activation of 
T cells) and SLP-76 (SH2 domain containing leukocyte protein of 76kDa).25 Together, both 
phosphorylated proteins form a complex with the adapter protein Gads.26 This complex activates 
the phosphatidylinositol 3-kinase (PI 3-kinase) to catalyze the reaction of phosphatidylinositol 4,5-
biphosphate (PIP2) into phosphatidylinositol 3,4,5-triphosphate (PIP3). On its own, the activation 
of the PI 3-kinase by the LAT:Gads:SLP-76 complex is only weak.27 It is enhanced, however, by 
co-stimulatory activation of CD28 on the T cell by CD80 (B7.1) or CD86 (B7.2) presented on the 
APC.28 PIP3 is a second messenger with a hydrophobic tail anchored in the membrane, along 
which it can transduce a signal. In this context, it activates the Akt pathway, which leads to an 
increase in cellular metabolic activity necessary for proliferation.29 Together with the 
LAT:Gads:SLP-76 complex, PIP3 also activates PLC-γ (phospholipase C-γ) and Vav (a guainine 
nucleotide exchange factor).30 ADAP is an adapter protein binding to the LAT:Gads:SLP-76 
complex, leading to oligomerization of the complex.31 Most likely, this is an additional mechanism 
to upregulate T cell activation. Together, these four proteins form the molecular basis of different 
aspects of T cell activation:  
Akt activation leads to metabolic activation needed for extensive proliferation.  
Vav activation leads to the rearrangement of the cytoskeleton. 
PLC-γ activation leads to transcription factor activation. 
ADAP recruitment modulates the response through oligomerization of the complex. 
Additionally, other proteins and modulating mechanisms are involved as well in this pathway, 
many of which are actively investigated.32, 26 This work, however, will focus on PLC-γ as key 
element in the downstream activation of IL-2 expression as a key cytokine stimulating T cell 
proliferation. PLC-γ catalyzes the reaction of PIP2 into diacylglycerol (DAG), a membrane bound 
second messenger, and inositol 1,4,5-trisphosphate (IP3), a soluble second messenger.33 This is 
the first step in the pathways activating the transcription factors AP-1 (Activator protein-1), NFAT 
(Nuclear factor of activated T-cells), and NF-κB (nuclear factor κ-light-chain-enhancer of activated 
B cells). If all three are present, IL-2 expression is induced, which stimulates proliferation of 
activated T cells proliferation.  
 Activation of NF-κB 
As shown in Figure 2, upstream of NF-κB, the D1 domain of PKC-θ (protein kinase C-θ) binds 
DAG and subsequently phosphorylates CARMA1 (caspase-recruitment domain membrane 
associated guanylate kinase).34 CARMA1 is a scaffold protein, which forms the origin to 
oligomerize with BCL-10 and MALT1.35 The resulting CBM complex recruits and activates TRAF-
6 (tumor necrosis factor receptor-associated factor 6), which mediates ubiquitination of NEMO 
(NF-κB essential modulator).36 Ubiquitination leads to the degradation of NEMO by the 
proteasome.37, 38 As NEMO usually binds to and inactivates IKK (inhibitor of NF-κB kinase), IKK 
now can be activated by phosphorylation. This happens independently of the CBM complex by 
TAK1, which is ultimately also activated by PKC-θ. Phosphorylated IKK in turn phosphorylates the 
inhibitor of NF-κB (IκB) leading to its dissociation from NF-κB. NF-κB is then translocated into the 





Figure 2. Induction of IL-2 transcription through AP-1 and NF-κB pathways by diacylglycerol (DAG). 
 Activation of AP-1 
DAG in the plasma membrane binds the D1 domain of the soluble protein Ras-guanyl-releasing 
protein (RasGRP), thereby anchoring it in the plasma membrane (Figure 2).39 This facilitates the 
exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the membrane 
bound kinase Ras. Ras then phosphorylates Raf, a mitogen activated protein kinase kinase kinase 
(MAPKKK).40 Raf then phosphorylates MEK1 (MAPK/ERK kinase 1), a MAPKK, and MEK1 
phosphorylates ERK (extracellular signal-regulated kinase), a MAPK. Similar cascades of MAP 
kinases are common for signal transduction and amplification in cellular pathways. All three MAP 
kinases are supported on the scaffold protein KSR (Kinase Suppressor of Ras) to enable a swift 
signal relay. Additionally, the scaffold protein is involved in the regulation of the cascade. In the 
end, ERK phosphorylates Elk-1 (E26 transformation-specific like protein 1), a transcription factor 
for the gene of Fos. When expressed, Fos forms the heterodimer AP-1 together with Jun. To 
activate AP-1 however, Jun needs to be phosphorylated. Through PCK-θ and CARMA1, which 
are also involved in NF-κB signaling, and a series of MAP kinases, the Jun kinase (JNK) is 
phosphorylated and translocated into the nucleus.34 then, by phosphorylating Jun, JNK activates 




Figure 3. Induction of IL-2 transcription through the NFAT pathway by inositol 1,4,5-trisphosphate (IP3). 
 Activation of NFAT 
As shown in Figure 3, IP3 activates the IP3 receptor (IP3R) located in the membrane of the 
endoplasmic reticulum (ER). This leads to the release of Ca2+ stored in the ER into the cytosol. 
This depletion of the endoplasmic Ca2+ storage prompts the opening of store operated Ca2+ 
channels in the plasma membrane.41 These channels termed CRAC (calcium release-activated 
channels) consist of ORAI1 pore subunits and are activated by STIM1 transmembrane proteins 
located in the ER membrane. A decrease in Ca2+ concentration in the ER is sensed at the N-
terminus of STIM1 molecules in the ER lumen. This leads to the oligomerization of STIM1 
molecules at contact sites between the ER and the plasma membrane. There, the C-termini of 
STIM1 open the CRAC channels followed by an influx of Ca2+ into the cell. This prompts the 
cytoplasmic calcium sensing protein calmodulin to activate, among other proteins, calcineurin. 
The activated phosphatase calcineurin subsequently cleaves phosphates from NFAT located in 
the cytosol. Upon dephosphorylation, NFAT migrates into the nucleus to activate the expression 
of cytokines like IL-2 stimulating proliferation of T lymphocytes.  
All three transcription factors, NF-κB, AP-1, and NFAT, are needed for the expression of IL-2. 
Thus, if one pathway is inhibited, it prevents the IL-2 mediated proliferation of activated T cells.   
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2.1.3. T cell regulation 
By coordinating the immune response and neutralizing effected cells, T cells are a central element 
of the immune system. Thus, their regulation, and the regulation of this regulation, is essential to 
a functioning immune system, which will be outlined in the following.  
  
Figure 4. Schematic description of some factors determining the fate of a given T cell after activation. leading 
either towards T cell proliferation and subsequent differentiation into effector cells or towards the development 
of Treg cells. 
 Regulation by APCs  
In case of apoptotic cells, fragments are generated and taken up by macrophages.42 As APCs, 
macrophages also present antigens on their surface Yet in this case, a recognition of the cell 
fragments could lead to autoimmunity. To prevent this, anti-inflammatory cytokines like 
transforming growth factor-β (TGF-β) and IL-10 are excreted by Treg cells. Additionally, secretion 
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of pro-inflammatory cytokines, like TNF-α, IL-1 or IL-12 is suppressed. If the function of 
macrophages to clear cell debris is impaired, it can lead to secondary necrosis of apoptotic cells. 
As it is accompanied by the release of TNFα, secondary necrosis can trigger an immune reaction. 
This malfunction is discussed as a possible origin of the autoimmune disease systemic lupus 
erythematosus (SLE), where autoantibodies against DNA and nucleus fragments are found. 
 Development of Treg cells 
While most T cells activated by self-peptide:self MHC complexes in the thymus undergo clonal 
selection, some CD4+ T cells differentiate into CD25+, Foxp3+ natural regulatory T cells (nTreg 
cells) with the purpose to suppress activation of other autoreactive T cells.43 Similar to regular T 
cell activation, signals from the TCR, CD28, and IL-2 are necessary to induce nTreg differentiation. 
The survival of autoreactive T cells as nTreg cells in the thymus, however, seems to be dependent 
on the presence of TGF-β. In general, a strong activation (high affinity or long binding half-life t1/2) 
of the TCR, a high ligand density, or a long duration of TCR signaling favor clonal selection over 
Treg formation. Moderate activation, however, favors Treg differentiation. Another factor is the age 
of the person. Most Treg cells are produced in the thymus early in life and production declines over 
time. Later in life, regulatory T cells in the thymus are almost exclusively used as a reservoir to 
maintain the balance between regulatory and conventional T cells in circulation.44 Together with 
positive and negative selection, this contributes to central tolerance.22 
However, some autoreactive T cells evade central tolerance. As no pathogen is present during 
activation, the pro-inflammatory cytokine pattern from the innate immune system is missing. This 
can facilitate the differentiation into peripheral regulatory T cells (pTreg cells).45 Thus, pTreg cells 
can induce self-tolerance also to self-antigens not found in the thymus, thereby contributing to 
peripheral tolerance.22 Analogous to the development of nTreg cells from the thymus, the presence 
of TGF-β favors the differentiation into pTreg cells. Recent research also points at the relevance of 
dendritic cells for this process.46 
Different paths leading to either clonal selection, T cell activation or differentiation into Treg cells 
are summarized in Figure 4.  
 Mechanisms of Treg cell function 
IL-2 is the main cytokine to promote proliferation in activated T cells.47 While naïve T cells are not 
susceptible to IL-2, Treg cells are. Thus, Treg cells are constantly proliferating on some level to 
create a balance between conventional and regulatory T cells. Consequently, when a conventional 
T cell becomes activated and produces IL-2, the proliferation of Treg cells increases as well. This 
increases the chance of a fitting Treg cell to recognize an autoreactive T cell thereby preventing an 
autoreactive response. Four basic mechanisms, by which Treg cells inhibit the immune response 
to autoantigen, are discussed: Inhibitory cytokines, cytolysis, metabolic disruption, and 
modulation of dendritic cells.48 
IL-10 and TGF-β are the most prominent inhibitory cytokines produced by Treg cells. While IL-10 
seems to suppress local inflammation,49 TGF-β increases the induction of pTreg cells, a mechanism 
also exploited by tumors.50  
The second mechanism, cytolysis, uses the perforin/granzyme pathway, which induces 
apoptosis in target cells.51 This process is similar to the cytotoxic effects of CD8+ T cells and 
Natural Killer (NK) cells. It is most likely used to kill APCs that present self-antigens, which can 
again be prevented by cells expressing inhibitors of granzyme B on their surface.48 Also, other 
apoptosis inducing pathways like TRAIL-DR5 (tumor-necrosis-factor-related apoptosis-inducing 
ligand-death receptor 5) are investigated as mechanisms in regulatory T cells. 
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Metabolic disruption of effector T cells by regulatory T cells is another possible way of inhibition. 
One example is the capture of IL-2 by CD25. As IL-2 is needed for effector T cells to proliferate, 
the binding to CD25 on regulatory T cells can lead to a decrease of effector T cell proliferation.48 
This seems to be a mechanism specifically limiting activation of CD8+ T cells.52  
The fourth mechanism discussed is the modulation of dendritic cells as the most important 
APCs. There, Treg cells have been shown to influence dendritic cells towards the production of 
immunosuppressive metabolites and the downregulation of co-stimulatory molecules. 53, 54 
The importance of each of these mechanisms in vivo is still unclear and so is their interplay.48 As 
all of them rely on either cell-cell contact or local cytokine concentrations, a common prerequisite 
seems to be the spatial proximity to either effector T cells or dendritic cells. 
2.1.4. Autoimmune diseases 
Most autoimmune diseases can be explained with the failure of one or more regulatory 
mechanisms like in the case of SLE.55 The variety of possible antigens from different organs, 
tissues, and cells in the human body generates a broad spectrum of clinical conditions considered 
as autoimmune diseases. Experimental evidence for autoimmunity can be obtained by transferring 
the reacting immune species into a healthy individual, where it will cause the same effects.56 
However, due to practical and ethical limitations of these experiments, the attribution is not always 
clear. In a review from 2012, Hayter and Cook counted 81 disorders with good evidence for 
autoimmunity.57 Additionally, a range of autoimmune diseases with less clear evidence exists.58 
From data, mostly collected in the United States of America, the overall prevalence of autoimmune 
diseases is estimated at 4.5% with a higher prevalence in women (6.4%) than men (2.7%). 
Although the mechanisms leading to autoimmune diseases are not yet fully understood, the 
presence of autoreactive T cells are a common denominator of many autoimmune conditions. 
Examples are celiac disease59, psoriasis60, diabetes mellitus type I, rheumatoid arthritis61 and 
multiple sclerosis62. Thus, the knowledge about signal transduction in T cells is used to find new 
treatment options for autoimmune diseases. 
 Origin 
Much is known by now about cell types and compartments involved in the immune response. 
Some is known about the interactions between these actors. But least is known about the 
mechanisms leading the immune system to fail and cause an autoimmune disease. No solely 
responsible factor leading to autoimmune diseases was found. Thus, it can only be described as 
a complex interplay between environmental and genetic factors that increase or decrease the 
chance of an autoimmune reaction. With psoriasis alone, 1338 genes were found to be associated 
with the disease and, more recently, 101 gene loci that increase the risk for rheumatoid arthritis.63, 
64 However, some mutations can significantly increase the risk of autoimmunity. One example is 
the FOXP3 gene encoding a protein important to the function of Treg cells.65 Mutations in this gene 
often lead to Immune dysregulation, polyendocrinopathy, enteropathy, or immunodysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a severe autoimmune disease 
effecting multiple organs and tissues.  
 Autoimmunity and transplantation 
A special case in terms of immune diseases are transplantations of kidneys, lungs, blood, bone 
marrow or other organs.66 There, instead of the immune system recognizing a self-antigen as 
foreign, a foreign organ or tissue introduced into the body is recognized. Two main concerns are 
associated with this. Firstly, the foreign organ elicits an immune response from the recipient, 
which, without immunosuppression, would lead to graft rejection. Secondly, especially in case of 
bone marrow transplants, the donor’s immune system remaining in the transplant can attack the 
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recipient. This is known as graft versus host disease (GvHD). Both, GvHD and graft rejection, 
need to be treated, similar to autoimmune diseases, with the use of immunosuppressant drugs. 
 Autoimmunity vs. Tumor Tolerance  
Under normal circumstances, the immune system maintains a balance between immunity and 
tolerance.65 While it defends the body against pathogens, it promotes tolerance to itself by 
preventing natural occurrences of autoreactive T cells or autoantibodies from becoming 
autoimmune diseases. Also, it avoids the tolerance of pathogens or abnormal cells that could 
otherwise develop into cancer. Thus, regulatory failures in the immune system can tip that scale 
in both directions. On one hand, the absence or lacking functionality of Treg cells, for example by 
impairment of FOXP3, can lead to autoimmune disease. On the other hand, Treg cells can promote 
tolerance against some tumors. 67 A therapeutic goal can thus be the depletion of the tumor of Treg 
cells to break this tolerance. But, this could also lower the tolerance for self-antigens, which might 
then lead to the emergence of autoreactive T cells. To avoid these problems in practice, a strategy 
can be to only target specific subsets of Treg cells and simultaneously support the immune reaction 
against the tumor itself. Thereby, the effect on the whole organism could be limited. 
 Therapy of autoimmune diseases 
Generally, the treatment of autoimmune diseases focusses on the prevention of excessive 
immune responses to relieve symptoms and progression of the respective disease. A range of 
therapeutics has been developed over the last seven decades approaching different targets. For 
an overview about the drugs in question, the Anatomical Therapeutic Chemical (ATC) 
classification system of the World Health Organization Collaborating Centre for Drug Statistics 
Methodology (WHOCC) was used.68 Information about classification, market introduction and 
mechanisms of action were obtained from the DrugBank 5.0 database 
(https://www.drugbank.ca).69 This analysis focusses on immunosuppressant drugs (ATC 
classification L04) and only takes glucocorticoids, a class of corticosteroids (ATC classification 
S01BA), into account as a second option in the treatment of autoimmune diseases. Primarily anti-
inflammatory drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) were not considered. 
Thus, this analysis is not a manual to treat autoimmune diseases, but an overview of available 
immunosuppressant therapies. 
 
Figure 5. Distribution of drug types among immunosuppressant drugs contained in the ATC classification L04 




Figure 5 shows the distribution of drug types among all immunosuppressant drugs classified in 
ATC L04. Almost half of the drugs in this category are, mostly monoclonal, antibodies with different 
target proteins in the immune system. The second largest group are small molecules acting 
through diverse mechanisms. The third largest group are fusion proteins targeting interleukins of 
co-stimulatory signals in the activation of T cells. Additionally, some more unusual treatments such 
as oligonucleotides, enzymes, or fat derived stem cells are used. Glucocorticoids are not classified 
as “immunosuppressants” in the ATC classification system and thus are not included in Figure 5. 
They are, however, important in the management of autoimmune diseases.  
 Glucocorticoids 
Glucocorticoids are used for many indications, but are can be valuable in the management of 
inflammatory and autoimmune diseases. Several different glucocorticoids are available with 
different pharmacological profiles. There, dexamethasone, a drug now also considered in the 
treatment of acute COVID-19, is an example for a drug with a longer biological half-life, while 
cortisol is an example for a glucocorticoid with a shorter half-life.70 Several mechanisms contribute 
to the action of glucocorticoids.71 On a genomic basis, glucocorticoids bind to the glucocorticoid 
receptor. This leads to the suppression of inflammatory cytokines and the induction of anti-
inflammatory cytokines. These effects, as they impact the expression of cytokines and require 
diffusion into the cell to reach the cytoplasmic glucocorticoid receptors, need some time to develop 
after administration. Short term effects are mediated primarily by membrane associated 
glucocorticoid receptors, for example on T cells. This needs higher doses, but leads to a broad 
impairment of signaling and thus, a rapid quenching of inflammation.  
Because of these effects, glucocorticoids could be seen as the magic bullet against inflammatory 
diseases. However, they also effects glucose levels, adrenal hormones, and the musculoskeletal 
system. This leads to severe side effects, which primarily depend on the dose and the longitude 
of the treatment. In conclusion, although it is an important therapy, the necessity for high doses of 
glucocorticoids in the treatment of autoimmune diseases makes them less suited for long term 
disease management. 
 Antibody based therapies 
The first immunosuppressant antibody therapeutics were approved in 1981 using equine anti-
lymphocyte immunoglobulins. After inoculation of horses with human T lymphocytes, the equine 
immune system produces immunoglobulins against human T lymphocytes. Those are isolated 
and administered in humans to prevent lymphocytes from rejecting a transplant, for example 
hematopoietic stem cells.72 Antibodies obtained in this way are polyclonal antibodies as they are 
produced by a group of different equine B cells reacting to T lymphocytes. Monoclonal antibodies 
are obtained from only one B cell clone with a defined receptor specificity, which is selected and 
fused to a myeloma cell in the lab to obtain hybridoma cells.73 This can be used to target specific 
epitopes. Antibodies are macromolecules. This requires them to be administered either 
intravenously or subcutaneously to enable the uptake and avoid their degradation in the 
gastrointestinal tract. As antibodies itself are also foreign structures, they themselves can induce 
an immune reaction.74 When antibodies against the drug are formed, this can result in a loss of 
activity and requires alternative treatments. Nowadays, to lower the risk of immunogenicity, 
humanized antibodies can be engineered, which contain constant regions from humans. A range 
of more or less humanized monoclonal antibodies is currently used as immunosuppressant drugs. 
One target for antibodies is C5, a component of the complement pathway in the innate immune 
system. Other antibodies are designed to inhibit the function of pro-inflammatory cytokines. For 
this, they target interleukins (e.g. IL-1, IL-6, or IL-23), their receptors (e.g. for IL-2 or IL-6), or 
TNF-α. Also, cell type specific clusters of differentiation, for example CD20 on B cells, can be used 
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to limit the effect of the treatment on this cell type. Overall, the specificity of monoclonal antibodies 
is of great value in the treatment of autoimmune diseases, but their administration is limited by the 
necessity for injecting them and their possible immunogenicity.  
 
 
Figure 6. Small molecule drugs listed in the Anatomical Therapeutic Chemical (ATC) 
Classification System as selective immunosuppressants (L04AA). 
 Cell based therapies 
A field of active investigation is the use of induced Treg cells (iTreg cells), which are primed in vitro 
for the antigen(s) in question. This yields either monoclonal iTreg cells against one specific antigen 
or polyclonal iTreg cells against different antigens present on target cells. Administered to the 
patient, they are intended to restore tolerance against the respective antigen and could therefore 
stop the autoimmune response. The first clinical trials on this new form of therapy have been 
conducted for GvHD and Type I diabetes. Since then, two treatments have been approved 
(“Kyriah” from Novartis and “Yescarta” from Kite, now Gilead) for different forms of leukemia in 
2017.75 Both treatments are based on the expression of a chimeric antigen receptor (CAR) in T 
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cells previously collected from the patient. The CAR-T cells recognize CD19 expressed on 
leukemic cells and leads to their destruction. However, as this process is individual to each patient, 
it is very laborious and expensive. This warrants significant developments in the field to find a 
broader application. 
 Small molecule drugs 
Several small molecule drugs are currently used for the treatment of autoimmune diseases like 
rheumatoid arthritis, psoriasis, and multiple sclerosis. In the ATC classification system, three 
groups of compounds contain small molecule drugs. Small molecule drugs considered selective 
immunosuppressants are shown in Figure 6, calcineurin inhibitors in Figure 7, and other 
immunosuppressants in Figure 8. 
While compounds like cyclosporine prevent T cell proliferation by inhibiting calcineurin in the NFAT 
pathway, selective immunosuppressants have different mechanisms of action. Drugs like 
leflunomide or mycophenolic acid inhibit the synthesis of nucleotides needed for DNA 
polymerization and thereby inhibit the proliferation of fast-growing cells like activated T cells. 
Tofacitinib and its more recent analogues baricitinib and upacitinib are inhibitors of Janus kinases 
(JAK) thereby blocking the reaction to pro-inflammatory cytokines. Sirolimus (also known as 
rapamycin) and its derivative everolimus are inhibitors of the complement system through the 
mammalian target for rapamycin (mTOR), which in turn inhibits T cells activation and proliferation. 
Fingolimod is an example for a modulator of the sphingosine-1-phosphate receptor. Sphingosine-
1-phosphate is a phospholipid and second messenger inducing the emigration of T cells from 
lymphoid tissues.76 In this manner, fingolimod prevents autoreactive T lymphocytes from reaching 
their target tissues, a mechanism beneficial in the treatment of multiple sclerosis. Apremilast is an 
inhibitor of the phosphodiesterase 4 (PDE4), which prevents the formation of cyclic adenosine 
monophosphate (cAMP), a ubiquitous second messenger involved in the immune response.77 
 
Figure 7. Small molecule drugs listed in the Anatomical Therapeutic Chemical (ATC) Classification System as 
calcineurin inhibitors (L04AD). 
While some of the “other immunosuppressants” like methotrexate or azathioprine also target 
nucleotide synthesis of fast proliferating cells, the mechanisms of immunomodulation by 




Figure 8. Small molecule drugs listed listed in the Anatomical Therapeutic Chemical (ATC) Classification 
System as other immunosuppressants (L04AX). 
 Natural products as new immunosuppressive drugs 
A breakdown of structural origins of small molecule immunosuppressant drugs shows two thirds 
of the structures to be of synthetic origin, counting compounds like cladribine, which are inspired 
by primary metabolites like nucleotides. Although new methods for the discovery of new chemical 
entities have been introduced over the last decades, natural products are still the most important 
source of new chemical entities in the development of new drugs.78 Plants contain a vast diversity 
of chemical entities over all plant families. Considering that all immunosuppressant drugs with a 
natural product background are of either fungal or bacterial origin, plant derived natural products 
are, so far, underexplored in this area. To identify possible new lead structures from plants, a 
library of plant extracts obtained by sequential extraction with solvents of low, intermediate, and 
high polarity can be used.79 In an academic setting, this is a good tradeoff between the use of 
crude extracts, where compounds like tannins can interfere with the respective assay, and pure 
natural products, which require extensive isolation effort.80 Additionally, as they have been used 
with some evidence over a long period of time, focused libraries of traditionally used plants, for 
example in Traditional Chinese Medicine (TCM), could increase the probability of finding active 
extracts.81 Generally, the advances in modern technologies like HPLC-(HR)MS, preparative 
HPLC, centrifugal partition chromatography (CPC), or NMR have significantly reduced the time 
needed for dereplication, isolation, and identification of compounds.  
 Finding new immunosuppressant natural products 
To, however, find new immunosuppressant lead compounds an appropriate assay is crucial. It 
should be compatible with the use of extracts, thus preferring a cell based assay over one using 
isolated proteins. Also, it should enable a medium or high throughput of extracts and, in the next 
step, micro fractions obtained from HPLC. And, it should model immune suppression in vivo as 
closely as possible. All these criteria are met by an assay monitoring the proliferation inhibition of 
primary T cells utilizing carboxyfluorescein diacetate succinimidyl ester (CFSE).82 For this assay, 
T cells are isolated from human blood samples and incubated with the dye. After washing of the 
excess dye, T cells are activated with anti-human CD3 and anti-human CD28 antibodies, thus 
imitating the activation of the TCR in the presence of co-stimulatory signals. This is either 
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performed in the presence of only medium, cyclosporine A as positive control, camptothecin as 
control for apoptosis induction, or a test substance. The negative control is not stimulated. After 
72 h, the cells are analyzed by a fluorescence activated cell sorter (FACS). With each cell division, 
the fluorescence in the cells divided between two cells. This allows the identification of proliferating 
cells, non-proliferating cells and dead cells, which lost their fluorescence. In this manner, extracts 
inhibiting the proliferation of human T cells can be identified and their activity can be distinguished 
from cytotoxic or apoptosis inducing extracts. The assay is also applicable to the use for HPLC 
activity profiling. The chromatographic data (retention times, UV spectra, mass spectra) can be 
used to tentatively identify compounds in the extract. This is then used to dereplicate known 
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2.2. Absolute Configurations of Natural Products 
2.2.1. The issue of chirality 
Chirality describes the mirror-symmetry between non-superimposable objects like hands. Even 
though both hands seem identical (not considering scars or wedding rings), it is not possible to 
superimpose them by only rotating or translating them (Figure 9). The difference between both 
hands is probably one of the oldest known examples for a chiral object and the word “chiral” is 
derived from the ancient Greek word for hand, χείρ (cheir).  
 
Figure 9. Representation of chirality in organic chemistry. 
In chemistry, chirality is important as a property of organic molecules containing at least one 
carbon with four different substituents, for example the amino acid alanine. (S)- and (R)-alanine 
are mirror images. As they are non-superimposable using only mathematically proper operations 
(rotation, translation), they are enantiomers of each other. The description of one specific mirror 
image is its absolute configuration (AC). If two molecules are only mirror images regarding some 
stereogenic centers, but not all, they are diastereomers.83 While enantiomers are chemically 
equivalent, diastereomers are not. Thus, enantiomers appear the same in most analytical 
techniques like HPLC, UV, IR, and NMR, but diastereomers do not. Enantiomers are only 
distinguishable when interacting with other chiral elements, making them behave as 
diastereomers. Examples are chiral HPLC stationary phases, chiral shift reagents in NMR, or the 
interaction with polarized light. Different methods applying this principle can be used to assign the 
absolute configuration of a molecule by distinguishing enantiomers. 
Another source of chirality in molecules are rotational barriers. In atropoisomerism, the rotation 
around a bond is hindered by large substituents resulting in two stable atropoisomers differing in 
conformation. This is the case for substituted biphenyls84 but can also occur in natural products 
like abyssomyxin C and atrop-abyssomycin C85. On a larger scale, this is also the case for 
secondary structures of proteins or DNA, which are inherently chiral. But, although the methods 
described in the following are also applied to these cases, this work focuses on the absolute 
configurations of natural products. 
 Chirality in natural products 
Many natural compounds contain at least one chiral center. For primary metabolites, the chirality 
of these centers was mostly stable in evolution. Glucose naturally occurs as D-glucose and natural 
amino acids are always present in the L-configuration, when referring to the Fischer 
nomenclature.86 The chirality of secondary metabolites however is much less conserved as their 
structures were subject to more evolutionary variability.87 This is illustrated by different biological 















On one hand, this three dimensional diversity makes natural products a valuable source for new 
lead structures. On the other hand, it poses a challenge for drug development. The most infamous 
example is that of thalidomide, where only the R-enantiomer was found to be responsible for the 
desired sedative effect.89 The drug itself was administered as a racemate and caused teratogenic 
side-effects, but also racemizes under physiological conditions, if only one enantiomer is given. 
Thus, it is almost impossible to find out, if only one or both enantiomers are responsible for the 
long term side effects. This case illustrates both the challenges and the necessity for the rigorous 
investigation of chiral properties in drug discovery. And, due to the extensive media coverage, it 
has initiated an awareness for chirality in drug design that is present until today.90 The other reason 
for the importance of absolute configurations in drug discovery is more recent. As more and more 
screening procedures are done in silico, three dimensional input structures are needed to study 
the interactions with target proteins. Thus, each enantiomer or diastereomer needs to be screened 
separately. For a compound with n chiral carbons in its structure, 2n structures need to be 
screened individually. This increases the needed computational effort exponentially with each 
additional undefined chiral carbon in a structure. And, if a hit is produced on a specific absolute 
configuration, it might not be the one existing in nature.91 But, if the naturally occurring absolute 
configuration of a compound is known, only this configuration needs to be screened. And, if it is 
active, it can be made available for wet-lab experiments. 
 Optical rotation 
The measurement of Optical Rotation (OR) is the oldest variant to distinguish enantiomers.92 It 
measures the rotation of linearly polarized light when shone through a chiral sample, which can 
be a crystal, a solution, or a vapor. At any used wavelength, the angle observed for a rotation 𝛼𝛼𝜆𝜆 
behaves analogous to the Beer-Lambert-Bouguer law.93-95 It is proportional to the path length l, 
the concentration c and the specific optical rotation [α]λ of the compound. As this effect is 
dependent on the wavelength it could at first only be observed at available single wavelengths.96 
These were the principal Fraunhofer lines of which the D line (Na line) at 589 nm is used to date 
in most OR measurements. This is illustrated by the conventional use of [𝛼𝛼]𝐷𝐷25, which indicates the 
OR value to be measured at 589 nm and 25°C. Two corresponding enantiomers always give the 
same specific optical rotation, but exhibit opposite signs. This inherent property can be used to 
identify enantiomers and to determine their optical purities. 
 Determining the relative configuration 
In compounds possessing more than one stereo center, the knowledge of configurations of stereo 
centers relative to each other is the relative configuration (RC). Most commonly, relative 
configurations are determined by NMR. There, apart from using coupling constants (JHH and JCH), 
the Nuclear Overhauser Effect (NOE) is of great value.97, 98 This is implemented in Nuclear 
Overhauser Effect SpectroscopY (NOESY) or Rotating frame nuclear Overhauser Effect 
SpectroscopY (ROESY) experiments, which identify protons closer than 5 Ǻ from each other. 
NOESY gives positively phased peaks for smaller molecules and negatively phased peaks for 
macromolecules (Figure 10). The sign depends on the product of the spectrometer’s angular 
frequency 𝜔𝜔0 and the molecular rotational correlation time 𝜏𝜏𝑐𝑐. However, if 𝜔𝜔0𝜏𝜏𝑐𝑐 ≈ 1, no NOE effect 
is observed.99 This is mostly the case for “intermediately” sized molecules between 1000 and 
2000 Da.98 In general, both experiments give similar information. But, to avoid signals close to 
zero, ROESY is often used for molecules larger than 500 Da. Another difference are the artefacts 
observed in the spectra. In NOESY, COSY correlations can in some cases be observed, while in 




Figure 10. Strength and sign of observed NOE and ROE effects depending on 𝒍𝒍𝒍𝒍𝒍𝒍(𝝎𝝎𝟎𝟎𝝉𝝉𝒄𝒄). Republished with 
permission of Elsevier, from Claridge, 200998; permission conveyed through Copyright Clearance Center, Inc. 
A crosspeak in either NOESY or ROESY indicates a close contact between two protons. This 
information can be combined into a three dimensional model of the molecule. This works best in 
rigid structures with known conformations (e.g. chair conformation of six-membered rings). As this 
is recorded over the whole measuring time, information from crosspeaks between 
conformationally flexible groups in a molecules is often ambiguous (see examples (B) and (D) in 
Figure 11). 
 
Figure 11. Imaginary examples of different molecules analyzed with NOESY. (A) Full relative configuration (B) 
Part of relative configuration (C) Relative configurations for independent parts of the molecule (D) No 
information on relative configuration. The planar structures with observed NOESY contacts are shown in the 
upper part. ACs compliant with the NOESY data are shown below with enantiomer pairs divided by the mirror 
plane (dashed line). 
Thus, after critical assessment of the data, the result from NOESY or ROESY analysis can be (A) 
a full relative configuration, (B) a relative configuration with one or more undefined stereogenic 
centers, (C) independent relative configurations for different parts of the molecule, or (D) no 
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information about the relative configuration (Figure 11). Which case is true for a specific molecule 
determines the further strategy to determine the absolute configuration. 
2.2.2. Electronic Circular Dichroism (ECD) 
A common way to determine the absolute configuration is electronic circular dichroism (ECD). As 
modern instruments only need minute amounts (<100 µg) of sample, it is ideal for natural product 
research. A good knowledge of the investigated structure, however, is necessary for valid results. 
 Introduction 
Right and left handed circularly polarized light can be absorbed differently by chiral compounds 
depending on the wavelength. This circular dichroism (CD) can be measured, in principle, in the 
whole electromagnetic spectrum.100 As a convention, the absorption of the right handed circularly 
polarized light (AR) is subtracted from the absorption of the left handed circularly polarized light 
(AR) for each wavelength: 
𝐶𝐶𝐶𝐶 =  𝐴𝐴𝐿𝐿 − 𝐴𝐴𝑅𝑅 (𝟏𝟏) 
The measured CD is usually obtained from the instrument as ellipticity θ in the unit millidegree 
[mdeg] and can be transformed into CD using the following equation:101 
𝜃𝜃 (𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚) =  33000 𝐶𝐶𝐶𝐶 (𝟐𝟐) 
To yield a value independent of concentration (c [mol/L]) or pathlength (l [cm]) in the cell used, the 
Beer-Lambert-Bouguer law is employed:93-95  




The values of ∆ε [M-1cm-1] for two enantiomers at any given wavelength have opposite signs. As 
it is a differential spectroscopy (Equation 1), a CD effect can only be measured, if a corresponding 
absorption A is observed. The relation between CD and absorption A can be expressed by the 








Usually, g is between 10-3-10-5 as the CD effect is significantly smaller than the corresponding 
absorption. Thus, compared to absorption spectra, stronger light sources and more sensitive 
detectors are needed to measure CD spectra.101 Generally, circular dichroism can be measured 
in the far UV region (130-195 nm), the UV-Vis region (195-750 nm), the near infrared region 
(1,000-2,500 nm), and the infrared region (2,500-12,500 nm).102, 103 Due to practical limitations, 
however, the most common applications of CD are ECD in the UV-Vis region followed by 
Vibrational Circular Dichroism (VCD) and Raman Optical Activity (ROA) in the infrared region 
(2,500-12,500 nm or 3500-750 cm-1). Equations 1-4 are valid for all CD experiments. The 
measurement of Optical Rotations at different wavelengths, or Optical Rotation Dispersion (ORD) 




 Theory of ECD 
 
Figure 12. Examples of simple organic chromophores with their main transitions. Electronic transition dipoles 
are shown in red, magnetic ones in purple. Republished with permission of Royal Society of Chemistry, from 
Berova et al., 2007101; permission conveyed through Copyright Clearance Center, Inc. Reproduced with 
permission from Berova et al.  
As ECD is complementary to UV/Vis-spectroscopy, a suitable chromophore is needed. Some 
common chromophores with their respective typical absorption frequencies are shown in Figure 
12. Each transfer of an electron from state “i” to state “j” can be divided into a linear charge 
displacement with an electronic dipole 𝝁𝝁�⃗𝒊𝒊𝒊𝒊 as well as the electron’s rotation causing a magnetic 
transition dipole 𝒎𝒎���⃗ 𝒊𝒊𝒊𝒊. Together, both determine the oscillator strength fij, which is proportional to 
the intensity of the respective UV absorption: 
𝒇𝒇𝒊𝒊𝒊𝒊 ≈ �𝝁𝝁�⃗𝒊𝒊𝒊𝒊�
𝟐𝟐 + �𝒎𝒎���⃗ 𝒊𝒊𝒊𝒊�
𝟐𝟐 (𝟒𝟒) 
In contrast, the CD effect is dependent on the rotational strength Rij of an electronic transition, 
which is determined by the scalar product of the transition dipoles: 
𝑹𝑹𝒊𝒊𝒊𝒊 ≈ 𝝁𝝁�⃗𝒊𝒊𝒊𝒊 ∙ 𝒎𝒎���⃗ 𝒊𝒊𝒊𝒊 (𝟓𝟓) 
Therefore, if the dipole vectors 𝜇𝜇𝑖𝑖𝑖𝑖 and 𝑚𝑚��⃗ 𝑖𝑖𝑖𝑖 are not orthogonal, Rij is ≠ 0 and a Cotton effect (CE) 
can be observed.  
 Interpretation of ECD spectra 
Simple examples of chromophores are helical 1,3-dienes, where the angle C=C-C=C is ≠ 0 and 
can be either positive or negative (Figure 13).  
 
Figure 13. Nonplanar conformations of 1,3-dienes. The sign gives the respective sign of the angle ω.  
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1,3-dienes generals absorb light in the UV region around 220 nm for cis-1,3-dienes and around 
240 nm for trans-1,3-dienes. For both configurations, the respective electron transitions from the 
π-Molecular Orbital (MO) of one double bond and to the π*-MO of the other double bond (𝜋𝜋 → 𝜋𝜋∗). 
As it is mainly an electron transfer in space, the effect of the electronic dipole 𝜇𝜇𝑖𝑖𝑖𝑖 is significantly 
larger than of the magnetic dipole 𝑚𝑚��⃗ 𝑖𝑖𝑖𝑖. This is classified as an allowed transition. As the rotational 
strength Rij and its sign depend on the angle ω, ECD is sensitive towards conformational changes 
This must be considered in the interpretation of ECD spectra. 
 
 
Figure 14. UV- (left) and ECD spectra (right) of two diastereomeric seco-tanapartholides isolated from Artemisia 
argyi. 
In the case of 1,3-enones, additional to the 𝜋𝜋 → 𝜋𝜋∗ transition absorption band (K-band) a weaker 
one around 310 nm is observed (R-band). It arises due to the transition of an electron from a non-
binding n-MO of the oxygen to an  antibonding π*-MO (𝑛𝑛 → 𝜋𝜋∗-transition). This is an example for 
a “forbidden” transition, as the contribution of the magnetic dipole 𝑚𝑚��⃗ 𝑖𝑖𝑖𝑖 is stronger than that of the 
electronic dipole 𝜇𝜇𝑖𝑖𝑖𝑖.105 The different magnitudes of transitions can be observed in the case of two 
seco-tanapartholides from Artemisia argyi shown in Figure 14.106 There, one trans-enone and one 
cis-enone are present. Generally, the ECD contribution of the cis-enone-chromophore is weaker 
than that of the trans-enone. This leads to opposite spectra for opposite configurations next to the 
trans-enone. The CE at 230 nm originating from the 𝜋𝜋 → 𝜋𝜋∗ transition is exemplary and 
corresponds to significant absorption in the UV-spectrum. The 𝑛𝑛 → 𝜋𝜋∗-transition, however, which 
causes the CE at 330 nm does only show very little UV absorption. 
Starting from these effects observed in simple compounds, empirical rules for the interpretation of 
ECD spectra have been proposed. Examples are the Diene Helicity Rule107 and the Quadrant 
Rule108 for dienes, the Enone Helicity Rule109 for enones, and sector rules110 for aromatic 
chromophores. These rules, together with different semi-empirical calculations, have been used 
intensively to gain insights into ECD spectra before ab initio calculations were affordable, but can 
still give insights today.111  
 Ab initio calculations  
Ab initio calculations use approximations of the Schrödinger equation to simulate data in silico 
without the input of experimental data.112 For example, absorption phenomena can be deducted 
from this description of a physical system over time. As the Schrödinger equation itself can only 
be solved for a system consisting of one hydrogen atom, approximations are used. This was 
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successfully implemented by Parr, Craig, and Ross in 1950 for benzene.113 Nowadays, density 
functional theory (DFT), which is based on the calculation of molecular orbitals, is most commonly 
used. For ECD, as excited states are necessary for the calculation of electronic absorption, time-
dependent DFT (TDDFT) is used. The specific method used for a calculation is described by the 
“Level of Theory” which is defined by the functional and the basis set. While the functional 
describes the correlation between electrons, the basis set describes the electron wave function. 
A common level of theory is the B3LYP functional (Becke, 3-parameter Lee-Young-Parr) used in 
combination with the basis set 6-31G(d,p). For more accuracy, optimized functionals like CAM-
B3LYP and larger basis sets like 6-31G+(3df,2p) including more orbitals can be used. As this 
usually comes with significantly higher computational cost, a good balance between accuracy and 
computational cost needs to be found. These level of theories are accessible, for example, with 
Gaussian.114 
 Ab initio calculations of ECD spectra 
Ab initio calculations allow for a convenient interpretation of ECD spectra. Instead of interpreting 
spectra of new molecules using empirical rules or by comparing them to spectra of compounds 
with known ACs, they can be compared to spectra generated individually for all stereoisomers. 
This extends the scope of ECD to include also unknown compounds. A comprehensive review on 
calculating ECD spectra was published in 2016 by Gennaro Pescitelli and Torsten Bruhn.115 It 
outlines the calculation procedure and gives a guide to a good computational practice. As ab initio 
calculations can only predict the ECD spectrum of one conformation at a time, ideally, all stable 
conformers should be calculated. Usually, a conformational search in a force field, either through 
molecular dynamics or molecular modeling, is used to identify the conformers representing energy 
minima. Then, for each selected conformer, geometry and frequencies are optimized in a first ab 
initio calculation at the respective level of theory. With the resulting structure, the excited states 
are calculated using TDDFT, which simulates the absorption of light by the electrons. This 
calculation yields the electronic dipole 𝜇𝜇𝑖𝑖𝑖𝑖 and the magnetic transition dipole 𝑚𝑚��⃗ 𝑖𝑖𝑖𝑖 together as 
rotational strength dependent on the wavelength. On its own, a line spectrum is generated, which 
needs to be fitted with Gaussian or Laurentzian curves to be comparable to the experimental 
spectrum. Finally, the calculated ECD spectra of each conformer are combined based on the 





 Limitations of ECD 
Although ECD is a very useful technique, its applicability is limited in molecules: 
- That lack a chromophore 
- For which the relative configuration is not known 
- For which no stable conformers in solution can be identified 
If a suitable chromophore is present and a ECD spectrum was recorded, the approach depends 
on the knowledge of the relative configuration. The different possibilities were outlined for cases 
(A)-(D) above (Figure 11). In case (A), where the full relative configuration was deduced from 
NMR, only one of the enantiomers needs to be calculated. If the relative configuration is correct 
and the ab initio calculation was done correctly, either the calculated spectrum or its mirror image 
can be overlaid with the experimental data. In case (B), one configuration from each enantiomer 
pair needs to be calculated. Ideally, one of them, or their mirror image, fits the experimental data 
and the respective AC can be assigned. If the undefined stereo center does not significantly impact 
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the calculated ECD spectrum, only the rest of the molecule can be assigned. This gives a partial 
AC and the remaining stereo center needs to be assigned in another fashion. Case (C) also needs 
the calculation of one configuration from each pair of possible enantiomers. If only one of the 
calculated spectra or their mirror image fits, the AC can be assigned. Otherwise, it can only be 
used to possibly exclude ACs and other methods are needed to complete the assignment. Due to 
the flexibility in case (D), no information about the relative configuration is available and the 
conformational search is more challenging. Thus, even if one configuration from each pair of 
enantiomers is calculated, it is often not possible to assign the AC. In any case, before an AC is 
finally assigned by ECD, the result should be checked self-critically to avoid misassignments. 
Some questions to address for that matter are: 
- Was the conformational search appropriate for the molecule? 
- Was the level of theory appropriate for the molecule? 
- Was the fit of the line-spectrum appropriate? 
- Was there a bias in the spectra comparison? 
If a compound lacks a chromophore, ECD is not suited to solve the AC. A shift into the infrared 
region of the electromagnetic spectrum, however, could do the trick. 
2.2.3. Vibrational Circular Dichroism (VCD) 
Vibrational interactions in the infrared range can be used to study absolute configurations of 
organic molecules. For this, over the last five decades, Raman optical activity (ROA) and 
vibrational circular dichroism (VCD) have been developed to measure vibrational optical activity 
(VOA).116 As VCD is more commonly used, it is the main topic in this chapter.  
 History of VCD 
The principal challenge in VCD is the signal strength, which is around four magnitudes smaller 
than that from ECD.117 Thus, although the effect was predicted earlier, first VCD effects were only 
measured in the 1970s.118, 119 The second challenge is the interpretation of VCD spectra, which 
relies almost exclusively on quantum mechanical calculations. These most often use the Born-
Oppenheimer approximation for the Schrödinger equation to calculate electrons and nuclei 
separately. For VCD however, as the movement of the nucleus defines a vibration the electronic 
contribution to the magnetic transition cannot be calculated.120 Thus, calculations using only the 
Born-Oppenheimer approximation were not suited as comprehensive descriptions of VCD 
phenomena.117, 121 An approach to calculate VCD spectra ab initio became only available around 
ten years after the first measurements.122 After further development in the 1990s towards routine 
DFT calculations, commercially available FT-VCD instruments, and the possibility to measure 
liquid samples, VCD became more broadly applicable to the study of ACs of organic 
compounds.123, 120 As of today, its application in the field of natural product research field is still 
underexplored. Possible reasons could be the necessary sample quantity (>3 mg), the lack of 
knowledge about the method, and the lack of available instrumentation.  
 Theory of VCD 
VCD measures the CD effect in the infrared region between 500 and 4000 cm-1. Like in ECD, the 
sign of the CD effect is opposite for enantiomers and its amplitude proportional to the rotational 
strength. The rotational strength in turn originates from the electric and magnetic dipole transition 
moments.124 As more bands can be used than in ECD, the method is very sensitive to 
conformational changes and can be used to determine configurations and conformations of a 
molecule. This potentially yields more information, but also makes the interpretation of VCD 
spectra a challenging task. 
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 Empirical rules 
Due to its late introduction, the only relatively recent advent of commercial VCD instruments, and 
the inherent complexity of VCD spectra, empirical rules comparable to the ones for ECD have not 
been established. An approach to understand VCD spectra in more detail is the visualization of 
the vibrational transition current density (VTCD).125 This method, however, needs itself extensive 
computational effort, which, so far, is only feasible for smaller systems (Figure 15).126 Thus, the 
interpretation of experimental VCD spectra relies almost entirely on the comparison to ab initio 
calculated spectra. 
 
Figure 15. 3D representation of the VTCD vector field for the 4th normal modes of d2ox by means of a streamline 
object. The red arrows depict the charge-weighted nuclear displacement vector for the normal mode. 
Republished with permission of Royal Society of Chemistry, from Fusè et al., 2019126; permission conveyed 
through Copyright Clearance Center, Inc. 
 Ab initio calculation of VCD spectra 
Different methods like DFT and gauge-invariant atomic orbitals (GIAO) have been adapted for the 
ab initio calculation of VCD spectra. Between those, the B3LYP functional was found to be a 
suitable compromise between accuracy and computational cost.127 In the ab initio calculation itself, 
the vibrations of the molecule as well as their dipole strengths and rotational strengths are 
calculated. As this does not need the calculation of excited states, it is computationally less 
demanding compared to ECD. Nevertheless, as VCD spectra are highly sensitive to 
configurational and conformational changes, a rigorous conformational search is needed as a 




Figure 16. Ab initio calculated transitional rotational strengths of (4S,5S,6S,7S)-seco-tanapartholide displayed 
as line spectrum with a Lorentzian fit using a bandwidth of 7 cm-1. (from VCDSpecTech128) 
When all relevant global minima are found, dipole and rotational strengths of bands in IR/VCD are 
calculated ab initio with their respective energies. The energies correspond to the wavenumbers, 
but are only consistent inside the calculation. Thus, the calculated spectra need to be scaled to 
the experimental ones prior to comparison. In the end, for comparison to measured data, band 
broadening is simulated with either a Lorentzian or a Gaussian fit as shown in Figure 16. The 
bandwidth should reflect the band broadening observed in the corresponding experimental 
spectrum. 
 Interpretation of VCD spectra 
 
Figure 17. (A) Comparison of the experimental VCD spectrum of (4S,5S,6S,7S)-seco-tanapartholide with its 
calculated spectrum plotted at x-axis scaling factors (sf.) 0.925, 0.975, 1.025, and 1.075. (B) SimVCD and SimVA 
indices plotted over the x-axis scaling factor comparing the experimental to the calculated VCD spectra shown 
in (A).  
VCD spectra contain significantly more bands than ECD spectra (Figure 17A). To interpret the 
multitude of bands, particularly in the crowded fingerprinting region between 1400 and 900 cm-1 
needs special care. Thus, in order to avoid human bias in this comparison, algorithms comparing 
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the similarity between spectra have been developed.129, 128 One example is the calculation of 
similarity indices from the overlap between calculated and experimental spectra. This results in 
SimVA for the comparison of IR spectra and SimVCD for the comparison of VCD spectra (Figure 
17B). SimVA and SimVCD can assume values from -1 to 1 where “1” corresponds to a perfect fit 
of the spectra and “-1” to a perfect fit to the opposite enantiomer. If SimVCD ≈ 0, the spectra do 
not correspond at all. In Figure 17B, the ideal overlap between calculated and measured VCD 
spectrum is found at a scaling factor of 0.98. This should also be in agreement with a maximum 
in SimVA. As the bands in the corresponding IR spectrum are usually broader compared to the 
VCD spectrum, maxima in SimVA are less pronounced. This shows the influence of the bandwidth 
used to fit the spectrum on the values SimVA and SimVCD. To avoid false attributions, the fitted 
bandwidth should be similar to the measured bands. As this is individual for each measured 
spectrum, the values of SimVA and SimVCD for all diasteromers can only be used as relative 
values and no absolute threshold can be defined. For this, the similarity plots of SimVA and 
SimVCD against the x-axis scaling factor are compared between all possible diastereomers. While 
SimVA assumes similar values between different calculated configurations, the configuration with 
the highest SimVCD value is the most likely fit for the correct absolute configuration. This should 
be verified by a visual comparison of characteristic bands at the respective x-axis scaling factor. 
If both, computational and visual comparison, show significant differences and are consistent, the 
AC can be assigned with good confidence.  
2.2.4. Strategies towards an Absolute Configuration 
Unfortunately, non-destructive spectroscopic methods like OR, ECD, and VCD are not applicable 
in all cases. Thus, other methods have to be considered as well and are described in the following. 
 Total Synthesis 
A historically important method to determine the absolute configuration is the total synthesis of 
a suspected structure or all possible diastereomers for comparison. Then, chiral properties like 
OR, ECD, or others can be compared to the isolated natural product, thereby identifying the 
absolute configuration. To synthesize natural products with defined absolute configurations, 
precursors of known chirality and stereoselective reactions are used. A famous example is the 
synthesis of the antimalarial drug artemisinin in 1982.130 Total synthesis ideally gives the absolute 
configuration together with the possibility of synthesizing close derivatives of lead structures to 
explore structural features responsible for the activity. However, it is a very time consuming and 
in some cases near impossible task to synthesize natural products131. Therefore, not all 
compounds can or should be synthesized, as is outlined nicely by a comment from Philip Ball in 
2015.132  
 Defined Degradation 
One faster and often easier method is the defined degradation of the molecule. There, known 
reactions are employed to break down the molecule into simpler fragments. Those are then 
compared to already known molecules or can be synthesized in an easier fashion133. One 
example of this is the original identification of hazaleanins A and B isolated from Fagara rhetza 
in 1992.134 In this work, some compounds from T. asiatica were hydrolyzed to identify the sugars 
and the configurations of the aglycons. This approach can take very different forms depending 
on the compound, but is usually limited by the quantities available for experiments. While 
hydrolyzed sugars can be identified from minute amounts via GCMS analysis, most other 
reactions require larger amounts to identify the products via NMR or other means.  
 X ray Crystallography 
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Another way to determine a molecules relative and, under the right conditions, absolute 
configuration is X ray diffraction on a suitable single crystal of the compound. For this, it is 
mounted on the tip of a needle in the diffractometer and monochromatic X rays are shot at it in a 
very concentrated parallel beam. The X-rays interact with the electrons in the ordered crystal 
lattice and get diffracted. The observed diffraction pattern on the detector are discrete dots of 
varying intensity, which correspond to the crystal lattice. This measurement is repeated at different 
angles of the crystal and taken together, the three dimensional crystal lattice can be defined. This 
can be compared to combining pictures of an object from all sides into a three-dimensional object, 
for example in a computer game.135 However, X ray diffraction patterns are not direct images of 
the molecules. They arise from constructive interferences between X rays diffracted from the 
crystal planes. Thus, only interferences that follow Bragg’s law136 are observed: 
𝑛𝑛𝑛𝑛 = 2𝑚𝑚 𝑠𝑠𝑠𝑠𝑛𝑛𝜃𝜃  
It depends on the wavelength λ, the distance between the planes d, the angle of the diffracted ray 
θ, and the order of the diffraction n. As wavelength and angle of the diffracted rays are known, the 
distance between the planes can be calculated. Through Fourier transformation, the information 
of all measurements is combined into a three-dimensional model of the electron cloud of the 
molecule. The atoms are then fit into the cloud leading to the three-dimensional model of the 
crystallized molecule or its enantiomer. This is hindered by the “phase problem”, as only the 
intensity but not the phase of the diffracted light is measured.137 Thus, the phase is initially guessed 
and subsequently optimized. While this usually works well for small molecules, protein structures 
require more effort.138 In any case, however, whether this can be solved, and which resolution of 
the structure is reached depends on the quality of the acquired data. Apart from the type of X ray 
radiation used, the data quality also influences, if the absolute configuration can be identified. 
Therefore, if a crystal is available, X ray diffraction is a reliable method to determine at least the 
relative, and ideally the absolute configuration of a compound. Yet, crystallizing some compounds, 
especially with low sample quantities, can prove rather difficult. This limits the application of single 
crystal X ray diffraction significantly. 
 Mosher ester analysis 
Mosher ester analysis is a derivatization method to determine the absolute configuration of 
secondary alcohols or amines.139 In this method, a compound is esterified with both enantiomers 
of Mosher’s acid separately (Figure 18) leading to two diastereomeric Mosher’s esters140.  
 
Figure 18. Mosher’s acids. 
Differences in 1H NMR or 19F NMR are then used to identify the absolute configuration at that 
stereogenic center. Here, the focus will be on 1H NMR, as this is more commonly used. The 
chemical shifts (δR) of the protons surrounding the chiral alcohol (α) in the ester with the (R)-
Mosher’s acid are subtracted from the ones (δS) in the (S)-Mosher’s ester. To interpret these 















Figure 19. Visualization of the plane through a (R)-Mosher’s ester (modified from Ohtani et al.140) 
For the main conformer present in the ester, a theoretical plane through the CF3-group, the ester 
bond and the chiral carbon Cα is constructed (Figure 19). Protons belonging to R1 in Figure 19 are 
on the same side of this plane as the benzene ring. Thus, their chemical shifts in the ester with 
the (R)-Mosher’s acid are found more upfield in the 1H-spectrum compared to the ester with the 
(S)-Mosher’s acid. After subtraction (δR - δS), the sign for protons belonging to R1 will be negative, 
while the sign for protons belonging to R2 will be positive. This allows the determination of the 
absolute configuration. The limitation of this method is the dependence on the ideal configuration. 
In most cases, this conformation is the dominant one. However, if this conformation is sterically 
impaired, the method will lead to inconclusive results.140 The derivatization reaction has been 
optimized over time since its first use, for example by using the acid chloride.143 Another limitation 
is the amount needed for the derivatization reaction as it needs to be performed with both Mosher 
acids and the product needs to be enough for 1H NMR analysis. This excludes Mosher ester 
analysis as a possibility in case of limited amounts available. 
 Other methods 
Apart from chiroptical methods, total synthesis, defined degradation, Xray diffraction, and the 
Mosher ester analysis there are several other notable methods for relative or absolute 
configurational assignment. Most are related to the ones above and essentially share some of the 
characteristics but are less used because of availability or practicability. Nevertheless, in specific 
cases, they can provide answers to questions outside the scope of standard methods. Thus, they 
should be shortly mentioned in the following.  
Complementary to total synthetic approaches, there are different kinds of semi-synthetic 
approaches. Some of them use natural products as starting materials for their chemical synthesis 
whereas others feed synthetically modified natural products to either isolated biosynthetic 
enzymes, cell extracts or whole cells to achieve products similar to the natural compound.144 
Related to Xray diffraction, Xray powder diffraction has been developed in the last three decades 
for crystallographic analyses without the need of a well grown crystal.145, 146 However, as the 
angles are unknown and overlap in this method, it is used more commonly used to identify known 
substances by their fingerprint.147 Analogously to Mosher’s ester method, other derivatization 
methods for NMR have been developed to identify absolute configurations, also involving other 
functional groups.148, 149 Other derivatization reactions aim at making compounds accessible to 
ECD or VCD. Another modern method to determine the absolute configuration of a molecule is 
the Coulomb explosion method. Opposed to all other methods, it is a more direct method, which 
visualizes the explosion shadow of a molecule. Unfortunately, this method is, so far, too limited in 
terms of molecule complexity to be of use for most natural products.150 
Overall, a spectrum of methods is available to determine the AC of a compound. In the end the 
decision, which ones to use for a given molecule depends primarily on the availability of 
chromophores, sample, time, and resources. Nevertheless, given nowadays possibilities and 
necessities for characterizing natural products, it should be at least attempted for any given 
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2.3. Artemisia argyi  
2.3.1. Traditional uses 
Artemisia argyi, commonly known as “wormwood” or “Chinese mugwort”, is found in China, Korea 
and neighboring countries.151 It is commercially grown in China with a long history in Quichun 
County (Hubei Province), from which its name (Qi ai) in Traditional Chinese Medicine (TCM) is 
derived. The herb or the leaves are used in TCM for various indications including abnormal 
menstruation, hematemesis, pregnancy bleeding, chronic bronchitis, bronchial asthma.152 The 
triturated leaves are called “moxa” and are used for “moxibustion”. For moxibustion therapy, the 
drug is burnt in the form of cones or “cigars”. This is done on, or close to, the skin to warm 
acupoints treating a wide range of illnesses.153, 154 Also, essential oils from the plant are used for 
different therapeutic applications, especially in the treatment of respiratory diseases.153, 155  
2.3.2. Bioactivity 
Bioactivities of A. argyi have been studied extensively in the past. Numerous studies have been 
published in Chinese journals describing effects of A. argyi extracts, preparations and applications. 
Examples are an in vivo study of preparations from A. argyi against chronic renal failure156 and 
studies on the effects of moxibustion on rheumatoid arthritis or immune modulation in rats.157, 158 
Adjacent research on A. argyi addresses topics like constituents found in endophytic fungi from 
its roots159 or the study of different bioactive water-soluble polysaccharides isolated from A. 
argyi.160-162 Thus, to limit the scope of this work to a reasonable size, only studies in English dealing 
with extracts of or compounds isolated from A. argyi have been included. 
The least common reports of activities from A. argyi are an insecticidal activity of the EtOH 
extract163 and antimicrobial activity of its essential oils.164 More commonly, antineoplastic 
effects were observed for A. argyi in several instances. This was found to be mediated through 
NF-κB inhibition and cytotoxicity in human gastric adenocarcinoma cells by an extract with 70% 
EtOH. From this, several active guaianolide sesquiterpene lactones were isolated.165 In another 
study, inhibition of CCRF-CEM leukemia cells was reported. The active constituents scopoletin 
und isoscopoletin also inhibit a multi-drug resistant sub line of leukemia cells. This indicates a 
significantly different mechanism compared to established cytostatic drugs like doxorubicin or 
vincristine.166 For Human Papillomavirus (HPV) 16, an inhibition of the oncoproteins E6 and E7 by 
an A. argyi MeOH extract is reported, which is attributed to jaceosidin as the active constituent.167 
Anti-inflammatory activity in different settings is the most frequently mentioned activity of A. 
argyi extracts. Two studies used extracts with 70% EtOH, which were orally administered to mice 
or rats in vivo. Both found reduced inhibition markers, one in sensitized skin on mice, and the other 
in the gastric mucosa of rats.168, 169 Another study found reduced inflammation after oral application 
of a MeOH extract in ovalbumin-induced asthmatic mice.170 The essential oil from A. argyi was 
described to suppress an inflammatory response in vitro in LPS-induced RAW264.7 
macrophages.171 
The anti-inflammatory effect of the essential oil was found to be mediated by the inhibition of 
JAK/STAT1/3.171 For extracts from A. argyi, activity was previously attributed to polyphenols as it 
was traced to enriched fractions.172 However, only the flavone jaceosidin was described to inhibit 
nitric oxide (NO) production.173 All other compounds isolated from A. argyi related to anti-
inflammatory or immunosuppressant activities were sesquiterpene lactones or their dimers.174 As 
mechanisms for these compounds, NF-κB inhibition and inhibition of NO production were 
described.175-178, 165 With this large potential in mind, the goal of this work was to identify and 
characterize potential immunosuppressant lead compounds from an A. argyi extract. 
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2.3.3. Constituents of Artemisia argyi 
The transcriptome of A. argyi has been sequenced and a wide range of genes involved in the 
synthesis of secondary metabolites was identified. From this study, the presence of several 
alkaloid classes, different flavonoids, phenolic compounds and a wide range of terpenoids could 
be expected.179 To compare this to the published compounds from A. argyi, the following list of 
publications was compiled (Table 1).  
Table 1. List of publications reporting compounds isolated from A. argyi. Compound classes are described 
only considering the scaffold. Most sesquiterpenes (guaianolides, eudesmanolides, germacranolides) are 
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From this, the most common compound classes found in A. argyi are flavonoids and 
sesquiterpenes. Most isolated sesquiterpenes are either guaiane- or eudesmane-type 
sesquiterpene lactones. As monoterpenes define much of its olfactory impression, they are almost 
exclusively found in the essential oil of A. argyi.197 The only exception to this is the presence of 
some monoterpenes fused with one or two guaiane-type sesquiterpene lactones resulting in the 
unusual structures of isoartemisolide175 and artemargyinolide A194 (Figure 20).  
Other unusual structures originate from aldol condensations of guaiane-type sesquiterpene 
lactones with diseco-guaianolides (artemisianes A-D).190 In addition, sesquiterpene lactone dimers 
connected by an ester bond are found. These exist as combination of guaianolides with 
eudesmanolides (artemillinin A),175 guaianolides with seco-guaianolides (artemisiane A)178, and 
diseco- with seco-guaianolides (artemisiane C).178 Examples of different terpene (hetero-)dimers 
isolated from A. argyi are shown in Figure 20. A close to comprehensive review of natural 
disesquiterpenoids was done recently by Ying-Hong Ma and coworkers.198  
When comparing this list to the transcriptome,179 the overall dominance of terpenoid structures in 
A. argyi is no surprise. Triterpenes, coumarins, phenylpropanoids, and flavonoids are expected to 
be found. However, compared to the transcriptome alkaloids are underrepresented among the 
isolated compounds. Only one simple indole alkaloid (1-H-indole-3-carboxylic acid) is described 
so far even though genes for the synthesis of isoquinoline, tropane, piperidine and pyridine 
alkaloids are present in the transcriptome of A. argyi. In any case, the broad diversity of terpenes 




Figure 20. Examples of fused sesquiterpene lactones isolated from A. argyi. 
2.3.4. Absolute configurations of sesquiterpene lactones 
Sesquiterpene lactones are so far the most frequently isolated compounds from A. argyi. The 
complexity and diversity of their structures features them as a worthwhile group of compounds to 
work on.199 Most sesquiterpene lactones contain multiple stereogenic centers, in case of 
artemargyinolide A, up to 15.194 This warrants suitable strategies for resolving the configuration of 
these molecules. 
 Relative Configuration 
Most sesquiterpene lactones from A. argyi belong to groups (A) or (B) (Figure 11) as the ring 
structure of guaiane- or eudesmane-type sequiterpene lactones provides a relatively rigid scaffold 











































































 Absolute configuration 
For the identification of absolute configurations of sesquiterpene lactones from A. argyi ECD is 
commonly used.176, 178, 195 This leads to the proposal of empirical rules for many cases of smaller 
compounds earlier.200 Nowadays, the experimental ECD spectra are usually compared to ab initio 
calculated spectra of possible stereoisomers, for example calculated with the B3LYP functional in 
combination with either 6-31G or 6-311G as basis set.175, 176, 190, 106, 177, 178, 195, 165 This procedure 
works in the case of group (A) and in the case of group (B), if the non-defined stereogenic centers 
do not affect the chromophore. Thus, for group (B), all possible diastereomers need to be 
calculated. This way, the influence of the stereogenic centers in question can be determined.  
Most chromophores present in sesquiterpene lactones are trans-enones. Thus, only two 
transitions, a medium 𝜋𝜋 → 𝜋𝜋∗ transition around 250 nm as well as a weak 𝑛𝑛 → 𝜋𝜋∗-transition around 
330 nm, are available for interpretation. With CD in the UV region (190 – 600 nm), this usually 
permits the distinction of enantiomers but not the differentiation between a multitude of possible 
stereoisomers. If enough material (ca. 3 mg) is available, VCD can be used on sesquiterpene 
lactones with good chances of success.  
In conclusion, circular dichroism is very useful for the assignment of absolute configurations to 
sesquiterpene lactones. The rigidity of most ring systems allows a reliable calculation of ab initio 
spectra for comparison to experimental data. This is true for ECD as well as for VCD. However, 
both methods need to be applied with caution to avoid misassignments. But, especially in 
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2.4. Toddalia asiatica 
2.4.1. Traditional uses 
Toddalia asiatica is a plant distributed in most parts of Asia and Africa.201 It is widely used in both 
African and Asian traditional medicine practice. Judging from a survey in Uganda, Tanzania and 
Kenya, all parts of the plant are used with the root bark being the most common. Most often, it is 
used against stomach problems, followed by malaria and coughs as indications.202 Surveys in 
Kenya and Zimbabwe corroborate the use of T. asiatica as traditional treatment for malaria.203, 204 
These and more indications have been described for the use in Indian Traditional Medicine.205 In 
TCM, the roots of T. asiatica are known under the name “Fei Long Zhang Xue”, but are not 
commonly used.206 
2.4.2. Bioactivity 
Although the treatment of stomach problems is common in practice, most available studies focus 
on antiplasmodial or antimalarial activity. Several screenings among traditionally used plants 
for antiplasmodial activity found T. asiatica extracts to be active in vitro.207, 208 This was also 
confirmed in in vivo xenograft models.209 Apart from that, antidiabetic and antihyperlipidemic 
effects of the leaf extract were observed in vivo.210, 211 Also, analgesic and immunosuppressive 
effects were observed in vivo.212, 213 Related to immunosuppression, effects on collagen-induced 
arthritis in vivo are described. 214 In vitro, spasmolytic activity is described in one study.215 In the 
process of understanding these bioactivities, a range of compounds was isolated. 
2.4.3. Constituents of Toddalia asiatica 
Several studies into compounds from T. asiatica were performed. The results from an extensive 
literature survey are summarized in Table 2. 
Table 2. List of publications reporting compounds isolated from T. asiatica. Compound classes are described 
only considering the scaffold. 








Sharma, 1980216 -  Coumarin 
Dimeric coumarins 
2 (1 new) Roots, 
95% EtOH 
Sharma, 1981217 -  Coumarins 5 (2 new) Roots, 
95% EtOH 
Sharma, 1982218 -  benzophenanthridines 
triterpenes 
7 (1 new) Roots, 
95% EtOH 
Ishii, 1983219 -  coumarin 1 -  
Ishii, 1991220 -  Coumarin-quinolone-
dimer 
1 new Root bark 
Ishii, 1992221 -  coumarins 5 Root bark 












Ishii, 1993223 -  Coumarin dimer 1  
Gakunju, 1995224 Antimalarial activity Benzophenanthrene 
(nitidine) 
1 Root bark, 
CH2Cl2 
Tsai, 1997225 -  Dimeric coumarin 
Cyclohexyl amides 
benzophenanthrenes 
7 (3 new) Roots, 
MeOH 








Antiplasmodial Coumarin 1 Roots, 
EtOAc 
Iwasaki, 2006228 Tumor selective 
cytotoxicity 
dihydronitidine 1 Stem, 50% 
EtOH 
Iwasaki, 2010229 Tumor selective 
cytotoxicity 




antimicrobial coumarins 2 Leaves, 
EtOAca 
Hu, 2014231 Cytotoxic, 
antimicrobial, 
antifungal 






21 (7 new) Roots, 
95% EtOH 
Phatchana, 2014233 cytotoxicity Coumarins 
Phenolics 
Coumarin dimer 
16 Stem bark, 
EtOAcb 




coumarins 3 Stems, 
MeOH 
Hu, 2015235 -  Amides 4 (3 new) Root, 80% 
EtOH 




coumarins 1 Stems, 
MeOH 
















Li, 2017238 -  Coumarins 
phenolics 
42 (9 new) Stems, 
95% EtOH  
Kumagai, 2018239 Anti-inflammatory Coumarins 2 Stems, 
MeOH 






Concluding from this, coumarins are most often isolated from T. asiatica followed by 
benzophenthrene alkaloids. Typical are coumarins with a 5,7-methoxy substitution pattern as well 
as nitidine and related alkaloids.229, 232 Nitidine was also concluded to be responsible, at least in 
part, for the antimalarial activity of T. asiatica.241 Other alkaloids like 8-methoxynorchelerythrine 
and toddayanis were also found to have antimalarial effects.237 Significantly lower activity has 
been observed for a coumarin from T. asiatica.227 For the possible use of compounds from T. 
asiatica, the absolute configurations of the compounds are needed. While most isolated 
compounds from T. asiatica do not possess stereogenic centers, coumarins and glycosylated 
coumarins need to be studied in more detail. 
2.4.4. Absolute configurations of glycosylated coumarins 
The representative coumarin from T. asiatica, toddalolactone, has only one stereogenic center, 
which can be assigned using OR, ECD or NMR with Eu(hfc)3.221 For glycosylated coumarins, six 
stereogenic centers need to be addressed. Thus, further steps are required to determine the 
absolute configurations of glycosylated coumarins.  
 
Figure 21. Scheme showing exemplary derivatization steps for GCMS analysis of a coumarin glycoside.  
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First, the identity of the sugar is determined. Using 13C NMR and NOE data, the relative 
configuration of the sugar moiety can be determined in good confidence. Secondly, for an  
assignment of the sugar, GCMS can be used.242 For this, a small amount of the compound is 
hydrolyzed and the sugars are obtained from the aqueous phase. Exemplary derivatization steps 
necessary for GCMS analysis of sugars are outlined in Figure 21. It is important to note that 
references of all possible sugars should be run with the same method as the sample. This way, 
false positive results from similar retention times can be avoided. The organic phase of the 
hydrolyzed sample can be used to identify the absolute configuration of the aglycone. It is however 
necessary to double check the resulting structure with NMR, as changes can occur through the 
hydrolysis conditions. If this is not the case, the absolute configuration can be determined through 
enantioselective HPLC, ECD, OR, or by using NMR with a shift reagent like Eu(hfc)3. 
Another option, as soon as the identity of the sugar is known, is ab initio calculation of NMR data 
for the full molecule as by then only diastereoisomers need to be distinguished. For this, all 
possible stereoisomers are calculated ab initio and the 13C and 1H NMR data is compared to the 
experimental data using the DP4 probability algorithm.243 More recently, the precision of this 
method was improved and extended to the use of unscaled data resulting in the DP4+ probability 
algorithm.244 
In conclusion, several suitable methods are well established to identify the absolute configurations 
of glycosylated coumarins. In the end, the choice depends mostly on the amount of compound 
available. Especially the spectroscopic analysis of the hydrolyzed aglycone is only feasible, if 
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ABSTRACT: A library of extracts from plants used in
Chinese Traditional Medicine was screened for inhibition of
T lymphocyte proliferation. An ethyl acetate extract from
aerial parts of Artemisia argyi showed promising activity and
was submitted to HPLC-based activity profiling to track the
active compounds. From the most active time window, three
guaianolides (1, 2, and 5) and two seco-tanapartholides (3 and
4) were identified and, in a less active time window, five new
sesquiterpene lactones (8−11, 17), along with six known
sesquiterpene lactones and two known flavonoids. The absolute configurations of compounds 1, 2, 5−10, 13−15, 17, and 18
were established by comparison of experimental with calculated electronic circular dichroism (ECD) spectra. For seco-
tanapartholides B (3) and A (4), ECD yielded ambiguous results, and their absolute configurations were determined by
comparing experimental and calculated vibrational circular dichroism (VCD) spectra. Compounds 1−5 showed significant,
noncytotoxic inhibition of T lymphocyte proliferation, with IC50 values between 1.0 and 3.7 μM.
Immunemalfunction is characterized by the body’s inability toadequately differentiate between non-self and self-antigen
structures. In immune deficiencies, the immune system fails to
identify and eliminate pathogens, while in autoimmune diseases
it fails to recognize endogenous cells from one’s self.1
Autoimmune diseases such as type I diabetes, rheumatoid
arthritis, or multiple sclerosis are characterized by an increased T
cell proliferation.2 Presently, no causal therapies are available,
and autoimmune diseases are typically treated symptomatically
with immunosuppressive drugs.3 As these substances often show
severe side effects, the search for compounds with newmodes of
action and fewer adverse effects is warranted. Natural products
have a successful track record for providing immunosuppressive
compounds with unique modes of action, such as cyclosporine
A, tacrolimus, rapamycin, mycophenolic acid, and myriocin.4
Compared to actinomycetes and fungi, higher plants have been
much less investigated as a source for immunosuppressive lead
compounds. In an effort to explore the potential of plant
secondary metabolites, a focused library of extracts from plants
used in Traditional Chinese Medicine (TCM) was screened for
their ability to inhibit T cell proliferation in vitro.
■ RESULTS AND DISCUSSION
Compound Isolation and Structure Elucidation. A
library of 435 extracts was screened at a single concentration of
20 μg/mL for the ability to inhibit T lymphocyte proliferation.5
A total of 40 extracts inhibited proliferation by ≥70% without
exhibiting cytotoxicity at this concentration. This was verified by
annexin V and propidium iodide (PI) double staining. These
extracts were then tested at four concentrations ranging from 3
to 100 μg/mL. The ethyl acetate extract from aerial parts of
Artemisia argyi Levl. et Vant. (Asteraceae) exhibited significant
activity (IC50 16.2 μg/mL) and was submitted to HPLC-based
activity profiling.6,7 Microfractions were collected and tested at
four different dilutions, and a theoretical IC50 value was
calculated and normalized to 100% (residual proliferation) as
a measure of activity.
Pronounced inhibition of T cell proliferation was found in the
time window of 10−12 min, and moderate activity in the
window of 16−20 min (Figure 1). Preparative isolation of
compounds 1−18 for structure elucidation and biological
testing was achieved by a combination of open column
chromatography on silica gel and semipreparative and
preparative HPLC on C18 and cyano columns.
The UV spectra of compounds 1−11, 13−15, and 18 showed
absorption maxima between 200 and 220 nm, while compounds
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12 and 16 exhibited two UV maxima between 270 and 275 nm
and 340−345 nm indicative of flavones.8
Compounds 6 and 7 were identified as the known
eudesmanolide sesquiterpene lactones eudesmaafraglaucolide
(6)9 and santamarin (7).10 The absolute configuration of 6 has
not been established up to now and was determined by
electronic circular dichroism (ECD) in comparison to the
calculated spectrum as (1R,3S,5S,6R,10R) (Figure S42,
Supporting Information).
3α,4α-Epoxyrupicoline D (13) and E (14) were isolated as a
mixture and identified by comparison of their NMR spectra with
published data (Table S5, ORTEP diagram in Figure S68,
Supporting Information).11 Compound 14 crystallized from the
mixture, but the X-ray diffraction data were not of sufficient
quality (Flack parameter (0.10(19)) to determine the absolute
configuration. An ECD spectrum was recorded for the mixture
and compared with the corresponding calculated spectra
(Figure S67, Supporting Information). Thus, the absolute
configuration of the scaffold in 13 and 14 was established as
(1S,3R,4S,5R,6S,7R,8S). Given the lack of a suitable chromo-
phore in the vicinity of C-2′, the absolute configuration of this
stereocenter in 13 could not be determined by ECD.
Arteglasin A (15) was isolated as white crystals and identified
by X-ray diffraction analysis (Table S7, ORTEP diagram in
Figure S70, Supporting Information). NMR data were in good
agreement with literature values.12 The absolute configuration
of 15 was determined as (3R,4S,5S,6S,7R,8S) (Flack parameter
= 0.06 (15)) and confirmed by comparison of experimental and
calculated ECD spectra (Figure S69, Supporting Information).
The flavones jaceosidin (12) and eupatilin (16) had been
previously reported from Artemisia argyi.13
The NMR data of 1, 2, and 5 indicated that they are
stereoisomers possessing a planar structure corresponding to
that of canin (1).14 Two of themwere identified as canin (1) and
artecanin (5) (Figure 2).15
The ECD spectrum of 1 exhibited a strong positive Cotton
effect (CE) at 200 nm and a broad negative CE at 250 nm
(Figure 3). The calculated spectrum for (1R)-canin was in good
agreement with the experimental data obtained. An independent
confirmation of the absolute configuration was obtained from
the vibrational circular dichroism (VCD) spectrum that was
compared to the calculated spectra of 1, 2, and 5 (at the B3LYP/
6-31+G(d,p) level of theory) (Figure 4). For an unbiased
comparison of VCD spectra, similarity indices SimVA (for
vibrational absorption) and SimVCD were calculated with VCD
SpecTech.16 Similarity indices calculated for scaling factors
between 0.939 and 1.009 are shown in Figure 4. The maximal
value of SimVCD was determined for (1R)-canin (1) at a
wavenumber scale factor of 0.9865, which was used to plot the
calculated spectra. A visual inspection of the main bands at 1772
Figure 1. HPLC-ESIMS (base peak chromatogram) and activity profile (gray bars) of a EtOAc extract of A. argyi. Residual proliferation levels of T
lymphocytes are expressed in % on inoculation with 1 min HPLC microfractions. Bold numbers in the chromatogram refer to compounds 1−18.
Chart 1
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(−), 1260 (+), 1205 (−), and 1150 (−) cm−1 in the VCD
confirmed the assignment of the absolute configuration as (1R)-
canin (1).
The absolute configuration of 5 was determined as
(1S,2R,3S,4R,5S,6S,7S,10R), corresponding to (1S)-artecanin,
by comparison of the experimental and calculated ECD spectra
(Figure S38, Supporting Information). Additionally, the VCD
spectrum of 5 was measured in DMSO-d6 and compared to the
computed spectra of compounds 1, 2, and 5 (Figure S40,
Supporting Information). Although the relative configuration of
5 was clearly established from the NOESY correlations, the
experimental VCD spectrum showed the best fit with the
calculated spectrum of 1 when an automated comparison was
used. Visual comparison of the experimental and the calculated
spectra of 1 and 5 showed that they were all very similar with
respect to the major CEs (e.g., 1277 (+), 1257 (+), 1215 (−),
1154 (−), and 1133 (+) cm−1). However, a positive CE at 1385
cm−1 was seen in the experimental and calculated spectra of 5,
whereas a negative CE was present at this wavenumber in the
calculated spectrum of 1.
In contrast to 1 and 5, compound 2 exhibited NOESY
correlations between Me-15 (δH 1.41), H-5 (δH 2.26), and H-7
(δH 2.57), placing them in an α-orientation opposite H-6 (δH
4.12). A NOESY correlation between H-5 and Me-14 indicated
a β-orientation of the two epoxy groups as in 5. Therefore,
compound 2 was the 10-epimer of artecanin. A compound with
this structure was previously published as 10-epi-canin.17 The
structural assignment was at that time solely based on 1H NMR
data, but some of the published chemical shifts differed
significantly from those measured for 2 (e.g., H-5 and H-7
reported: δH 2.62 and 3.40; measured for 2: δH 2.26 and 2.57
ppm, Table S1, Supporting Information). Thus, the structural
assignment for the previously published 10-epi-canin is likely
incorrect. The absolute configuration of 2 was determined as
(1S,2R,3S,4R,5S,6S,7S,10S) by comparison of experimental and
calculated ECD spectra (Figure S17, Supporting Information).
Compounds 3 and 4 were obtained as stereoisomers with the
planar structure of seco-tanapartholides.17,18 The 1H and 13C
NMR chemical shifts of 3 and 4 differed slightly, but the
compounds exhibited the same correlations in their COSY,
HMBC, and NOESY spectra (Table S2 and Figures S18−S29,
Supporting Information). For both compounds, a NOESY
correlation betweenH-5 (3 δH 2.23, 4 δH 2.50) andMe-14 (3 δH
1.41, 4 δH 1.45) was used to establish their orientations as cis-α
or cis-β. The scalar coupling between H-6 and H-7 (3 J6,7 3.1, 4
J6,7 5.8) indicated a trans orientation of H-6 (3 δH 4.45, 4 δH
4.52) and H-7 (3 δH 3.27, 4 δH 3.50). The dihedral angles
between these two protons in the two most populated
conformers in chloroform were determined as −115° and
132° for compound 3 and as 132° and 120° for compound 4.
Both the relative configurations of (4S*,5S*,6S*,7S*)-seco-
tanapartholide B (3) and (4R*,5R*,6S*,7S*)-seco-tanapartho-
lide A (4) were in accord with the NMR data, and only the J
values between geminal H-5 and H-6 differed (3 J5,6 7.3, 4 J5,6
2.1). On the basis of this difference, Kawazoe et al. previously
po s t u l a t e d 3 a s ( 4S* , 5S* , 6S* , 7S* ) and 4 a s
(4R*,5R*,6S*,7S*).19 However, the two most populated
conformers of compound 3 showed dihedral angles of 172°
and 77° between H-5 and H-6, while angles of 72° and 173°
were obtained for compound 4. Thus, an assignment based on
geminal J values was ambiguous.
Compounds 3 and 4 had enantiomer-like ECD spectra
(Figure 5) but, given that the compounds had been separated on
nonchiral stationary phases, could not be enantiomers.
Calculated ECD spectra of 3 and 4 (absolute configuration as
drawn) reproduced these CEs, although the experimental
spectrum of 3 could also be explained by the computed
enantiomeric spectrum of 4 and vice versa. Thus, the absolute
configuration of 3 was either (4S,5S,6S,7S) or (4S,5S,6R,7R),
and that of 4 was (4R,5R,6S,7S) or (4R,5R,6R,7R).
The experimental VCD spectrum of 3 in chloroform (Figure
6) was compared to calculated spectra of the (4S,5S,6S,7S) (3)
and the (4R,5R,6S,7S) (4) stereoisomer. A good fit between the
experimental and calculated spectra of 3 was obtained with a
scaling factor of 0.9815 and confirmed by a visual comparison of
major CEs at 1271 (+), 1323 (+), 1365 (−), 1380 (+), 1711 (+),
and 1718 (+) cm−1 in the measured and calculated IR and VCD
spectra. Hence, the absolute configuration of 3 was established
as (4S,5S,6S,7S). In the same manner (Figure S31, Supporting
Information) the absolute configuration of 4 was determined as
(4R,5R,6S,7S).
Argyinolides K (8) and L (9) were obtained as an inseparable
mixture. In the HRESIMS, the sodium adduct ion (m/z =
Figure 2. Selected NOESY correlations for compounds 1−5.
Figure 3. Comparison of experimental and calculated ECD spectra for
compound 1 in MeOH.
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447.2018 [M + Na]+, calcd for C22H32O8Na 447.1989)
indicated amolecular formula of C22H32O8 for both compounds.
Analysis of 1H NMR and 13C NMR data (Table 1) pointed to a
eudesmanolide scaffold similar to that in 6, but with the
methylene group replaced by an sp3-hybridized carbon (C-4, δC
= 72.8) connected to a methyl group (Me-15 δH = 1.29, δC =
17.7) and a hydroxy group. Additional methyl signals were
assigned to a 2-methylbutyryl moiety in 8 (Me-4′, δH 0.87, dd, J
= 7.5, 7.5;Me-5′, δH 1.07, d, J = 7.0), a 3-methylbutyryl moiety in
9 (Me-4′/5′ δH 0.92, d, J = 6.7), and an acetyl group (Me-2″, δH
2.01, δC 20.6) in both compounds. Me-2″ showed HMBC
correlations to C-13 (δH 4.72, δC 54.6). HMBC correlations
between H-3 (δH = 4.60) and both butyryl carbonyl carbons (8
δC = 175.0; 9 δC = 171.6) led to the identification of two
regioisomers. The ratio between 8 and 9 was estimated as 2:1,
based on the integrals of the Me-4′ (8 δH = 0.87; 9 δH = 0.92)
andMe-5′ (8 δH = 1.07; 9 δH = 0.92) resonances in the 1HNMR
spectrum. This ratio was confirmed by the integration of theMe-
15 resonances (8 δH = 1.29; 9 δH = 1.28). The relative
configurations of 8 and 9 were determined from the NOESY
Figure 4. Comparison of experimental and computed VCD spectra in chloroform for compound 1. The region of 1900−1050 cm−1 is shown (A).
Similarities (SimVA and SimVCD) of the experimental VA and VCD spectra of 1 to the calculated spectra of possible stereoisomers were plotted as
functions of wavenumber scale factor (B). The wavenumber scale factor corresponding to the maximal SimVCD value in B (0.9865) was used to scale
the computed spectra in A.
Figure 5.Comparison of experimental and calculated ECD spectra of 3
and 4 in MeOH.
Figure 6. Comparison of experimental and computed VCD spectra in CDCl3 for compound 3. The region of 1900−1050 cm−1 is shown (A).
Similarities (SimVA and SimVCD) of the experimental VA and VCD spectra of 3 to the calculated spectra of possible stereoisomers were plotted as
functions of wavenumber scale factor (B). The wavenumber scale factor corresponding to the maximal SimVCD value in B (0.9810) was used to scale
the computed spectra in A.
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spectrum. Only the configuration at C-2′ in 8 could not be
determined (Figure 7).
The ECD spectrum of the mixture (Figure S51, Supporting
Information) showedmaxima at 200 and 252 nm together with a
minimum at 228 nm. Spectra were calculated for 9 and for both
possible stereoisomers of 8. The three spectra showed a positive
CE at 200 nm and negative CEs between 215 and 235 nm. Only
the maximum at 252 nm in the experimental spectrum was not
reproduced in the calculations. Therefore, the absolute
configurations of the rings in compounds 8 and 9 were
established as (1R,4S,5S,6R,10R). Due to the limited amount
available, it was not possible to measure the VCD spectrum of
the mixture as an attempt to establish the absolute configuration
of C-2′ in 8.
Argyinolide M (10) gave a molecular formula of C20H28O7
(HRESIMS data m/z 403.1750 [M + Na]+, calcd for
C20H28O7Na, 403.1727), which suggested seven degrees of
unsaturation. NMR data (Table 2, Figures S52−57, Supporting
Information) indicated a guaianolide scaffold similar to that in a
previously published compound.20 In compound 10, a 2-
methylbutyryl group was attached at C-8, as indicated by the
HMBC correlations between H-8 (δH 5.24) and C-1′ (δC
175.2). The relative configuration of 10 was established through
NOESY correlations (Figure 8), and the absolute configuration
of the scaffold of 10 was determined via comparison of
experimental and computed ECD spectra (Figure S58,
Supporting Information) as (1S,3R,4S,5R,6S,7R,8S). As in the
case of 8, the absolute configuration at C-2′ could not be
established.
Argyinolide N (11) was determined as being a regioisomer of
10 containing a 3-methylbutyryl unit instead of a 2-
methylbutyryl group at C-8. Apart from the resonances
attributed to the side chain, correlations in COSY, HMBC,
and NOESY spectra were similar to those of 10. The UV and
ECD spectra were measured (Figures S65 and S66, Supporting
Information). A strong positive CE at 195 nm in the calculated
ECD spectrum was in agreement with the experimental data.
However, the strong negative CE at 220 nm and a weak positive
CE at 250 nm were not present in the experimental spectrum,
and an unambiguous assignment of the absolute configuration
was thus not possible for compound 11.
Compound 18 was identified as 8-acetylarteminolide.21 Its
relative, but not its absolute configuration, has been reported
previously. The absolute configuration was established as
(5S,6R,7R,8S,12S,1′R,4′R,5′S,6′S,7′S,10′R) by comparison of
measured and calculated ECD and VCD spectra (Figures S77,
S78, and S79, Supporting Information).
Argyinolide O (17) gave a molecular formula of C30H34O6
(HRESIMS m/z 513.2261 [M + Na]+, calcd for C30H34O6Na,
513.2248), corresponding to 14 degrees of unsaturation.
Inspection of the NMR data (Table 3, Figures S71−76,
Supporting Information) indicated that themolecule 17 consists
of two distinct portions, each containing a γ-lactone ring. Thus,
the structure of 17 resembled that of 18, with one sesquiterpene
portion being identical in these compounds.21 In the other
portion of 17, a contiguous spin system between C-6 and C-9
was determined from the COSY spectrum (Figure 9).
Substituents at the bridgehead C-5 were characterized by
HMBC correlations fromMe-14 (δH 1.27) to C-4 (δC 155.3), C-
5 (δC 38.4), and C-6 (δC 39.5). The orientation of the
cyclopentenone ring was established by diagnostic HMBC
correlations from the olefinic protons H-3 and H-4 to C-1, C-2,
and C-5. A γ-lactone moiety was attached to the seven-
membered ring at C-8 (δC 43.7) and C-7 (δC 75.4). The linkage
of the two sesquiterpene portions A and B was established by
HMBC correlations. Me-14′ (δC 16.1) and the diastereotopic
protons at C-13 (δH 1.62, 2.50) of portion B, and H-8 (δH 2.32)
of portion A, exhibited HMBC cross-peaks with C-12 (δC 61.3),
and H2-13 also with C-1′. The relative configuration of 17 was
established via a series of diagnostic ROESY correlations (Figure
9). Correlations between H-5′ (δH 2.96), H-7′ (δH 3.39), and
Hα-13 (δH 2.50, correlations not drawn in Figure 9) and between
H-6′ (δH 4.00), H-2′ (δH 6.17), Hβ-13 (δH 5.35), and Hβ-9 (δH
6.17) indicated their respective cofacial orientation and thus
helped determine the linkage of the lactone ring at C-6′ (δC
79.6) and C-7′ (δC 43.0) as trans. The β-orientation of Me-15′
(δH 1.38) was indicated by a ROESY cross-peak with H-2′. The
configuration of C-12 was established through correlations
betweenMe-14′ (δH 1.54) and H-7 (δH 4.77) and between H-3′
(δH 5.90) and H-8 (δH 2.32). The UV and ECD spectra of 17
were measured and compared to calculated data (Figures S74
and S75, Supporting Information). A strong negative CE in the
ECD spectrum at 210 nm was present in the calculated
spectrum, but not the broad negative CE occurring in the
experimental spectrum between 230 and 290 nm. Considering
the relative magnitudes of the absorption maxima in the UV
Figure 7. Selected COSY (blue bonds), HMBC (green arrows), and
NOESY correlations (red arrows) for compounds 8 and 9.
Figure 8. Selected COSY (blue bonds), HMBC (green arrows), and
NOESY correlations (red arrows) for compounds 10 and 11.
Figure 9. Selected COSY (blue bonds), HMBC (green arrows), and
ROESY for compound 17. For better visibility, ROESY correlations
(red arrows) are shown in a spatial representation (right). A and B refer
to the two sesquiterpene lactone portions.
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spectrum, the negative CE at 210 nm was considered as being
more relevant, and the absolute configuration assigned
tentatively as (5S,7R,8R,12S,1′R,4′R,5′S,6′S,7′S,10′R). This is
also in accord with the absolute configuration of compound 18.
The absolute configurations of canin (1) and its stereoisomers
2 and 5 had not been previously determined, and the
representation of their structures since their first description in
1969 followed a previous convention.15 We determined the
absolute configurations of canin (1) and artecanin (5) using
ECD and VCD in combination with ab initio calculations. In
addition, the absolute configurations of other sesquiterpene
lactones were determined if a reliable assignment of such
information was lacking. However, this was not established for
the 2-methylbutyryl side chain in compounds 8, 10, and 14, due
to the lack of a suitable chromophore in proximity, and the
limited amounts of pure compounds precluded the measure-
ment of VCD spectra. In the case of seco-tanapartholides B (3)
and A (4), the rotatable bond between the two chromophores
impeded an assignment of the absolute configuration via ECD.
However, analysis of the VCD spectra proved to be successful.
For compounds 1, 5, and 18, a comparison of experimental and
computed VCD spectra confirmed the absolute configuration
determined by ECD, and for arteglasin A (15) the X-ray
crystallographic data supported the assigned absolute config-
uration. Automated comparison of VCD spectra using SimVCD
and SimVA proved to be helpful in the case of 1, 3, 4, and 18.
However, a visual examination of spectra is warranted to avoid
false attributions, as would have been the case with compound 5.
Immunosuppressant Activity. Compounds were tested
for their ability to inhibit proliferation of stimulated T
lymphocytes at a concentration range of 0.01−30 μg/mL.
FACS analyses of the forward and side scatters in the
proliferation experiments were used to simultaneously assess
immunosuppressive activity and cytotoxicity. The results for
compounds 1 and 3 are shown in Figure 10, and IC50 values for
all compounds tested were determined (Table 4, Figure S2,
Supporting Information).
Compounds 3, 4, and 15 and the mixture of 13 and 14
significantly inhibited T lymphocyte proliferation, having IC50
values of <2 μM. For 3 and 4, beginning cytotoxicity was seen at
a concentration that was 10-fold higher than the IC50 value in the
T-cell proliferation assay. For compound 15, signs of
cytotoxicity were observed at a concentration that was 3-fold
higher than the IC50 value. Compounds 1, 5, and 18 were less
active (IC50≤ 4 μM), and compounds 6−9, 12−14, and 16 had
no significant activity in the T-cell proliferation assay. When
comparing the activity profile (Figure 1) with the IC50 values of
pure compounds, it appeared that sesquiterpenes 1 and 3−5
contribute to a large extent to the activity of the extract.
Figure 10. Inhibitory effects of compounds 1 and 3 on the proliferation of T lymphocytes. Data of three independent experiments were summarized
and depicted as means± standard deviation in relation to the untreated, stimulated control (PC; = 100%± SD). Nonstimulated cells were used as the
negative control (NC), cyclosporin A (CsA) was used as a known inhibitor of T cell proliferation, and camptothecin (CPT) was used as a known
inducer of apoptosis. *p < 0.05, **p < 0.01, ***p < 0.001.
Table 1. 1H and 13C NMR Spectroscopic Data (500 MHz,
CDCl3) for Compounds 8 and 9
8 9
position δC, type δH (J in Hz) δC, type δH (J in Hz) HMBC
b
1 73.3, CH 3.29, dd (11.9,
3.7)
73.3, CH 3.29, dd
(11.9, 3.7)
9, 10, 14
2α 33.3, CH2 1.59
a 1.59a 1, 3, 4, 10
2β 1.76, m 33.3, CH2 1.76, m 1, 4, 10
3 76.6, CH 4.60, dd (12.5,
4.6)
76.6, CH 4.60, dd
(12.5, 4.6)
1′, 4, 15
4 72.8, C 72.8, C
5 56.0, CH 1.41, d (11.3) 56.0, CH 1.41, d
(11.3)
4, 6, 9, 10,
14, 15
6 79.2, CH 5.32, d (11.3) 79.2, CH 5.32, d
(11.3)
4, 5, 7, 11,
12
7 171.8, C 171.8, C
8a 22.3, CH2 2.92, dd (13.3,
2.3)
22.3, CH2 2.92, dd
(13.3, 2.3)
8b 2.39a 2.39a 9, 11
9a 39.6, CH2 2.06, dd (13.3,
5.0)a
39.6, CH2 2.06, dd
(13.3,
5.0)a
9b 1.12, m 1.12, m
10 40.6, C 40.6, C
11 117.8, C 117.8, C
12 171.0, C 171.0, C
13 54.6, CH2 4.72, s 54.6, CH2 4.72, s 1’’, 7, 11,
12
14 13.0, CH3 0.98, s 13.0, CH3 0.98, s 1, 5, 9, 10
15 17.8, CH3 1.29, s 17.8, CH3 1.28, s 3, 4, 5
1′ 175.0, C 171.6, C
2′ 40.5, CH 2.37a 43.1, CH2 2.17, dd (7.0,
4.9)
1′, 3′, 4′, 5′
3′a 26.4, CH2 1.58a 25.6, CH 2.00a 1′,c 4′, 5′
3′b 1.46, ddq (13.9,
7.5, 6.9)
1′,c 4′,c 5′c
4′ 11.2, CH3 0.87, dd (7.5,
7.5)
22.2, CH3 0.92, d (6.7) 2′, 3′
5′ 16.4, CH3 1.07, d (7.0) 22.2, CH3 0.92, d (6.7) 1′,c 2′, 3′
1″ 170.1, C 170.1, C
2″ 20.6, CH3 2.01, sa 20.6, CH3 2.01, sa 1′, 13
aOverlapped signals. bHMBC spectrum for compounds 8 and 9 as
observed in the mixture. cObserved solely for compound 8.
dObserved solely for compound 9.
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■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured at a concentration of 1 mg/mL in chloroform utilizing a
PerkinElmer 341 polarimeter with a 10 cm microcell. UV and ECD
spectra were recorded in methanol (66−400 μg/mL) on a Chirascan
CD spectrometer using 1 mm path precision cells (110 QS, Hellma
Analytics). IR and VCD spectra were recorded on a Bruker PMA 50
accessory coupled to a Tensor 27 Fourier transform infrared
spectrometer. A photoelastic modulator (Hinds PEM 90) set at l/4
retardation was used to modulate the handedness of the circular-
polarized light. Demodulation was performed by a lock-in amplifier
(SR830 DSP). An optical low-pass filter (<1800 cm−1) in front of the
photoelastic modulator was used to enhance the signal/noise ratio.
Solutions of 3−8 mg in 130−400 μL of deuterated solvent (CDCl3 or
DMSO-d6) were prepared and measured in a transmission cell
equipped with CaF2 windows and a 200 μm spacer. The VCD
spectrum of the pure solvent served as the reference and was subtracted
from the VCD spectrum of the compound in order to eliminate
artifacts. For both the sample and the reference, ca. 24 000 scans at 4
cm−1 resolution were averaged. NMR data were recorded on a Bruker
Avance III NMR spectrometer operating at 500.13 MHz for 1H and
125.77 MHz for 13C nuclei. 1H NMR data and COSY, HSQC, HMBC,
and NOESY spectra were measured at 18 °C in a 1 mmTXI probe with
a z-gradient. 13C NMR/DEPTQ spectra were recorded at 23 °C in 3
mm tubes with a 5 mm BBI probe. Spectra were analyzed by Bruker
TopSpin 3.0 and ACDLabs Spectrus Processor. Either a Bruker Kappa
Apex 2 diffractometer or a Stoe StadiVari diffractometer equipped with
a Pilatus 300 K detector was used to collect X-ray diffraction data. The
structure was solved with Superflip22 and refined using Crystals.23
HPLC-PDA-ELSD-ESIMS data were recorded in the positive mode on
a Shimadzu LC-MS/MS 8030 triple quadrupole MS connected via a T-
splitter (1:10) to a Shimadzu HPLC system consisting of degasser,
binary high-pressure mixing pump, autosampler, column oven, and
diode array detector, and via a T-splitter to an Alltech 3300 ELSD
detector. Data acquisition and processing was performed with
LabSolution software. Semipreparative HPLC separations were carried
out with an Agilent HP 1100 Series system consisting of a quaternary
pump, autosampler, column oven, and a diode array detector
(G1315B). Chemstation software was used for data acquisition and
processing. Waters SunFire C18 (3.5 μm, 3.0 × 150 mm i.d., equipped
with a guard column 10 × 3.0 mm i.d.), SunFire Prep C18 (5 μm, 10 ×
150 mm i.d., equipped with a guard column 10 × 10 mm i.d.), and
SunFire Prep C18 OBD (5 μm, 30× 150 mm i.d., equipped with a guard
column 10 × 20 mm i.d.) columns were used for analytical,
semipreparative, and preparative separations, respectively. HPLC-
grade methanol, acetonitrile (Scharlau Chemie), and water from a
Milli-Q water purification system (Merck Millipore) were used for
Table 2. 1H and 13C NMR Spectroscopic Data (500 MHz,
DMSO-d6) for 10 and 11
10 11b
position δC, type δH (J in Hz) HMBC δC, type δH (J in Hz)
1 78.4, C 78.4, C
2α 46.8, CH2 1.61, dd (14.2,
4.3)a
1, 3, 4, 10 46.8, CH2 1.61, dd (14.2,
3.8)
2β 2.62, dd (14.2,
6.0)




3 77.6, CH 3.55, dd (6.0,
4.7)
1, 4, 5 77.5, CH 3.55, dd (6.0,
4.0)
4 79.2, C 79.2, C
5 60.6, CH 2.28, d (9.8) 1, 4, 6, 7,
10, 14,
60.7, CH 2.28, d (9.8)a
6 75.4, CH 4.38, dd (9.8,
9.8)
4, 5, 7, 8 75.4, CH 4.38, dd (9.6,
9.6)
7 41.2, CH 4.15, dddd
(9.8, 9.8, 3.4,
3.2)
5, 6, 11, 12 41.1, CH 4.14, dddd
(9._, 9.5,
3.1, 2.4)




72.5, CH 5.24, dd (9.8,
4.3)
9 121.4, CH 5.33, brd (4.9) 1, 7, 10, 15 121.6, CH 5.34, d (4.3)
10 143.9, C 143.7, C
11 138.7, C 138.5, C
12 169.4, C 169.4, C
13a 120.9,
CH2
6.06, d (3.4) 7, 8, 11, 12 121.0,
CH2
6.05, d (3.1)
13b 5.54, d (3.0) 7, 8, 12 5.57, d (2.4)
14 23.1, CH3 1.24, s 3, 4, 5 23.1, CH3 1.24, s
15 24.9, CH3 1.81, s 1, 9, 10 24.9, CH3 1.81, s
1′ 175.2, C 171.9, C





42.4, CH2 2.26, d (7.0)
3′a 26.0, CH2 1.65, ma 1′, 2′, 4′,
5′






4′ 11.5, CH3 0.88, dd (7.2,
7.2)
2′, 3′ 22.1, CH3 0.93, d (6.4)a
5′ 16.4, CH3 1.10, d (7.0) 1′, 2′, 3′ 22.1, CH3 0.93, d (6.4)a
aOverlapping signals. bHMBC data for the core structure were
identical to those of 10.
Table 3. 1H and 13C NMR Spectroscopic Data (500 MHz,
CDCl3) for 17
position δC, type δH (J in Hz) HMBC
1 130.7, C
2 185.5, C
3 126.1, CH 6.21, d (9.8) 1, 5
4 155.3, CH 6.78, d (9.8) 2, 6, 10, 14
5 38.4, C
6α 39.5, CH2 2.45, dd (15.3, 2.1) 4, 5, 7, 8, 14
6β 1.57, dd (15.3, 4.9) 4, 5, 14
7 75.4, CH 4.77, ddd (4.9, 4.9, 2.1) 6, 9
8 43.7, CH 2.32a 9, 11, 12
9α 28.3, CH2 2.04, m 1, 8, 10, 12




13α 37.6, CH2 2.50, d (11.9) 1′, 2′, 8, 10, 11, 12
13β 1.62, d (11.9) 2′, 5′, 8, 11, 12
14 24.9, CH3 1.27, s 4, 5, 6
15 10.8, CH3 1.90, s
a 1, 10
1′ 63.2, C
2′ 139.0, CH 6.17, d (5.8) 1′, 3′, 4′, 5′
3′ 137.1, CH 5.90, d (5.8) 1′, 2′, 4′, 5′, 14′
4′ 61.4, C
5′ 65.2, CH 2.96, d (10.0) 1′, 2′, 3′, 4′, 6′, 7′, 13
6′ 79.6, CH 4.00, dd (9.8, 9.8) 5′, 8′
7′ 43.0, CH 3.39, m
8′α 23.6, CH2 2.28a 6′, 7′, 9′
8′β 1.45, m 10′
9′a 34.8, CH2 1.89, m;a 1.83a 1′, 7′, 10′




13′a 118.7, CH2 6.07, d (3.7) 7′, 11′, 12′
13′b 5.35, d (3.4) 7′, 11′
14′ 16.1, CH3 1.54, s 3′, 4′, 5′, 12
15′ 29.9, CH3 1.38, s 1′, 9′, 10
aOverlapping signals.
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HPLC separations. The mobile phase used for analytical HPLC
contained 0.1% formic acid. An analytical Nucleodur 100-5 CN column
(5.0 μm, 4.0 × 125 mm i.d.) and a semipreparative Nucleodur 100-5
CN column (5.0 μm, 10.0× 150mm i.d.) (bothMacherey-Nagel) were
used for normal-phase HPLC separations. NMR spectra were recorded
in CDCl3 (Sigma-Aldrich) or DMSO-d6 (Armar Chemicals).
Technical-grade solvents purified by distillation were used for
extraction and open column chromatography. Silica gel (63−200 μm
and 15−40 μm, Merck) was used for open column chromatography.
HRESIMS data were measured on a LQT XL Orbitrap mass
spectrometer (Thermo Scientific) via direct injection.
Plant Material. Artemisia argyi whole plants, batch number
150788859, were purchased from Peter Weinfurth, Bochum, Germany,
in March 2016. A voucher specimen (number 00 979) has been
deposited at the Division of Pharmaceutical Biology, University of
Basel, Switzerland.
Microfractionation. Microfractionation of A. argyi EtOAc extract
was carried out by analytical RP-HPLC on an LC-MS 8030 system
(Shimadzu) connected with an FC 204 fraction collector (Gilson). A
solution of 10 mg/mL extract in DMSO was prepared. In total, three
injections were performed: 2 × 30 μL using only DAD for detection for
collection (0.6 mg of extract in total) and 1 × 10 μL with UV-ELSD-
ESIMS detection without collection. Water with 0.1% formic acid (A)
and acetonitrile with 0.1% formic acid (B) were used as mobile phase.
The gradient was 5% to 100% B in 30 min followed by 5 min at 100% B.
Fractions of 1 min each were collected from minute 2 to minute 32,
resulting in 30 microfractions in total. Microfractions of two successive
injections of the extract were collected into the corresponding wells of a
96-deep-well plate. The plate was dried in a Genevac EZ-2 evaporator.
Extraction and Isolation. A 400 g aliquot of plant material was
ground using a M20 universal mill (IKA). The powdered material was
mixed with 400 g of sea sand and percolated with EtOAc (ca. 12 L) to
afford 42 g of crude extract. A portion (20 g) of the extract was
fractionated by column chromatography (CC) on silica gel (80 × 5 cm,
63−200 μm) using a gradient of n-hexane−EtOAc−MeOH (95:5:0 to
0:100:0 to 0:50:50) as mobile phase. Fractions A−R were combined
based on TLC patterns (silica gel, n-hexane−EtOAc, 70:30, 50:50, and
35:65, respectively; detection with 1% ethanolic vanillin and 10%
sulfuric acid, followed by heating). Fraction M (80 mg) was submitted
to preparative RP-HPLC [H2O (A), MeCN (B); 15→ 100% B (0−30
min), 100% B (30−35 min), flow rate 25 mL/min; sample
concentration 100 mg/mL in DMSO; injection volume 700 μL],
yielding jaceosidin (12, 8.7 mg, tR 15.1 min), santamarin (7, 3.9 mg, tR
16.0 min), and eupatilin (16, 21.8 mg, tR 17.4 min). Fraction P (769
mg) was submitted to preparative RP-HPLC [H2O (A), MeCN (B); 25
→ 60% B (0−30 min), 60 → 100% B (30−32 min), 100% B (32−37
min), flow rate 20 mL/min; sample concentration 100 mg/mL in
DMSO; injection volume 1000 μL], yielding fractions P1−P26. Fraction
P5 afforded crystals of artecanin (5, 18.5 mg). P14 consisted of
eudesmaafraglaucolide (6, 15.9 mg, tR 15.6 min), and P17 was found to
be a mixture of 8 and 9 (2.0 mg, tR 18.8 min). P26 consisted of 8-
acetylarteminolide (18, 7 mg, tR 28.0 min). P3 was purified by
semipreparative HPLC on a Nucleodur 100-5 CN column [n-heptane
(A), isopropanol (B); 5% B (0−3 min), 5 → 15% B (3−6 min), 15%
(6−16 min), flow rate 3 mL/min; sample concentration 20 mg/mL in
2:1 isopropanol−n-heptane; injection volume 75 μL] to afford canin (1,
2.9 mg, tR 16.2 min), seco-tanapartholides B (3, 8.1 mg, tR 16.9 min) and
A (4, 4.8 mg, tR 17.9min), and 10-epi-artecanin (2, 0.8 mg, tR 18.8min).
Fraction K (452 mg) was separated by preparative RP-HPLC [H2O
(A), MeCN (B); 45% (0−2 min), 45 → 70% B (2−30 min), 60 →
100% B (30−31 min), 100% B (31−40 min), flow rate 20 mL/min;
sample concentration 75mg/mL inDMSO; injection volume 100−900
μL]. K11 consisted of a mixture of 3α,4α-epoxyrupicolines E and D (13
and 14, 2.3 mg, tR 21.3 min). Crystals formed in the vial were identified
by X-ray crystallography as 3α,4α-epoxyrupicolin E (14). K5 consisted
of arteglasin A (15, 3.0 mg, tR 14.7 min). From a second portion of
extract (20 g) a targeted isolation of compounds 8 and 9was performed.
For this, the extract was fractionated on anMPLC glass column (Büchi)
packed with silica gel (40 × 7 cm, 15−40 μm) utilizing an Interchim
Puriflash 4100 system [n-hexane (A), EtOAc (B); 20% B (0−15 min)
20 → 30% B (15−20 min), 30% B (15−50 min), 30 → 80% (50−80
min), 80% (80−130 min), 80→ 95% (130−160 min), 95% (160−215
min), flow rate 30 mL/min; sample introduction via dry load, with 20 g
of extract adsorbed on 40 g silica gel 15−40 μm]. Separation was
monitored by HPLC-ESIMS, and fractions containing the target
molecules were combined, dried, and submitted to preparative RP-
HPLC [H2O (A), MeCN (B); 25% B (0−3 min), 25→ 30% B (3−10
min), 30% B (10−40min); flow rate 20mL/min; sample concentration
130 mg/mL in DMSO; injection volume 900 μL]. This separation
yielded compounds 10 (1.9 mg, tR 27.3 min) and 11 (1.7 mg, tR 29.8
min) and a peak (5.4 mg, tR 36.1 min), which was further purified by
semipreparative HPLC (Nucleodur 100-5 CN) [H2O (A), MeCN (B);
17→ 20% B (0−27 min), 20→ 100% B (27−29 min), 100% B (29−40
min); flow rate 4 mL/min; sample concentration 20mg/mL in DMSO;
injection volume 100 μL] to afford a mixture of 8 and 9 (1.4 mg, tR 20.3
min).
Canin (1): white solid; [α]D
25 +7 (c 0.1 g/100 mL, CH2Cl2); UV λmax
(MeOH) (log ε) 209 (4.0) nm; ECD (MeOH, c 0.96 mM, 0.1 cm);Δε
+4.0 (202 nm) −0.9 (252 nm); 1H and 13C NMR, see Table S1,
Supporting Information; HRESIMS m/z 301.1054 [M + Na]+ (calcd
for C15H18O5Na, 301.1052).
10-epi-Canin (2): UV λmax (MeOH) (log ε) 207 (3.9) nm; ECD
(MeOH, c 0.54 mM, 0.1 cm); Δε +4.9 (195 nm) −0.8 (257 nm); 1H
and 13C NMR, see Table S1, Supporting Information; HRESIMS m/z
301.1057 [M + Na]+ (calcd for C15H18O5Na, 301.1052).
(−)-seco-Tanapartholide B (3): colorless gum; [α]D25 −62 (c 0.1 g/
100 mL, CHCl3); UV λmax (MeOH) (log ε) 213 (4.2) nm; ECD
(MeOH, c 0.60 mM, 0.1 cm); Δε +10.0 (228 nm) −1.8 (330 nm); 1H
and 13C NMR see Table S2, Supporting Information; HRESIMS m/z
301.1055 [M + Na]+ (calcd for C15H18O5Na, 301.1052).
(+)-seco-Tanapartholide A (4): colorless gum; [α]D
25 +79 (c 0.1 g/
100 mL, CHCl3); UV λmax (MeOH) (log ε) 209 (4.2) nm; ECD
(MeOH, c 0.60 mM, 0.1 cm); Δε −13.1 (228 nm) +1.8 (330 nm); 1H
and 13C NMR, see Table S2, Supporting Information; HRESIMS m/z
301.1057 [M + Na]+ (calcd for C15H18O5Na, 301.1052).
Artecanin (5): UV λmax (MeOH) (log ε) 211 (4.2), 208 (3.7) nm;
ECD (MeOH, c 1.44 mM, 0.1 cm);Δε +2.7 (202 nm),−0,5 (251 nm);
1H and 13C NMR, see Table S1, Supporting Information; HRESIMS
m/z 301.1054 [M + Na]+ (calcd for C15H18O5Na, 301.1052).
Eudesmaafraglaucolide (6): white solid; UV λmax (MeOH) (log ε)
215 (4.0), 288 (2.7) nm; ECD (MeOH, c 1.1 mM, 0.1 cm); Δε +3.2
(217 nm),−0.8 (243 nm); 1H and 13C NMR, see Table S3, Supporting
Information; HRESIMS m/z 387.1431 [M + Na]+ (calcd for
C19H24O7Na, 387.1414).
Table 4. In Vitro Inhibitory Concentrations of Artemisia argyi
Extract and Selected Constituents Leading to Inhibition of T-
Cell Proliferation by 50% (IC50) in [μg/mL] (Middle
Column) and [μM] (Right Column)
compounda IC50 [μg/mL] ± SD IC50 [μM] ± SD
1 0.8 ± 0.3 2.7 ± 0.9
3 0.3 ± 0.1 1.0 ± 0.4
4 0.3 ± 0.1 1.2 ± 0.3
5 1.0 ± 0.3 3.7 ± 1.1
6 5.0 ± 2.2 13.8 ± 5.9
7 4.9 ± 1.3 19.6 ± 5.3
8 + 9 (ratio 2:1) 7.1 ± 3.9 16.8 ± 9.2
12 1.9 ± 0.6 5.8 ± 1.7
13 + 14 (ratio 1:1) 0.7 ± 0.2 1.8 ± 0.4
15 0.6 ± 0.2 1.9 ± 0.7
16 4.0 ± 0.5 11.7 ± 1.4
18 1.7 ± 0.7 3.2 ± 1.3
CsA 0.3 ± 0.2 0.2 ± 0.2
extract 16.1 ± 3.6
aCompounds 2, 10, 11, and 17 were not tested due to the limited
amounts available.
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Santamarin (7): white solid; UV λmax (MeOH) (log ε) 211 (4.2),
273 (3.8), 334 (3.9) nm; ECD (MeOH, c 0.26 mM, 0.1 cm); Δε +2.4
(202 nm); 1H and 13C NMR, see Table S3, Supporting Information;
HRESIMS m/z 271.1317 [M + Na]+ (calcd for C15H20O3Na,
271.1305).
Argyinolides K (8) and L (9): white solid; UV λmax (MeOH) (log ε)
210 (3.7) nm; ECD (MeOH, c 0.85 mM, 0.1 cm); Δε −2.4 (225 nm);
1H and 13C NMR see Table 1; HRESIMS m/z 447.2018 [M + Na]+
(calcd for C24H31O8Na, 447.1989).
Argyinolide M (10): yellow solid; UV λmax (MeOH) (log ε) 200
(4.0) nm; ECD (MeOH, c 0.79 mM, 0.1 cm); Δε +8.5 (195 nm) −0.4
(255 nm); 1H and 13C NMR see Table 2; HRESIMSm/z 403.1750 [M
+ Na]+ (calcd for C20H28O7Na, 403.1727).
(+)-Argyinolide N (11): yellow solid; [α]D
25 +20 (c 0.15 g/100 mL,
CHCl3); UV λmax (MeOH) (log ε) 200 (4.1) nm; ECD (MeOH, c 0.79
mM, 0.1 cm);Δε +9.0 (195 nm)−0.5 (256 nm); 1H and 13C NMR see
Table 2; HRESIMS m/z 403.1748 [M + Na]+ (calcd for C20H28O7Na,
403.1727).
Jaceosidin (12): yellow solid; 1H and 13C NMR, see Table S4,
Supporting Information; HRESIMS m/z 353.0649 [M + Na]+ (calcd
for C17H14O7Na, 353.0656).
3α,4α-Epoxyrupicolines D and E (13 and 14): UV λmax (MeOH)
(log ε) 285 (2.8) nm; ratio 1:1; identification by 1H and 13C NMR, see
Table S5, Supporting Information; HRESIMS m/z 385.1634 [M +
Na]+ (calcd for C20H26O6Na, 385.1622).
(+)-Arteglasin A (15): [α]D
25 +86 (c 0.07 g/100mL, CHCl3); UV λmax
(MeOH) (log ε) 195 (4.2) nm; ECD (MeOH, c 0,65 mM, 0.1 cm);Δε
+7.4 (209 nm) −1.0 (231 nm); 1H and 13C NMR, see Table S5,
Supporting Information; HRESIMS m/z 327.1220 [M + Na]+ (calcd
for C17H20O5Na, 327.1203).
Eupatilin (16): yellow solid; identification by 1H and 13C NMR see
Table S4, Supporting Information; HRESIMS m/z 367.0808 [M +
Na]+ (calcd for C18H16O7Na, 367.0788).
(−)-Argyinolide N (17): white solid; [α]D25 −120 (c 0.08 g/100 mL,
CHCl3); UV λmax (MeOH) (log ε) 205 (4.2) nm; ECD (MeOH, c 0.31
mM, 0.1 cm); Δε +12.3 (195 nm), +27.5 (207 nm); 1H and 13C NMR
see Table 3; HRESIMS m/z 513.2261 [M + Na]+ (calcd for
C30H34O6Na, 513.2248).
(+)-8-Acetylarteminolide (18): white solid; [α]D
25 +27 (c 0,1 g/100
mL, CHCl3); UV λmax (MeOH) (log ε) 253 (3.8) nm; ECD (MeOH, c
0.73 mM, 0.1 cm);Δε−8.4 (210 nm), +0.7 (240 nm),−1.2 (269 nm);
1H and 13C NMR, see Table S6, Supporting Information; HRESIMS
m/z 571.2313 [M + Na]+ (calcd for C32H36O8Na, 571.2308).
X-ray Analysis of 3α,4α-Epoxyrupicolin E (14). A crystal of 14
with the dimensions 0.11 × 0.13 × 0.21 mm, obtained as a colorless
block from CHCl3, was mounted on a Bruker Kappa Apex 2
diffractometer and was kept at 123 K during data collection (CCDC
1862952). The orthorhombic space group P212121 was observed using
Cu Kα radiation (L̂ = 1.541 78 Å, a = 9.1487(7) Å, b = 10.3308(7) Å, c
= 20.0261(14) Å, α = β = γ = 90°, V = 1892.7(2) Å3), giving 3419
independent reflections. The structure was solved with Superflip22 and
refined using Crystals.23 Non-hydrogen atoms were refined anisotropi-
cally, and hydrogen atoms were fixed at the calculated positions. The
final indices were R = 0.0473, Rw = 0.0496 and goodness of fit = 1.0832.
X-ray Analysis of Arteglasin A (15). A crystal of 15 with the
dimensions 0.05 × 0.09 × 0.14 mm, obtained as a colorless block from
CHCl3, was mounted on a Stoe StadiVari diffractometer equipped with
a Pilatus 300 K detector and was kept at 123 K during data collection
(CCDC 1862953). The orthorhombic space group P212121 was
observed using Ga Kα radiation (L̂ = 1.341 43 Å, a = 19.8206(4) Å, b =
9.5646(2) Å, c = 8.4390(2) Å, α = β = γ = 90°, V = 1599.83(6) Å3),
giving 3101 independent reflections. Non-hydrogen atoms were refined
anisotropically, and hydrogen atoms were fixed at the calculated
positions. The final indices were R = 0.0265, Rw = 0.0294 and goodness
of fit = 1.1151.
Computational Methods. Conformational analysis was per-
formed with Schrödinger MacroModel 9.8 (Schrödinger, LLC, New
York, USA) employing the OPLS2005 (optimized potential for liquid
simulations) force field in H2O or chloroform for ECD or VCD
calculations, respectively. Selected conformers within a 8 kcal/mol
energy window from the global minimum were submitted to
geometrical optimization and energy calculation applying density
functional theory (DFT) with the Beck’s nonlocal three-parameter
exchange and correlation functional and the Lee−Yang−Parr
correlation functional level (B3LYP), using the B3LYP/6-31G**
basis set, the SCRF method, and the CPMC model for solvation
(MeOH for ECD calculations) with the Gaussian 09 program
package.24 Vibrational analysis was done at the same level to confirm
minima. Excitation energy (denoted by wavelength in nm), rotator
strength (Rstr), dipole velocity (Rvel), and dipole length (Rlen) were
calculated in MeOH by TD-DFT/B3LYP/6-31G(d,p). ECD curves
were obtained on the basis of rotator strengths with a half-band of 0.3
eV using SpecDis v1.64.25 Vibrational frequencies (given as wave-
numbers in cm−1), rotator strength (Rstr), IR intensity (IRinten), and
dipole strength (Rstr) were calculated in chloroform or dimethyl
sulfoxide with B3LYP/6-31+G(d,p). While the conformational search
for compounds measured in chloroform was also performed in
chloroform, it was carried out in water for samples measured in
methanol or DMSO-d6. VCD curves were obtained on the basis of
rotator strengths with a bandwidth of 10 cm−1 using VCDspecTech
v22.0.26,27 ECD and VCD spectra were calculated from the spectra of
individual conformers according to their contribution calculated by
Boltzmann weighting. Comparison was done visually and by calculation
of similarity indices (SimVA, SimVCD) which were generated by
VCDspecTech v22.0.16 The SimVCD values were plotted against the
scaling factors of the x axis, and graphs compared between the different
stereoisomers.
Ethics Statement. Patients gave their written consent to donate
blood for scientific research. All experiments conducted on human
material were approved by the Ethics Committee of the University of
Freiburg (55/14).
Preparation and Cultivation of Human Peripheral Lympho-
cytes. Peripheral blood mononuclear cells (PBMCs) were isolated
from the blood of healthy adult donors obtained from the Blood
Transfusion Centre (University Medical Center, Freiburg, Germany).
Venous blood was centrifuged on a LymphoPrep gradient (density:
1.077 g/cm3, 20 min, 500g, 20 °C; Progen). After centrifugation, cells
were washed twice with phosphate-buffered saline (PBS) and
subsequently cultured in RPMI 1640 medium supplemented with
10% heat-inactivated fetal calf serum (GE Healthcare Life Sciences), 2
mM L-glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin
(all from Life Technologies). The cells were cultured at 37 °C in a
humidified incubator with a 5% CO2/95% air atmosphere.
T Cell Proliferation Assay. Lymphocytes were isolated, washed
twice in cold PBS, and resuspended in PBS at a concentration of 5× 106
cells/mL. Cells were stained for 10 min at 37 °C with carboxy-
fluorescein diacetate succinimidyl ester (CFSE; 5 μM: Sigma-Aldrich,
St. Louis, MO, USA). The staining was stopped by washing twice with
complete medium. Stained lymphocytes (2 × 106 cells/mL) were
stimulated with anti-human CD3 (clone HIT3a) and anti-human
CD28 (clone 28.2) mAbs (each 100 ng/mL; eBioscience) in the
presence of either medium, cyclosporin A (CsA; 4.16 μM; Novartis
Pharma), camptothecin (CPT; 300 μM; Tocris), or plant extracts/
single compounds (concentration range 0.01−100 μg/mL) and
incubated for 72 h. The negative control remained unstimulated.
Flow cytometric analysis of the cell division was performed using a
FACSCalibur instrument (BD Biosciences).
Determination of Apoptosis and Necrosis of T Cells.
Lymphocytes were isolated, washed twice in cold PBS, and resuspended
inmedium at a concentration of 2× 106 cells/mL. Cells were stimulated
with anti-human CD3 (clone HIT3a) and anti-human CD28 (clone
28.2) mAbs (each 100 ng/mL; eBioscience) in the presence of either
medium, camptothecin (CPT; 300 μM; Tocris), 0.5% Triton-X 100, or
plant extracts/single compounds (concentration range 0.01−100 μg/
mL) and cultivated for 48 h. The negative control remained
unstimulated. Cultured cells were washed with PBS and stained with
annexin V-FITC using the apoptosis-detection kit (eBioscience)
according to the manufacturer’s instructions. Propidium iodide
(eBioscience) was added, and cells were stained for 15 min at room
temperature in the dark. Apoptosis and necrosis rates were determined
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.8b00791
J. Nat. Prod. 2019, 82, 1424−1433
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by flow cytometric analysis using a FACSCalibur instrument (BD
Biosciences).
Testing of Microfractions. The dried microfractions in 96-deep-
well plates were dissolved in 25 μL of DMSO by sonication and mixing
with a pipet. Of these stock solutions, dilutions of 1:1, 1:3, 1:10, and
1:30 were prepared and tested in duplicates for T lymphocyte
proliferation inhibition as described above. Assuming an equal
distribution of 200 ng substance in each of the microfractions,
theoretical IC50 values were calculated to be used as a relative measure
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Table S1. 1H and 13C NMR Spectroscopic Data (500 MHz, CDCl3) for compounds 1, 2, and 5. 
 
 1  2c  5b 
position δC, type  δH (J in Hz)  δC, type  δH (J in Hz)  δC, type  δH (J in Hz) 
1 79.8, C    78.2, C    77.8, C   
2 58.7, CH  3.47, d (0.9)  55.4, CH  3.54, d (0.9)  56.0, CH  3.63, br. s 
3 58.3, CH  3.28, d (0.9)  57.6, CH  3.35, d (0.9)  57.0, CH  3.40, br. S 
4 73.7, C    71.8, C    70.2, C   
5 50.3, CH  2.55, d (11.9)  44.7, CH  2.26, d (10.7)  42.5, CH  2.81, d (11.0) 
6 78.3, CH  4.22, dd (11.9, 9.5)  81.1, CH  4.12, dd(10.7, 10.7)  82.4, CH  3.91, dd (11.0, 10.4) 
7 45.2a, CH  3.39, m  51.3, CH  2.57, m  44.0, CH  3.25, m 
8 23.7, CH2  2.35, m   20.2, CH2  1.98, m   22.2, CH2  2.10, m  
   1.52, ma    1.62, ma    1.45, ma 
9 34.3, CH2  2.01, ddd (15.0, 6.1, 4.3)  42.2, CH2  2.17, ddd (15.6, 6.4, 2.8)   37.0, CH2  1.68, m 
   1.83, ddd (15.0, 10.7, 6.1)      1.80, ddd (15.0, 11.4, 3.2)     
10 72.4, C    69.4, C    70.4, C   
11 139.6, C    138.8, C    139.6, C   
12 169.4, C    169.2, C    169.8, C   
13 120.2, CH2  6.21, d (3.4)   118.3, CH2  6.16, d (3.1)   118.8, CH2  6.02, d (3.7)  
    5.50, d (3.1)     5.44, d (3.1)     5.57, d (3.4) 
14 19.4, CH3   1.57, sa  19.6, CH3  1.57, sa  19.6, CH3  1.41, sa 
15 27.2, CH3  1.16, s  27.6, CH3  1.41, s  26.9, CH3  0.94, s 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S5. 1H and 13C NMR Spectroscopic Data (500 MHz, CDCl3) for compounds 13 - 15. 
  
 13b  14b  15c 
position δC, type  δH (J in Hz)  δC, type  δH (J in Hz)  δC, type  δH (J in Hz) 
1 81.8, C    81.8, C    136.3, C   
2a 40.9, CH2  2.21, brd (15.3)a  40.9, CH2  2.21, brd (15.3)a  33.0, CH2  2.63, d (17.7) 
2b   1.89, bd (15.3)    1.89, brd (15.3)    2.41a 
3 64.3, CH  3.54, brs  64.3, CH  3.54, brs  63.1, CH  3.32, s 
4 67.4, C    67.4, C    66.5, C   
5 61.0, CH  2.33, dd (11.3, 3.1)  61.0, CH  2.33, dd (11.3, 3.1)  51.2, CH  3.01, d (10.7) 
6 75.2, CH  3.92, ddd (11.1, 9.1, 6.4)  75.2, CH  3.92, ddd (11.1, 9.1, 6.4)  77.7, CH  3.64, dd (10.2, 10.2) 
7 46.8, CH  3.23, m  46.8, CH  3.23, m  56.1, CH  3.06, dddd(10.2, 10.2, 2.9, 
2.9) 
8 73.1, CH  4.95, m  73.1, CH  4.95, m  70.1, CH  4.71, ddd (10.7, 10.7, 1.8) 
9a 35.4, CH2  2.55, ddd (15.2, 7.3, 2.9)   35.4, CH2  2.55, ddd (15.2, 7.3, 2.9)   41.2, CH2  2.42a  
9b    2.26, m a    2.26, ma    2.15, dd (13.6, 2.0) 
10 140.7, C    140.7, C    127.9, C   
11 168.7, C    168.7, C    168.3, C   
12 136.6, C    136.6, C    136.8, C   
13a 122.7, CH2  6.18, d (3.4)  122.7, CH2  6.18, d (3.4)  120.1, CH2  6.07, d (3.0)  
13b   5.60, dd (4.7, 3.2)d    5.60, dd (4.7, 3.2)d    5.48, d (3.0) 
14 18.6, CH3  1.63, s  18.6, CH3  1.63, s  18.6, CH3  1.59, s 
15 118.0, CH3  5.53, brd (3.4)   118.0, CH3  5.53, brd (3.4)   21.9, CH3  1.66, s 
   4.98, brs    4.98, brs     
1' 175.9, C    172.4, C    169.4, C   
2' 41.5, CH  2.42, ddq (13.9, 13.9, 7.0)  43.5, CH2  2.25, ma  20.7, CH3  2.04, s 
3'a 26.4, CH2  1.73, m    25.6, CH  2.14, tqq (6.7, 6.7, 6.7)     
3'b   1.49, m         
4' 11.8, CH3  0.94, dd (7.5, 7.5)  22.43, CH3  0.98, d (6.7)a     
5' 16.8, CH3  1.19, d (7.0)  22.46, CH3  0.99, d (6.7)a     


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S3. 1H NMR spectrum of compound 1 (500 MHz, CDCl3).  
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Figure S4. 13C spectrum of compound 1 (125 MHz, CDCl3).  
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Figure S5. 13C-DEPTq spectrum of compound 1 (125 MHz, CDCl3).  
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Figure S6. 1H-1H COSY spectrum of compound 1 (500 MHz, CDCl3).  
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Figure S7. . 1H-1H NOESY spectrum of compound 1 (500 MHz, CDCl3).  
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Figure S8. HSQC-DEPT spectrum of compound 1 (500 MHz, CDCl3).  
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Figure S11. 1H NMR spectrum of compound 2 (500 MHz, CDCl3).  
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Figure S12. 13C-DEPTq spectrum of compound 2 (125 MHz, CDCl3).  
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Figure S13. 1H-1H COSY spectrum of compound 2 (500 MHz, CDCl3).  
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Figure S14. 1H-1H NOESY spectrum of compound  2 (500 MHz, CDCl3).  
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Figure S15. HSQC-DEPT spectrum of compound 2 (500 MHz, CDCl3).  
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Figure S18. 1H NMR spectrum of compound 3 (500 MHz, CDCl3).  
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Figure S19. 13C-DEPTq spectrum of compound 3 (125 MHz, CDCl3).  
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Figure S20. 1H 1H COSY spectrum of compound 3 (500 MHz, CDCl3).  
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Figure S21. 1H 1H NOESY spectrum of compound 3 (500 MHz, CDCl3)  
 32 









Figure S22. HSQC-DEPT spectrum of compound 3 (500 MHz, CDCl3).  
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Figure S23. HMBC spectrum of compound 3 (500 MHz, CDCl3). 
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Figure S24. 1H NMR spectrum of compound 4 (500 MHz, CDCl3).   
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Figure S25. 13C-DEPTq spectrum of compound 4 (125 MHz, CDCl3).  
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Figure S26. 1H-1H COSY spectrum of compound 4 (500 MHz, CDCl3).  
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Figure S27. 1H-1H NOESY spectrum of compound 4 (500 MHz, CDCl3).  
 38 









Figure S28. HSQC-DEPT spectrum of compound 4 (500 MHz, CDCl3).  
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Figure S32. 1H NMR spectrum of compound 5 (500 MHz, DMSO).  
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Figure S33. 13C-DEPTq spectrum of compound 5 (125 MHz, DMSO).  
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Figure S34. 1H-1H COSY spectrum of compound 5 (500 MHz, DMSO).  
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Figure S35. 1H-1H NOESY spectrum of compound 5 (500 MHz, DMSO).  
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Figure S36. HSQC-DEPT spectrum of compound 5 (500 MHz, DMSO).  
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Figure S44. 1H NMR spectrum of compounds 8 and 9 (500 MHz, DMSO).  
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Figure S45. 13C NMR spectrum of compounds 8 and 9 (125 MHz, CDCl3).  
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Figure S46. 1H-1H COSY spectrum of compounds 8 and 9 (500 MHz, CDCl3).  
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Figure S47. . 1H-1H NOESY spectrum of compounds 8 and 9 (500 MHz, CDCl3).  
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Figure S48. HSQC-DEPT spectrum of compounds 8 and 9 (500 MHz, CDCl3).  
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Figure S52. 1H NMR spectrum of compound 10 (500 MHz, DMSO).  
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Figure S53. 13C-DEPTq spectrum of compound 10 (125 MHz, DMSO).  
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Figure S54. 1H-1H COSY spectrum of compound 10 (500 MHz, DMSO).  
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Figure S55. 1H-1H NOESY spectrum of compound 10 (500 MHz, DMSO).  
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Figure S56 HSQC-DEPT spectrum of compound 10 (500 MHz, DMSO).  
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Figure S59. 1H NMR spectrum of compound 11 (500 MHz, DMSO).  
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Figure S60. 13C-DEPTq spectrum of compound 11 (125 MHz, DMSO).  
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Figure S61. 1H-1H COSY spectrum of compound 11 (500 MHz, DMSO).  
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Figure S62. 1H-1H NOESY spectrum of compound 11 (500 MHz, DMSO).  
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Figure S63. HSQC-DEPT spectrum of compound 11 (500 MHz, DMSO).  
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Figure S64. HMBC spectrum of compound 11 (500 MHz, DMSO). 
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 exp. for 11
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Figure S66. Comparison of experimental and computed ECD spectra for compound 11 in MeOH. 
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 exp. for mixture 13 and 14
 calcd. for (1S,3R,4S,5R,6S,7R,8S,2'S)-13a
 calcd. for (1S,3R,4S,5R,6S,7R,8S,2'R)-13b
 calcd. for (1S,3R,4S,5R,6S,7R,8S)-14
 
Figure S67. Comparison of experimental ECD spectrum of the mixture of compounds 13 and 14 in MeOH (270 μg/mL) to the 
computed spectra of 13a, 13b, and 14. Combined curves were mixed in the ratio of 1:1 as determined between compounds 13 and 14 











































































































































































































































































































































































































































































































































































































































































Figure S70. ORTEP diagram of compound 15 from the X-ray diffraction experiment.
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Figure S71. 1H NMR spectrum of compound 17 (500 MHz, CDCl3).  
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Figure S72. 13C-DEPTq spectrum of compound 17 (125 MHz, CDCl3)   
 84 









Figure S73. 1H-1H COSY spectrum of compound 17 (500 MHz, CDCl3).  
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Figure S74. 1H-1H NOESY spectrum of compound 17 (500 MHz, CDCl3).  
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Figure S75. HSQC-DEPT spectrum of compound 17 (500 MHz, CDCl3).  
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3.2. Immunosuppressive Activity of Artemisia argyi Extract and 
Isolated Compounds 
Amy M. Zimmermann-Klemd†, Jakob K. Reinhardt†, Anna Morath, Wolfgang W. Schamel, Peter 
Steinberger, Judith Leitner, Roman Huber, Matthias Hamburger, Carsten Gründemann 
Front. Pharmacol. 2020, 11, 402. doi: 10.3389/fphar.2020.00402 
 
The need for novel drugs for the treatment of autoimmune diseases is high, since available 
pharmaceuticals often have substantial side effects and limited efficacy. Natural products are a 
good starting point in the development of immunosuppressive leads. Since enhanced T cell 
proliferation is a common feature of autoimmune diseases, we investigated the T cell proliferation 
inhibitory potential of an extract library of plants used in traditional Chinese medicine. Using a 
newly established cell-based screening platform, an ethyl acetate extract of Artemisia argyi H.Lév. 
& Vaniot (Asteraceae, A. argyi) was found to suppress the proliferation of human primary T 
lymphocytes in vitro in an IL-2-dependent manner. Flow cytometry- and ELISA-based techniques 
further demonstrated that the A. argyi extract reduced the activation and function of T cells. 
Transcription factor analysis and flow cytometric calcium influx investigations indicated that the 
immunomodulatory effect was based on specific modification of T cell signaling in a non-cytotoxic 
manner which is mediated via the NFAT pathway and a non-sequestrant inhibition of the calcium 
influx. A series of guaianolide and seco-guaianolide sesquiterpene lactones, as well as a 
flavonoid, were identified in a previous study as the bioactive compounds in the A. argyi extract. 
The effects of these bioactive compounds were compared to those of the crude extract. The tested 
sesquiterpene lactones act via the transcription factor NFAT and NF-kB, thereby exhibiting their 
immunosuppressive potential, but have an overall effect on T cell biology on a more-downstream 
level than the crude A. argyi extract. 
 
 
Preparation of the tested extract, selection of compounds, preparation of chemical structures, 
writing of manuscript draft regarding results and discussion on “Effects of isolated compounds”, 
and the discussion of other tested Asteraceae were my contributions to this publication. Other 
than that, I contributed to the design, implementation of the research, and in finalizing the 
manuscript. 
†contributed equally to this work 
 
 
Jakob K. Reinhardt 
 
  
Frontiers in Pharmacology | www.frontiers
Edited by:
Judit Hohmann,
University of Szeged, Hungary
Reviewed by:
Edgar Serfling,
Julius Maximilian University of
Würzburg, Germany
Orazio Taglialatela-Scafati,




†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 17 December 2019
Accepted: 17 March 2020
Published: 08 April 2020
Citation:
Zimmermann-Klemd AM,
Reinhardt JK, Morath A,
Schamel WW, Steinberger P,
Leitner J, Huber R, Hamburger M
and Gründemann C (2020)
Immunosuppressive Activity of





published: 08 April 2020
doi: 10.3389/fphar.2020.00402Immunosuppressive Activity of
Artemisia argyi Extract and Isolated
Compounds
Amy M. Zimmermann-Klemd1†, Jakob K. Reinhardt2†, Anna Morath3,4,5,
Wolfgang W. Schamel3,4,6, Peter Steinberger7, Judith Leitner7, Roman Huber1,
Matthias Hamburger2 and Carsten Gründemann8*
1 Center for Complementary Medicine, Institute for Infection Prevention and Hospital Epidemiology, Faculty of Medicine,
University of Freiburg, Freiburg, Germany, 2 Pharmaceutical Biology, Pharmacenter, University of Basel, Basel, Switzerland,
3 Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany, 4 Faculty of Biology, University of
Freiburg, Freiburg, Germany, 5 Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg,
Germany, 6 Center for Chronic Immunodeficiency, Medical Center Freiburg and Faculty of Medicine, University of Freiburg,
Freiburg, Germany, 7 Center for Pathophysiology, Infectiology, and Immunology, Institute of Immunology, Medical University
of Vienna, Vienna, Austria, 8 Translational Complementary Medicine, Department of Pharmaceutical Sciences, University of
Basel, Basel, Switzerland
The need for novel drugs for the treatment of autoimmune diseases is high, since available
pharmaceuticals often have substantial side effects and limited efficacy. Natural products
are a good starting point in the development of immunosuppressive leads. Since enhanced
T cell proliferation is a common feature of autoimmune diseases, we investigated the T cell
proliferation inhibitory potential of an extract library of plants used in traditional Chinese
medicine. Using a newly established cell-based screening platform, an ethyl acetate extract
of Artemisia argyi H.Lév. & Vaniot (Asteraceae, A. argyi) was found to suppress the
proliferation of human primary T lymphocytes in vitro in an IL-2-dependent manner. Flow
cytometry- and ELISA-based techniques further demonstrated that the A. argyi extract
reduced the activation and function of T cells. Transcription factor analysis and flow
cytometric calcium influx investigations indicated that the immunomodulatory effect was
based on specific modification of T cell signaling in a non-cytotoxic manner which is
mediated via the NFAT pathway and a non-sequestrant inhibition of the calcium influx. A
series of guaianolide and seco-guaianolide sesquiterpene lactones, as well as a flavonoid,
were identified in a previous study as the bioactive compounds in the A. argyi extract. The
effects of these bioactive compounds were compared to those of the crude extract. The
tested sesquiterpene lactones act via the transcription factor NFAT and NF-kB, thereby
exhibiting their immunosuppressive potential, but have an overall effect on T cell biology on a
more-downstream level than the crude A. argyi extract.
Keywords: Artemisia, immunosuppression, interleukin-2, T cell signalling, sesquiterpene lactonesin.org April 2020 | Volume 11 | Article 4021
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyiINTRODUCTION
T cells play a major role in the immune system. A complex
mechanism of antigen recognition and signal transduction
ensures a highly specific and highly efficient clearance of pathogens.
Upon T cell activation, several adaptor molecules and signaling
proteins are phosphorylated to initiate three main axis of signal
transduction in T cells. In this process, phosphatidylinositol-4,5-
bisphosphate (PIP2) is hydrolyzed to generate inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). While DAG is
membrane associated, IP3 binds to the IP3 receptor in the
membrane of the endoplasmic reticulum (ER) leading to calcium
ER store depletion. Upon calcium ER store depletion, release-
activated channels (CRAC channels) mediate a strong store-
operated calcium entry (SOCE) (Hogan et al., 2010). The rising
calcium concentration in the cytosol causes dephosphorylation and
thereby unmasking of the nuclear location sequence of the nuclear
factor of activated T cells (NFAT) via second messenger and
phosphatase activation (Srikanth et al., 2017). On a further axis the
mitogen-activated protein kinase (MAPK) pathway is triggered,
resulting the formation of activator protein 1 (AP-1) and its
nuclear transport (Myers et al., 2019). The third axis induces
phosphorylation of nuclear factor of the kappa-light-polypeptide-
gene enhancer in B cells inhibitor (IkB), leading to its degradation.
Subsequently, the nuclear factor kappa-light-chain enhancer of
activated B cells (NF-kB) is released for nuclear transport (Sun,
2012). The transcription factors NFAT, NF-kB, and AP-1 all bind to
the interleukin-2 (il-2) gene to allow transcription and secretion of
interleukin-2 (IL-2) (Myers et al., 2019). IL-2 autocrinally stimulates T
cell proliferation, and thus, is crucial for a proper immune response.
Consequently, IL-2 can be linked to immune overreactions.
Overreaction of the immune system can be linked to
autoimmune diseases such as rheumatoid arthritis or multiple
sclerosis (Chaplin, 2010; Wang et al., 2015). The treatment of
autoimmune diseases usually involves different classes of
immunosuppressive drugs (Her and Kavanaugh, 2016).
Glucocorticoids inhibit the function of immune cells as the
activated glucocorticoid receptor directly interferes with the
transcription factors NF-kB and AP-1 (van der Laan and Meijer,Abbreviations: AP-1, activator protein 1; APC, allophycocyanin; CD, cluster of
differentiation; CFSE, carboxyfluorescein succinimidyl ester; CPT, camptothecin;
CsA, cyclosporine A; CRAC channel, calcium release activated channel; DAG,
diacylglycerine; DMSO, dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic
acid; ELISA, enzyme-linked immunosorbent assay; ER, endoplasmic reticulum;
FACS, fluorescence-activated cell sorting; FCS, fetal bovine serum; FDA, Food and
Drug Administration; FITC, Fluorescein isothiocyanate; GFP, green fluorescent
protein; HPLC, High-performance liquid chromatography; IFN-, interferon-; IkB,
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor; IL-,
interleukin; IC50, half maximal inhibitory concentration; IP3, inositol 1,4,5-
trisphosphate; mAb, monoclonal antibody; MAPK, mitogen-activated protein
kinase; NCEs, new chemical entities; NFAT, Nuclear factor of activated T-cells;
NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; p, p-value;
Par, parthenolide; PIP2, phosphatidylinositol 4,5-bisphosphate; PBMC, peripheral
blood mononuclear cell; PBS, phosphate buffered saline; PE, phycoerythrin; PI,
propidium iodide; PMA, phorbol-12-myristat-13-acetate; RPMI, Roswell Park
Memorial Institute medium; SD, standard deviation; SOCE, store-operated
calcium entry; TNF-a, tumor necrosis factor alpha; TCM, traditional Chinese
medicine; TCR, T cell receptor.
Frontiers in Pharmacology | www.frontiersin.org 22008; Frenkel et al., 2015; Wang et al., 2017). Glucocorticoids are
quite effective, but this potency is accompanied by a range of side
effects (Ramamoorthy and Cidlowski, 2016). Drugs such as
cyclophosphamide or mycophenolate interfere with the cell cycle
and, thereby, inhibit lymphocyte proliferation (Allison, 2000; Wang
et al., 2015). Despite their clinical efficacy, these drugs also show
severe side effects (Allison, 2000; Wang et al., 2015).
Biopharmaceuticals, also called biologics, are widely used due to
minor toxicity and high levels of specificity. They intervene strongly
in the immune system and, therefore, lead to an increased
susceptibility to infections and paradoxical inflammation (Her
and Kavanaugh, 2016; Moroncini et al., 2017; Wagner, 2019).
Small-molecule drugs (e.g., cyclosporine A, tacrolimus, or
tofacitinib) interfering in T cell signaling lead to a suppression of
T cell proliferation by addressing different molecular targets
(Allison, 2000; Tedesco and Haragsim, 2012; Wiseman, 2016),
and they all show adverse effects, such as nephrotoxicity and an
increased susceptibility to infections (Allison, 2000).
Hence, compounds with novel modes of action and fewer side
effects are needed. Natural products remain a promising source
for the discovery and development of new drugs. A recent
analysis emphasized their relevance by demonstrating that one
third of new chemical entities (NCEs) approved by the Food and
Drug Administration (FDA) between 1981 and 2014 were based
on natural products (Newman and Cragg, 2016). Plant
secondary metabolites possess high structural diversity which
has likely evolved for serving different biological functions
(Atanasov et al., 2015).
Aiming the discovery of new plant derived drugs, we recently
tested a library of 435 extracts from plants used in traditional
Chinese medicine (TCM), whereby immunosuppressive activity
and inhibition of T lymphocyte proliferation in vitro, without
apparent cytotoxicity, was targeted. One of the best hits in this
library was an ethyl acetate extract of Artemisia argyi H. Lév. &
Vaniot (Asteraceae).A. argyi (also called “Chinesemugwort”) grows
in China, Japan, and Korea and is traditionally used for the
treatment of abdominal pain, dysmenorrhea, uterine hemorrhage,
and inflammation (Yun et al., 2016). In previous studies, fatty acids,
essential amino acids, sesquiterpene lactones, coumarins, sterols,
terpenes, and polyphenols were the main compound classes isolated
from A. argyi (Bao et al., 2013; Kim et al., 2015). A. argyi was
recently shown to have anti-inflammatory properties (Yun et al.,
2016). The anti-inflammatory effects were supported by in vivo
experiments that showed reduced cytokine levels and immune
infiltration in mouse models for contact dermatitis (Yun et al.,
2016) and allergic asthma (Shin et al., 2017). The anti-inflammatory
properties of A. argyi were linked to some compounds in the
extracts, such as the flavonoids jaceosidin, eupatilin, and luteolin,
and to a sesquiterpene dimer. These compounds were recently
shown to decrease the production of inflammatory mediators and
cytokines (Zeng et al., 2014; Li et al., 2018).
We previously showed that the A. argyi extract inhibited the
proliferation of stimulated human T lymphocytes in vitro, and a
series of related guaianolides and seco-guaianolides was found to be
responsible for most of the inhibitory effects of the extract
(Reinhardt et al., 2019). In the present study, we aimed to furtherApril 2020 | Volume 11 | Article 402
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyisubstantiate the rationale for the use of A. argyi as an anti-
inflammatory herbal drug. We here address the effects of A. argyi
extract and selected compounds on the activation and function of T
cells in vitro, as well as the effects of these compounds on relevant
signaling pathways.MATERIALS AND METHODS
Ethics Approval Statement
Written informed consent was obtained from patients prior to
blood donation for research purposes. All experiments conducted
on human material were approved by the Ethics Committee of the
University of Freiburg (55/14; 11.02.2014). All performed methods
are compliant with the regulations of the Ethics Committee of the
University of Freiburg.
Preparation and Cultivation of Human
Peripheral Lymphocytes
Preparation and cultivation of human peripheral lymphocytes
were performed as indicated (Zimmermann-Klemd et al., 2019).
Briefly, peripheral blood mononuclear cells (PBMCs) were
isolated from the blood of healthy adult donors, which was
obtained from a blood transfusion center (University Medical
Center, Freiburg, Germany). Venous blood was centrifuged on a
LymphoPrep™ gradient (1.077 g/cm3, 20 min, 500 × g, 20°C;
Progen, Heidelberg, Germany). After centrifugation cells were
washed twice with phosphate buffered saline (PBS) and
subsequently cultured in Roswell Park Memorial Institute
medium (RPMI) 1640 medium supplemented with 10% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 U/ml streptomycin (all from Life
Technologies, Paisley, UK). Cells were cultured at 37°C in a
humidified incubator with a 5% CO2/95% air atmosphere.
Activation and Treatment of Lymphocytes
Lymphocytes were activated with anti-CD3 (clone OKT3) and
anti-CD28 (clone 28.2) mAbs (each 100 ng/ml; both from
eBioscience, Frankfurt, Germany) in the presence of medium;
cyclosporine A (CsA; 4.16 µM; Sandimmun 50 mg/ml, Novartis
Pharma, Basel, Switzerland); camptothecin (CPT; 300 µM:
Tocris, Bristol, UK); 0.5% Triton-X 100; plant extract; or
isolated compounds from A. argyi, as described previously
(Zimmermann-Klemd et al., 2019). After cultivation, the cells
were used in biological tests.
Determination of Apoptosis and Necrosis
of T Cells
Determination of apoptosis and necrosis of T cells was performed as
described previously (Zimmermann-Klemd et al., 2019). Cells were
treated for 48 h. Cultured cells were washed with PBS and stained
with Annexin V-FITC using the apoptosis detection kit
(eBioscience, Frankfurt, Germany) according to instructions of
the manufacturer. Propidium iodide (PI; eBioscience, Frankfurt,
Germany) was added, and cells were stained for 15 min at room
temperature in the dark. The proportion of apoptotic/necroticFrontiers in Pharmacology | www.frontiersin.org 3lymphocytes was determined by flow cytometric analysis
(FACSCalibur instrument; BD Biosciences, Franklin Lakes, NJ).
Determination of T Cell Proliferation
The proliferation of T lymphocytes was determined using
carboxyfluorescein diacetate succinimidyl ester (CFSE) staining, as
described previously (Parish et al., 2009; Gründemann et al., 2012).
Lymphocytes were isolated, washed twice in cold PBS, and
resuspended in PBS at a concentration of 5 × 106 cells/ml. Cells
were stained for 10 min at 37°C with CFSE (5 µM; Sigma-Aldrich,
St. Louis, MO). The staining reaction was stopped by washing twice
with a complete medium. Stained cells were treated for 72 h. The
progress of cell division was determined by flow cytometric analysis
(FACSCalibur instrument; BD Biosciences, Franklin Lakes, NJ).
Analysis of Activation Marker of T Cells
The activation state of T lymphocytes was determined via cell-
surface analysis of CD25 and CD69, as previously reported
(Gründemann et al., 2014). Briefly, cells were treated for 24 h.
Then, cells were washed with PBS and stained with PE-labeled,
anti-CD25 mAbs; FITC-labeled, anti-CD69; and, for the
differentiation of CD4+ and CD4– T cells, with APC-labeled,
anti-CD4 mAbs (all from eBioscience, Frankfurt, Germany) for
20 min at 4°C. Afterward, cells were washed twice with PBS,
resuspended, and transferred into FACS vials. The expression of
CD25 and CD69 was measured for CD4+ and CD4– T cells,
respectively, by flow cytometric analysis (FACSCalibur
instrument; BD Biosciences, Franklin Lakes, NJ).
Determination of Cytokine Secretion
After 20 h of treatment, cells were restimulated with PMA (50 ng/
ml; Sigma-Aldrich, Taufkirchen, Deutschland) and ionomycin (500
ng/ml; Sigma-Aldrich, Taufkirchen, Deutschland) for 4 h.
Supernatants were stored at –20°C. The amount of cytokines was
quantified using ELISA technique according to manufacturer's
instructions (Affymetrix, Frankfurt, Germany).
Determination of Cytokine-Producing Cells
Cells were treated for 20 h, as described in section 2.3, and
restimulated with PMA (50 ng/ml; Sigma-Aldrich, Taufkirchen,
Deutschland) and ionomycin (500 ng/ml; Sigma-Aldrich,
Taufkirchen, Germany) for an additional 4 h at 37°C. During
this time, they were additionally treated with GolgiPlug (0.5 µl;
BD Biosciences, Heidelberg, Germany). After incubation, cells of
each sample were divided into three approaches: one for the
determination of IL-2, one for the determination of TNFa, one
for the determination of IFN-g. The cells were fixed with 100 µl
of 4% PFA (Morphisto, Frankfurt, Germany) for 10 min at room
temperature and washed with PBS. Afterward, permeabilization
was performed using 100 µl of 1× BD Perm/Wash Puffer (BD
Biosciences, Heidelberg, Germany) per sample for 15 min at 4°C.
Finally, cells were stained with 1 µl anti-IL-2 or anti-IFN-g (both
Affymetrix, Frankfurt, Germany) for 30 min at 4°C. After two
washing steps samples were analyzed by flow cytometric analysis
(FACS LSR Fortessa Instrument; BD Biosciences, Franklin
Lakes, NJ).April 2020 | Volume 11 | Article 402
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A CD107a surface staining was performed, as described
previously (Gründemann et al., 2013), to determine the T cell
degranulation capacity. Cells were treated for 20 h and then
restimulated for 4 h with PMA (50 ng/ml; Sigma-Aldrich,
Taufkirchen, Deutschland) and ionomycin (500 ng/ml; Sigma-
Aldrich, Taufkirchen, Deutschland). To each well containing 200
µl of cell suspension, 2.5 µl (~0.25 µg) of PE-conjugated, anti-
CD107a mAbs (eBioscience, Frankfurt, Germany) was added.
After incubation at 37°C for 1 h, 2 µl of 1/10 diluted GolgiStop
(Becton Dickinson, Franklin Lakes, NJ) was added per well, and
the cells were incubated for another 3 h. Samples were analyzed
by flow cytometric analysis (FACSCalibur instrument; BD
Biosciences, Franklin Lakes, NJ).
Reporter Cell Experiments for the
Determination of NFAT-, NF-kB-, and AP-1
Activity
A 96 well F-bottom cell culture plate was coated with anti-
human CD3 mAb (clone OKT3, 1 µg/ml, 50 µl/well) or PBS
(unstim. control) at 4°C over-night. Reporter cells (Jutz et al.,
2016) were harvested, washed twice with PBS, and seeded in a 5%
FCS RPMI cell culture medium (0.15 × 106 cells in 200 µl/well).
Cells were treated with inhibitors (1 nM SP100030 for AP-1, 5
µg/ml cyclosporine A for NFAT, and 20 µM parthenolide for
NF-kB), plant extract or isolated compounds from A. argyi or
remained untreated (unstim. control, stim. control). Cells were
incubated at 37°C for 8 h (AP-1) or 24 h (NFAT and NF-kB).
Cells were washed twice with PBS and the expression of eGFP
was determined by flow cytometric analysis (FACSCalibur
instrument; BD Biosciences, Franklin Lakes, NJ).
Determination of Intracellular Calcium
Jurkat cells (0.5 × 106) were stained in 200 µl RPMI medium,
containing 1% FCS, 2.6 µM Fluo3 AM (Life Technologies, Carlsbad,
California), 5.5 µM FuraRed AM (Invitrogen, Carlsbad, California),
and 0.1% (w/v) Pluronic F-127 (Invitrogen, Carlsbad, California) in
the presence of test substances (30 µg/ml A. argyi extract or 10 µg/
ml compound/compound mix; merely for the determination of the
calcium ER store depletion) for 45 min at 37°C. For differentiation
of calcium ER store depletion and SOCE, the staining solution was
further supplemented with 0.6 mM ethylenediaminetetraacetic acid
(EDTA). Cell suspensions were gently mixed every 10 min. After
staining cells were resuspended in 100 µl of 1% FCS RPMI medium
containing the test substance (30 µg/ml A. argyi extract or 10 µg/ml
compound/compound mix; merely for the determination of the
calcium ER store depletion). For themeasurement of calcium influx,
50 µl of cell suspension were prewarmed (37°C, 5 min) in 700 µl of
1% FCS RPMI medium supplemented with 0.6 mM EDTA (for
differentiation of ER store depletion and SOCE) and the test
substance (30 µg/ml A. argyi extract or 10 µg/ml compound/
compound mix; merely for the determination of the calcium ER
store depletion). Baseline calcium levels were determined by flow
cytometric measurement (FACS CyAn ADP; Beckman Coulter,
Brea, California) for 1 min. Afterward, calcium influx was induced
via stimulation with anti-CD3mAbs (clone OKT3, 1 µg/ml). After 2Frontiers in Pharmacology | www.frontiersin.org 4min, the test substance (30 µg/ml A. argyi extract or 10 µg/ml
compound/compound mix) was added, followed, 30 s later, by the
addition of calcium dichloride (1 mM). Calcium influx was
measured for 5 min.
Analysis of Data
For statistical analysis, data were processed with Microsoft Excel
and SPSS software (Version 22.0, IBM, Armonk, USA). Statistical
significance was determined with the SPSS software by a one-way
ANOVA followed by Dunnett's post hoc pairwise comparisons.
Values are presented as mean ± standard deviation (SD) for the
indicated number of independent experiments. The asterisks
represent significant differences from controls (*p < .05).
Tested Compounds
The compounds used in this work were isolated from A. argyi
ethyl acetate extract in a previous study (Reinhardt et al., 2019).RESULTS
Anti-Proliferative Effects of the A. argyi
Extract on T Lymphocytes
Previously, we evaluated the effect of 435 plant extracts from a
focused extract library of TCM plants on the proliferative
capacity of primary expanded human T lymphocytes in vitro.
The ethyl acetate extract of A. argyi inhibited the proliferation of
human T lymphocytes in a concentration-dependent manner,
with a half maximal inhibitory concentration (IC50) of 16.2 µg/
ml (Reinhardt et al., 2019) (Figure 1A). The focused library also
comprised extracts from other plants of the Asteraceae family
(Supplement 2), but none of these exhibited notable activity in
the assay.
To verify that the observed immunosuppressive activity was
not due to cytotoxicity of the extract, flow cytometry analysis was
performed to analyze the apoptosis and necrosis events of the
cells. Using Annexin V/PI double staining, we found that the A.
argyi extract had no toxic effects in the concentration range that
was used for the mechanistic studies (Figures 1B, C).
Effects of the A. argyi Extract on
T Lymphocyte Function
Next, the effect of the A. argyi extract on the effector function of
human T cells was examined. Stimulation of T lymphocytes via the
T cell receptor (TCR) leads to the expression of the activation
markers CD25 and CD69. We found that after TCR stimulation the
treatment of T cells with the A. argyi extract significantly and
concentration-dependently lowered CD25 and CD69 expressions
(Figures 2A, B). This was the case in both the CD4+ and CD4– T
cells. In addition, we observed a significantly reduced CD25
expression of CD4– T cells after treatments with low
concentrations (3 and 10 µg/ml) of the A. argyi extract (Figure 2A).
Upon activation, T cells secrete IL-2, which is important for
proliferation, and interferon-g (IFN-g), which defines T cell
function. The A. argyi extract significantly suppressed IL-2 as
well as the IFN-g secretion capacity of activated T lymphocytes
(Figures 2C, D).April 2020 | Volume 11 | Article 402
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Transcription Factors AP-1, NFAT,
and NF-kB
To understand how the activation and proliferation of human T cells
is inhibited by the A. argyi extract, we analyzed the effect of the A.
argyi extract on the transcription factors AP-1, NFAT, and NF-kB.
All three transcription factors regulate the transcription of the il-2
gene, which is a key regulator in these processes. Jurkat T cell reporter
lines (Ratzinger et al., 2014; Jutz et al., 2016), in which eGFP is fused
to the response elements of these transcription factors, were used for
this purpose. After stimulation with anti-CD3 mAbs, activity of the
transcription factors was quantified via flow cytometry. The
treatment with the A. argyi extract did not change the anti-CD3-Frontiers in Pharmacology | www.frontiersin.org 5induced AP-1 activity in comparison to untreated activated AP-1
reporter cells (Figure 3A). In contrast, NFAT andNF-kB activity was
reduced in a concentration-dependent manner by the A. argyi extract
(Figures 3B, C). In summary, the reporter cell experiments pointed to
a specific suppression of NFAT and NF-kB activities, but not to
suppression of AP-1.
Effects of the A. argyi Extract on TCR-
Induced Calcium Signaling
The previous experiments demonstrated that the A. argyi extract
lowered activity of NFAT, which was induced by TCR triggering.
Influx of calcium ions into the cytosol is upstream regulated of
NFAT activation (Robert et al., 2011). Hence, we performedA
B
C
FIGURE 1 | Overview of recently published results (A) and effect of the A. argyi extract on the viability of T lymphocytes (B, C). Expanded human lymphocytes (2 ×
105) were left unstimulated (unstim.) or were stimulated (stim.) with anti-CD3 and anti-CD28 mAbs (100 ng each) and incubated for 48 h with medium (unstim.,
stim.), camptothecin (CPT; 300 mM), Triton-X 100 (0.5%) or the A. argyi extract. Annexin V-FITC and PI double stainings were performed after incubation. The
proportions of viable, necrotic, and apoptotic cells were determined by flow cytometry. Data are depicted as dot plots (B), and the proportion of apoptotic/necrotic
lymphocytes in relation to the stimulated control was determined from two independent experiments. Data are depicted as mean ± SD (C).April 2020 | Volume 11 | Article 402
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influx to the cytosol was impaired. Inhibition of calcium influx
would prevent the translocation of NFAT to the nucleus and,
consequently suppress NFAT activity.
Jurkat cells were stained with the calcium indicators Fluo3
and FuraRed and treated with the A. argyi extract. Subsequently,
calcium influx was induced by TCR stimulation using an anti-
CD3 mAbs. The experiments demonstrated that the treatment of
the cells with the A. argyi extract led to a complete suppression of
the calcium influx (Figures 4A, B).
Next, we sought to characterize the inhibition of the calcium
influx. Jurkat cells were treated with the A. argyi extract or the
calcium ion chelator EDTA to determine whether the inhibition was
mediated via chelation of calcium. As expected, a strong calcium
influx was measured for untreated cells (control) after TCR
stimulation (Figure 4C). This influx was prevented in EDTA-
treated cells but restored by the addition of calcium dichloride to
the medium (Figure 4C). In contrast, in cells treated with the A.
argyi extract, the calcium influx capability could not be restored
with the addition of increasing concentrations of calcium dichloride
(Figure 4C). This suggested that the A. argyi extract did not inhibit
the calcium influx through calcium chelating properties.Frontiers in Pharmacology | www.frontiersin.org 6Upon TCR activation by antigen binding, the opening of a
calcium channel in the membrane of the ER initiates calcium release
from ER stores (ER store depletion). The depletion of these
intracellular calcium stores causes the formation of calcium
release-activated channels (CRAC) channels, which in turn leads
to a strong influx of calcium from the extracellular space to the
cytosol (store-operated calcium entry, SOCE) and allows
replenishment of the calcium stores in the ER (Robert et al.,
2011). To discriminate between these two options, we stained
Jurkat cells with Fluo3 and FuraRed in a medium supplemented
with EDTA. During the staining process, the cells were treated with
theA. argyi extract in a calcium-free setting to ensure a calcium-free,
extracellular compartment. Cells were stimulated via TCR to induce
the calcium influx. Given that the SOCE was prevented, calcium
store depletion could be measured. In comparison to the untreated
cells (control), treatment with the extract lowered calcium ER store
depletion (Figure 4D). To determine whether the SOCE was also
inhibited by theA. argyi extract, or just prevented due to the lacking
depletion of ER calcium store, we stained Jurkat cells with Fluo3 and
FuraRed in a medium supplemented with EDTA, and induced the
calcium ER store depletion by TCR stimulation. Next, the extract
and calcium dichloride were added and the SOCE was measured.A B
DC
FIGURE 2 | Effects of A. argyi extract on the function of T lymphocytes. For (A, B), lymphocytes (2 × 105) were left unstimulated (unstim.) or were activated with
anti-CD3 and anti-CD28 mAbs (100 ng each and incubated for 24 h with medium (unstim., stim.), cyclosporine A (CsA; 4.16 µM), camptothecin (CPT; 300 µM), or
the A. argyi extract. Cells were stained with anti-CD69-FITC and anti-CD4-APC (A) or anti-CD25-PE and anti-CD4-APC (B). Expression of surface markers (CD69,
CD25, CD4) was analyzed by flow cytometry, and the amounts of activated CD4+ and CD4– T lymphocytes were determined. For (C, D) expanded lymphocytes (2 ×
105) were incubated for 20 h with medium (unstim., stim.), cyclosporine A (CsA; 4.16 µM), camptothecin (CPT; 300 µM), parthenolide (20 µM) or the A. argyi extract.
Subsequently, the cells were stimulated with PMA/Ionomycin for 4 h at 37°C. IL-2 (C) and IFN-g (D) were quantified in the supernatants by ELISA. The results of
three different experiments are summarized and are depicted as mean ± SD in relation to the untreated, stimulated control. *p < 0.05. n.d.= below detection limit.April 2020 | Volume 11 | Article 402
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyiThe medium of control cells was supplemented with calcium
dichloride directly after depletion of the intracellular calcium
stores. The results showed that the A. argyi extract also lowered
the SOCE from the extracellular space (Figure 4D).
In summary, the strong reduction of calcium influx upon
TCR stimulation after treatment with the A. argyi extract
resulted from suppression of the ER calcium store depletion
and a reduction of the SOCE.Frontiers in Pharmacology | www.frontiersin.org 7Effects of Isolated A. argyi Compounds on
the Activation and Function of
T Lymphocytes
We previously isolated a series of sesquiterpene lactones and
flavones from the active extract (Figure 7A), some of which
showed significant inhibitory effects on T lymphocyte
proliferation (Reinhardt et al., 2019) (Figure 1A). Several of the
most-active compounds were tested: two stereoisomeric
guaianolides, artecanin and canin (1 and 5), artanomaloide (2),
arteglasin A (3) differing from 1 and 2 in the decoration of the 7-
membered ring, the moderately active flavone jaceosidin (4), and
two stereoisomeric seco-guaianolides, seco-tanapartholides B and A
(6 and 7) (Figure 5).
To better understand their contribution to the activity of the
extract, their influence on activation, cytokine production, and
degranulation capacity of human T lymphocytes was investigated.
The compounds 1, 2, 3, 5, and the compound mix significantly
reduced the expression of CD25 in CD4– and CD4+ T cells at 10
and/or 3 µg/ml. Compound 6 suppressed the CD25 expression in
CD4+ T cells at all tested concentration levels, while compound 7
suppressed it at 10 and 3 µg/ml. Compounds 6 and 7 had no
significant effect on CD4– T cells. The isolated flavone 4 showed no
effect on CD25 expression (Figure 6A).
All isolated compounds, with the exception of compound 4,
significantly and strongly suppressed IL-2-producing cells at 10
µg/ml. While the effect was only miniscule for the flavone (4),
compounds 1, 3, 5-7, and the mix also showed significant
inhibition at 3 µg/ml. A similar pattern was observed for the
suppression of tumor necrosis factor a-(TNFa) and IFN-g-
producing cells. The strongest suppression of IL-2- and IFN-g-
producing cells was observed from compound 6 (Figure 6B).
Upon release of perforin and granzymes, T lymphocytes
express the lysosomal-associated membrane protein 1 (LAMP-
1, CD107a) on their surface. Analysis of the LAMP-1 surface
expression, showed concentration-dependent effects for the
mixture of all compounds and the A. argyi extract (Figure 6C).
Effects of Isolated A. argyi Compounds on
the Transcription Factors NFAT and NF-kB
Jurkat-based NFAT and NF-kB reporter experiments were
performed to shed light on the interaction of compounds by
manipulation the T lymphocyte signaling. For the sesquiterpene
lactones, but not for the flavone (4), a concentration-dependent,
suppressive effect on the NFAT pathway was found, with IC50
values < 10 µM (< 3 µg/ml) (Figures 7C, D). Likewise, NF-kB
activity was significantly decreased by all compounds except
compound 4 (Figures 7B, D). We here focused on the effects of
the A. argyi extract and isolated compounds on the NFAT
signaling pathway.
Thus we tested whether the isolated compounds were able to
inhibit TCR-induced calcium signaling. To this end, we looked at
both the ER calcium store depletion (Supplement 1, left panel) and
the SOCE (Supplement 1, right panel), using the methodology,
described above. Single compounds and a mixture of all isolated
compounds were tested with the assumption that the mixture
would, at least in part, mimic the activity of the whole extract.A
B
C
FIGURE 3 | Effect of the A. argyi extract on the activity of transcription
factors AP-1 (A), NFAT (B) and NFkB (C) in Jurkat T cells. Jurkat reporter
cells (0.15 × 106) were seeded on a cell culture plate, coated with anti-CD3
mAbs, and incubated with medium, inhibitors (AP-1: 1 nM SP100030, NFAT:
4.16 µM CsA, NF-kB: 20 µM parthenolide) or the A. argyi extract in different
concentrations for 8 (AP-1) or 24 h (NFAT and NF-kB). The GFP expression
was measured by flow cytometry after incubation. The results of three
independent experiments are summarized and depicted as mean ± SD.
*p < 0.05.April 2020 | Volume 11 | Article 402




FIGURE 4 | Effect of the A. argyi extract on the calcium influx in Jurkat T cells. Jurkat cells (0.5 × 106) were stained with Fluo3 and FuraRed for 45 min at 37°C in
the presence of medium, 0.6 mM EDTA or 30 µg/ml A. argyi extract. The results show the anti-CD3-induced (black arrows) calcium influx as the Fluo3/FuraRed ratio
(A) and the median of this ratio (B) for untreated cells (ctr.) and cells treated with 30 µg/ml A. argyi extract. Calcium influx was induced by anti-CD3 stimulation (black
arrows) of the TCR (C), and, after 1 min 1 mM calcium dichloride was added (red arrows). The calcium influx (ratio Fluo3/FuraRed) of untreated cells (ctr.), cells
treated with 0.6 mM EDTA, and cells treated with 30 µg/ml A. argyi extract are shown. The ER store depletion in presence of the A. argyi extract was analyzed (D).
Jurkat cells (0.5 × 106) were stained with Fluo3 and FuraRed in a calcium-free medium for 45 min at 37°C. To determine the ER calcium store depletion, 30 µg/ml A.
argyi extract was present in the medium during staining and measurement, and the ER store depletion was triggered by TCR stimulation (black arrows). The control
cells remained untreated. For determination of the SOCE, cells were stained, and the ER calcium store depletion was induced by TCR stimulation (black arrows).
After 2 min 30 µg/ml A. argyi extract (green arrows) were added and, after another 30 s, 1 mM calcium dichloride (red arrows) was added. For the control (ctr.),
1 mM calcium dichloride was added directly after depletion of the ER calcium store. The results show the calcium influx (the ratio Fluo3/FuraRed) of the untreated
cells (ctr.) and the cells treated with 30 µg/ml A. argyi extract.Frontiers in Pharmacology | www.frontiersin.org April 2020 | Volume 11 | Article 4028
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyiThe A. argyi extract was used as a control. A slight inhibition of
calcium influx from the ER combined with a significant time delay
was observed for compound 5. A similar delay was observed for the
compound mix and, to a lesser extent, for compounds 1, 6, and 7.
Compounds 2 and 3 increased the intensity of the calcium influx.
However, neither the single compounds nor the compound mix
inhibited the calcium influx as effectively as did the A. argyi extract
(Supplement 1).DISCUSSION
We recently found that an ethyl acetate extract of A. argyi
suppressed the in vitro proliferation of human primary T
lymphocytes in a concentration-dependent, non-cytotoxic
manner (Figure 1) and we also isolated a series of compounds
that were responsible for this activity (Reinhardt et al., 2019).
Stimulation of TCR promotes the surface expression of the
transmembrane C-type lectin CD69 and the alpha-chain of the IL-2
receptor (CD25) on T cells (Malek, 2008). The A. argyi extract
lowered the expression of both activation markers (Figures 2A, B)
and of IL-2 production (Figure 2C) in stimulated T lymphocytes.
As IL-2 is pivotal for lymphocyte proliferation, inhibition of IL-2
production could explain the observed inhibition of T cell
proliferation. Further, the IFN-g secretion was reduced after
treatment with the A. argyi extract (Figure 2D). Our findings
provide evidence for IL-2-mediated, anti-inflammatory properties
of the extract, likely via IL-2-mediated T lymphocyte proliferation
inhibition, and thereby corroborate the traditional use of A. argyi as
an anti-inflammatory herbal drug (Yun et al., 2016).
The IL-2-dependent suppression of T lymphocyte proliferation
by the A. argyi extract is linked to suppression of the transcription
factors NFAT and NF-kB (Figures 3B, C), while AP-1 activity wasFrontiers in Pharmacology | www.frontiersin.org 9not affected (Figure 3A). ER calcium store depletion and the SOCE
were inhibited via a non-sequestrant mechanism (Figures 4A–D).
Our observation that it is impossible to restore the calcium influx by
generating an overage of calcium dichloride in the outer cell
compartment points to an irreversible blockage of the calcium
channels. Otherwise, binding and dissociation homeostasis would
trigger a stronger calcium influx without binding of the active
constituent(s) of the A. argyi extract to the calcium channels. The
effect of the extract was comparable to that of the calcium chelator
EDTA. Inhibition of the ER calcium store depletion and SOCE
explain the observed reduced NFAT activity.
To correlate the effects found for the A. argyi extract to the
compounds from the extract, selected T cell proliferation-inhibiting
compounds were investigated analogously. Jaceosidin (4) showed
no effect on either NFAT or NF-kB reporter cells, which is in accord
with its weak inhibition of all three pro-inflammatory cytokines
tested. A comparable inhibition of TNFa expression by jaceosidin
(4) has been reported (Li et al., 2018). Thus, it is unlikely for
jaceosidin to contribute significantly to the observed activity of the
extract. All tested sesquiterpene lactones were shown to inhibit
NFAT and NF-kB binding to the DNA. The inhibition of DNA
binding of NF-kB can presumably be compared to the effects
published for other sesquiterpene lactones, such as helenalin (a
guaianolide) and parthenolide (a germacranolide) (García-Piñeres
et al., 2001; García-Piñeres et al., 2004). Parthenolide inhibits the
IkB kinase complex b (IKKb) by alkylating a cysteine residue in its
activation loop (Kwok et al., 2001). Less is known about the effect of
sesquiterpene lactones on the NFAT pathway, which was the focus
of this work. Only helenalin was previously shown to suppress
abundance and nuclear translocation of NFATc2 (Berges et al.,
2009). The stereoisomeric guaianolides artecanin (1) and canin (5),
as well as the guaianolide dimer 2 and arteglasin A (3) showed very
similar effects to the A. argyi extract in general. However, in the ER1 2 3
4 5 6 7
FIGURE 5 | Chemical structures of (1S)-artecanin (1), 8-acetyl-artanomaloide (2), arteglasin A (3), jaceosidin (4), (1R)-canin (5), (4S, 5S, 6S, 7S)- and (4R, 5R, 6S,
7S) -seco-tanapartholide (6 and 7).April 2020 | Volume 11 | Article 402
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FIGURE 6 | Effect of the isolated compounds and the compound mix on activation (A) IL-2-, TNFa-, and IFN-g-producing T cells (B) and the degranulation capacity
of T cells (C). For (A), lymphocytes (2 × 106) were stimulated with anti-CD3 and anti-CD28 mAbs (100 ng each) and incubated for 48 h with medium (unstim., stim.),
cyclosporine A (CsA; 4.16 µM), the compounds, the compounds mixture, or the A. argyi extract (B). Cells were re-stimulated with PMA (500 µg/ml) and ionomycin
(500 ng/ml) and treated with GolgiPlug for 4 h. The cells were fixed, permeabilized, and stained with anti-IL-2, anti-TNFa or anti-IFN-g mAbs. The amount of IL-2-,
TNFa-, and IFN-g-secreting cells was determined via flow cytometry. Results from four independent experiments were summarized and are depicted as mean ± SD
in relation to the untreated, stimulated control. *p < 0.05. For (C) lymphocytes (2 × 105) were stimulated with anti-CD3 and anti-CD28 mAbs (100 ng each).
Afterward, cells were incubated for 20 h with medium (unstim., stim.), cyclosporine A (CsA; 4.16 µM), camptothecin (CPT; 300 mM), the compound mixture, or the A.
argyi extract. Cells (except the unstim. control) were restimulated with PMA (500 µg/ml) and ionomycin (500 ng/ml) for 4 h and stained with anti-CD107a-PE. The
amount of degranulating T lymphocytes, as indicated by a CD107a surface expression, was determined via flow cytometry. Data are depicted as histogram plots,
and data of three independent experiments are summarized as mean ± SD. *p < 0.05.Frontiers in Pharmacology | www.frontiersin.org April 2020 | Volume 11 | Article 40210
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyistore depletion and for the SOCE, the activity of the single
compounds was not comparable to that of the extract. Only canin
(5), but not its stereoisomer artecanin (1), showed some inhibition
of ER store depletion, which did not affect the SOCE. Thus, canin
(5) might be part of the explanation for the inhibition of the ER
store depletion by the A. argyi extract. The specific CD25 inhibition
by the two seco-guaianolides 6 and 7 in CD4+ cells but not inCD4–
cells is unusual and deserves further investigation. However, thisFrontiers in Pharmacology | www.frontiersin.org 11inhibition is not reflected in the activity of the A. argyi extract.
Althoughmost of the observed activity from theA. argyi extract can
be attributed to the presence of the tested guaianolides and seco-
guaianolides, none of the isolated compounds showed sufficient
inhibition of the ER calcium store depletion or the SOCE
(Supplement 1). This was also true for a mixture of the
compounds, suggesting that other, as yet unidentified compounds




FIGURE 7 | Overview of the published fractionation process (A) and effect of the A. argyi compounds on NF-kB (B) and NFAT (C) activity and corresponding IC50
values (D) in Jurkart T cells. Jurkat reporter cells (0.15 × 106) were seeded on a culture plate, coated with anti-CD3 mAbs, and incubated with medium, inhibitors
(NFAT: 4.16 µM CsA, NF-kB: 20 µM parthenolide) or A. argyi compounds in different concentrations for 24 h. The GFP expression was measured by flow cytometry.
The results of three independent experiments are summarized and depicted as mean ± SD. *p < 0.05 (B, C). The calculated IC50 values are presented in µg/ml and
in µM, as stated (D).April 2020 | Volume 11 | Article 402
Zimmermann-Klemd et al. Immunosuppressive Activity of Artemisia argyiThe initial screening (Reinhardt et al., 2019) included extracts
from additional herbal drugs of the family Asteraceae, but none of
these inhibited T cell proliferation at the concentrations tested. The
lack of activity can be possibly explained, by an absence of
sesquiterpene lactones from the extracts (Carthamus tinctorius,
Artemisia scoparia, and Artemisia apiacaea). So far, sesquiterpene
lactones have only been reported from Artemisia capillaris (Feng
et al., 2017) and Centipeda minima (Eisenbrand and Tang, 2011),
and their concentrations in the plants were very low, in the range of
0.001% in A. capillaris (Wu et al., 2012; Feng et al., 2017).
Furthermore, the strength of T cell proliferation inhibition may
also depend on the specific sesquiterpene scaffold, as significant
differences were observed between eudesmanes, guaianolides, and
seco-guaianolides (Reinhardt et al., 2019). All reported sesquiterpene
lactones from C. minima are structurally related to helenalin, which
is a known NF-kB inhibitor (Lyss et al., 1997; Eisenbrand and
Tang, 2011).
We ascertained different modes of action for the capacity of theA.
argyi extract to inhibit the proliferation of T cells. We demonstrated
that theA. argyi extract, as well as different guaianolides isolated from
it, inhibited the activity of NFAT and NF-kB. Moreover, the crude
extract suppressed the TCR-induced calcium influx, but neither the
isolated single compounds nor a mixture of these sesquiterpene
lactones showed similar effects. This suggests that the A. argyi
extract likely contains compounds affecting signaling on a more
upstream target than the compounds isolated thus far. Our findings
corroborate the notion of a multitarget effect of herbal extracts
possibly resulting in pharmacological synergism (Fürst and
Zündorf, 2015; Colalto, 2018). The study also demonstrates that the
established cell-based screening platform approach is a powerful tool
for identifying and characterizing potential immunosuppressive leads
from natural product sources.DATA AVAILABILITY STATEMENT
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Supplement 1: Effect of isolated compounds and compound mix on the calcium flux in 
Jurkat T cells, in comparison to A. argyi extract. Jurkat cells (0.5 x 106) were stained with 
Fluo3 and FuraRed in calcium-free medium for 45 min at 37°C. During the staining process 
and measurement 30 µg/mL A. argyi extract or 10 µg/mL of the compounds, or 10 µg/mL of 
compound mix were present in the medium (only left panel). The calcium flux was induced by 
addition of the anti-CD3 mAbs (black arrows). For the investigation of SOCE, extract, 
compounds or compound mix were added (green arrows) after ER store depletion and calcium 
dichloride was supplemented (red arrows) subsequently. The results show the kinetics of 
calcium flux (median Fluo3/FuraRed) of untreated cells and cells treated with 30 µg/mL A. 
argyi or 10 µg/mL of each compound.  
  
Supplement 2: Table of all tested Asteraceae.  
Family Species Organ Extracts 
Asteraceae Centipeda minima Herb EtOAc ASE 
Asteraceae Centipeda minima Herb DCM ASE 
Asteraceae Centipeda minima Herb MeOH ASE 
Asteraceae Carthamus tinctorius Flowers/Buds EtOAc ASE 
Asteraceae Carthamus tinctorius Flowers/Buds DCM ASE 
Asteraceae Carthamus tinctorius Flowers/Buds MeOH ASE 
Asteraceae Artemisia apiacea Herb EtOAc 
Asteraceae Artemisia apiacea Herb DCM ASE 
Asteraceae Artemisia apiacea Herb MeOH ASE 
Asteraceae Artemisia argyi Herb EtOAc 
Asteraceae Artemisia argyi Herb DCM ASE 
Asteraceae Artemisia argyi Herb MeOH ASE 
Asteraceae Artemisia capillaris Herb EtOAc 
Asteraceae Artemisia capillaris Herb DCM ASE 
Asteraceae Artemisia capillaris Herb MeOH ASE 
Asteraceae Artemisia scoparia Herb EtOAc 
Asteraceae Artemisia scoparia Herb DCM ASE 




3.3. Compounds from Toddalia asiatica: Immunosuppressant activity 
and absolute configurations  
Jakob K. Reinhardt, Amy M. Zimmermann-Klemd, Ombeline Danton, Martin Smieško, Carsten 
Gründemann, Matthias Hamburger 
J Nat Prod. 2019, 82, 1424-1433. doi: 10.1021/acs.jnatprod.8b00791  
 
In a screening of an extract library from plants used in Traditional Chinese Medicine (TCM) the 
MeOH extract of Toddalia asiatica inhibited proliferation of human primary T cells with an IC50 of 
25.8 µg/mL. Activity in the extract was tracked by HPLC activity profiling, and a total of 15 
compounds was characterized. Two compounds, toddalic acid (6) and toddanolic acid (7), were 
new natural products, and two recently published compounds, 2’R-toddalolactone-3’-O-β-D-
glucopyranoside (10) and 2’S-toddalolactone-2’-O-β-D-glucopyranoside (11), were described in 
detail for the first time. The absolute configurations of compounds 8, 9, 10, 12, 13 and 15 were 
determined by comparison of experimental and calculated ECD spectra. For glycosides 9 and 10, 
ECD data and enantioselective HPLC of the aglycons after enzymatic hydrolysis confirmed the 
results. Nitidine chloride (4) inhibited proliferation of primary human T cells with an IC50 of 0.37 µM. 
 
 
Extraction of plant material, isolation, recording and interpretation of analytical data for structure 
elucidation (HPLC-PDA-ELCD-ESI-MS, 1D and 2D NMR [with support from Ombeline Danton], 
optical rotation, ECD), interpretation of data from VCD measurements (measurements and some 
advice from Thomas Bürgi), quantum chemical calculations of ECD and VCD spectra (some 
advice from Martin Smieško), writing of the manuscript draft, and preparation of figures (with the 
exception of Figure 3) were my contributions to this publication. [T-lymphocyte proliferation 
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ABSTRACT: In a screening of an extract library from plants used
in Traditional Chinese Medicine the MeOH extract of Toddalia
asiatica inhibited proliferation of human primary T cells with an
IC50 of 25.8 μg/mL. Activity in the extract was tracked by HPLC
activity profiling, and a total of 15 compounds were characterized.
Three compounds, toddalic acid (6) and both enantiomers (7a
and 7b) of toddanolic acid (7), were new natural products, and
two recently published compounds, (2′R)-toddalolactone 3′-O-β-
D-glucopyranoside (10) and (2′S)-toddalolactone 2′-O-β-D-
glucopyranoside (11), were described in detail for the first time.
The absolute configurations of compounds 8, 9, 10, 12, 13, and 15
were determined by comparison of experimental and calculated
ECD spectra. For glucosides 9 and 10, ECD data and chiral-phase HPLC of the aglycones after enzymatic hydrolysis confirmed the
results. Nitidine chloride (4) inhibited proliferation of primary human T cells with an IC50 of 0.4 μM.
Under normal conditions the immune system is able todifferentiate between self and nonself.1 However, auto-
immune diseases can develop if this function is impaired. In
rheumatoid arthritis, for example, autoreactive T cells attack
the synovial lining of the joints, resulting in tissue destruction
and inflammation.2 Autoimmune diseases are typically treated
with immunosuppressive drugs, but therapy may be accom-
panied by severe side effects.3 Thus, there is a need for better-
tolerated treatment options. To find new natural product leads
with immunosuppressive activity, a library of extracts from
plants used in Traditional Chinese Medicine (TCM) was
screened for their ability to inhibit T cell proliferation in vitro.
The MeOH extract from roots of Toddalia asiatica Lam.
(Rutaceae) was a promising hit, as it showed an IC50 value of
25.8 μg/mL without concomitant cytotoxicity (Figure S1,
Supporting Information). T. asiatica grows in most parts of
Asia and Africa.4 Its roots are only occasionally used in TCM
(Fei Long Zhang Xue),5 but more commonly as an
antimalarial drug in different African countries.6,7 The
phytochemistry of T. asiatica has been widely studied, and
numerous coumarins, alkaloids, and phenolic compounds have
been isolated from the roots of the plant.8−10 Most notably, a
structurally diverse set of coumarins have been identified,
including glucosides and prenylated derivatives.
■ RESULTS AND DISCUSSION
The active compounds in the extract were tracked by HPLC-
based activity profiling.11 The overlay of an analytical HPLC
chromatogram and the activity of 1 min microfractions
collected is shown in Figure S2 (Supporting Information).
Inhibition of T cell proliferation was found in the micro-
fractions eluted at 14, 15, and 26 min. Compounds 3−10 in
the time windows of activity were subsequently isolated by a
combination of liquid−liquid partitioning, centrifugal counter-
current chromatography, preparative flash chromatography,
and HPLC on RP stationary phases. In addition, compounds 1,
2, and 11−15 were isolated from adjacent regions in the
HPLC chromatogram (Figure S2, Supporting Information).
The active fraction at 26 min contained a minor peak with the
same mass as nitidine (4). However, this peak was not found
after further fractionation of the extract.
Compound 1 was identified as syringic acid by analysis of
HRESIMS and NMR data (Table S1, Supporting Information)
and comparison with literature data.12
Compound 2 had a molecular formula of C21H23NO5
(HRESIMS data m/z 370.1646 [M + H]+, calcd for
C21H24NO5
+, 370.1649). With the aid of 1D and 2D NMR
data recorded at 23 and 60 °C (Table S2) and comparison
Received: May 22, 2020
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with literature data, compound 2 was identified as
allocryptopine.13
Fagaridine (3b, identical to isofagaridine14) was obtained as
the major compound in a 4:1 mixture with dihydrofagaridine
(3a).15 Both were identified by comparison of their NMR data
(Table S3, Supporting Information) with the literature.14,15 To
prepare fagaridine (3b) as the respective chloride for biological
testing, the mixture was passed through an ion-exchange resin.
In the resulting compound a change was observed for the
chemical shifts of C-6 (δC 86.3) and H-6 (δH 5.53). The
presence of a methoxy group at C-6 was supported by an
HMBC correlation of H-6 to a carbon at δC 51.8. However, no
correlating protons were seen in the HSQC-DEPT spectrum.
This suggested the formation of the pseudobase of fagaridine
in the presence of methanol-d4 used for the NMR measure-
ments (Figure 1). Indeed, similar reactions have been
described before.16,17
Compound 4 was identified as nitidine by analysis of its 1D
and 2D NMR spectra in DMSO-d6 with trifluoracetic acid
(Table S4, Supporting Information). Nitidine chloride was
successively prepared using an ion-exchange resin.18 The 1H
NMR shifts in DMSO-d6 (Table S4, Supporting Information)
and MS data (HRESIMS data m/z 348.1223 [M]+, calcd for
C21H18NO4
+, 348.1230) were in good agreement with
published data.19
Compound 5 was identified as dihydronitidine (Table S4,
Supporting Information).20,21
For compound 6, a molecular formula of C12H10O6
(HRESIMS data m/z 251.0542 [M + H]+, calcd for
C12H11O6
+, 251.0550) was determined, which, in combination
with 1D and 2D NMR data (Table 1), suggested a coumarin.
However, no signals for the proposed carboxylic acid moiety at
C-6 appeared in the HMBC and 13C NMR spectra. The
compound was methylated with trimethylsilyl diazomethane
Chart 1
Figure 1. Isolated mixture of compounds 3a and 3b and proposed reaction of compound 3b to yield 3c.
Journal of Natural Products pubs.acs.org/jnp Article
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J. Nat. Prod. 2020, 83, 3012−3020
3013
(TMS-DAM) to obtain methyl ester 6a (Figure S17,
Supporting Information) with a molecular formula of
C13H12O6 (HRESIMS data m/z 265.0706 [M + H]
+, calcd
for C13H13O6
+, 265.0707), and the structure was corroborated
by NMR data as the methyl ester of 6. Thus, toddalic acid (6)
was confirmed as a new coumarin and only similar to buntasin,
another naturally occurring coumarin carboxylic acid found in
some Citrus species.22
The molecular formula of compound 7 was determined as
C16H22O7 (HRESIMS data m/z 327.1437 [M − H]−, calcd for
C16H23O7
−, 327.1449). NMR data (Table 2) indicated an
aromatic ring bearing one hydroxy group, two methoxy groups
(CH3-7 and CH3-8; δH 3.75 and 3.76), a 2-methylbutan-2,3-
diol side chain, and a propionic acid residue (C-3″; δC 178.1).
The location of substituents on the aromatic ring were
determined with the aid of 13C NMR and HMBC data, leading
to the 2D structure of 7. To determine the absolute
configuration at C-2′, an ECD spectrum was recorded and
compared to ab initio calculated spectra of the enantiomers
(Figure S3(B), Supporting Information). The measured ECD
spectrum had a low signal-to-noise ratio and showed no
significant features of an expected π→π* transition at 220 nm
hinting at a scalemic mixture. The enantiomers were
subsequently separated by chiral-phase HPLC. ECD spectra
(Figure S3(B), Supporting Information) and the specific
rotations of the single enantiomers were recorded. The specific
rotations and ECD values for compound 7b were smaller than
could be expected. This was most likely due to an impurity not
observed in the NMR. Comparison to the ab initio calculated
ECD spectra identified 7a as (−)-(2′S)-toddanolic acid and 7b
as (+)-(2′R)-toddanolic acid.
The 2D structure of compound 8 (Table S5, Supporting
Information) corresponded to that of hesperidin.23,24
Compounds 9 and 10 were identified by 1D and 2D NMR
data analysis as toddalolactones bearing a sugar moiety at C-3′.
Hydrolysis and subsequent GCMS analysis of the sugar
afforded D-glucose in both cases. Therefore, 9 and 10 were
epimers at C-2′, and this was corroborated by a difference in
13C chemical shifts of CH3-4′ (δC 21.9 in 9 and δC 23.0 in 10)
and CH3-5′ (δC 24.0 in 9 and δC 23.4 in 10). Compound 9
showed a specific rotation of [α]D
25 −45 and [α]D25 −2.5 for 10.
The (2′S)-epimer (9) was reported earlier by Lin et al. with a
specific rotation of [α]D
25 −44.25 In a recent publication,
however, the (2′R)-epimer 10 was reported as the
“enantiomer” of the (2′S)-epimer, with 13C NMR data virtually
identical to those of Lin’s (2′S)-epimer, but with exactly
opposite specific rotations.26 This was highly unexpected in
light of our data, and the absolute configuration of C-2′ in both
compounds was therefore examined in detail.
The absolute configuration at C-2′ was determined by ECD.
The experimental spectra of 9 and 10 showed Cotton effects
(CEs) at 225, 253, and 330 nm with opposite signs. In the
calculated spectra (Figure 2) the sign for the CE at 330 nm
was negative for both epimers. Therefore, the CEs at 225 and
253 nm were used for the assignment. The two negative CEs
measured for 9 were in good agreement with the calculated
CEs for (2′S)-toddalolactone 3′-O-β-D-glucopyranoside. The
spectrum measured for 10 showed positive CEs at 225 and 253
nm. The observed CE at 225 nm matched with a positive CE
Table 1. 1H and 13C NMR Spectroscopic Data (500 MHz,
Methanol-d4) for Compounds 6 and 6a
6 6a
position δC, type δH (J in Hz) δC, type
a δH (J in Hz)
2 163.2, C 162.2, C
3 113.2, CH 6.24, d (9.8) 113.5, CH 6.28, d (9.8)
4 140.9, CH 8.03, d (9.8) 140.0, CH 8.02, d (9.8)
4a 108.2, C 108, C
5 155.2, C 156.3, C
6 118.7a, C 115.1, C
7 161.7, C 161.6, C
8 96.1, CH 6.74, s 96.3, CH 6.79, s
8a 157.4, C 158.1, C
11 c 167.1, C
12 63.4, CH3 3.99, s 63.7, CH3 3.92, s
13 57.1, CH3 3.90, s 57.1, CH3 3.90, s
b
14 52.9, CH3 3.89, s
b
a13C extracted from 1H−13C 2D inverse-detected experiments.
bOverlapping signals. cSignal not found.
Table 2. 1H and 13C NMR Spectroscopic Data (500 MHz,
Methanol-d4) for Compound 7






6 96.7, CH 6.30, s 1, 2, 4, 5
7 62.2, CH3 3.75, s
a 3
8 56.1, CH3 3.76, s
a 5
1’ 27.2, CH2 2.66, dd (13.7, 10.1) 3, 4, 5, 2′, 3′
1’ 2.86a 3, 4, 5, 2′, 3′
2’ 79.9, CH 3.56, dd (9.8, 2.8) 1′, 3′, 4
3′ 74.2, C
4’ 25.4, CH3 1.23, s
a 2′, 3′, 5′
5′ 25.8, CH3 1.22, sa 2′, 3′, 4’
1″ 20.9, CH2 2.87a 2, 2″, 3″
2″ 35.3, CH2 2.54, t (8.2, 8.2) 1″, 3″
3″ 178.1, C
aOverlapping signals.
Figure 2. Comparison of experimental and calculated ECD spectra of
compounds 9 and 10 in MeOH (calcd spectrum shifted +5 nm).
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in the calculated spectrum of (2′R)-toddalolactone 3′-O-β-D-
glucopyranoside, but no interpretable CE was seen in the
calculated spectrum at 253 nm. To corroborate the assign-
ments, compounds 9 and 10 were subjected to acid hydrolysis
with HCl.25 This led to an almost quantitative formation of
ketone 9a and, via a rearrangement, to aldehyde 9b (Figures
S18 and S81−S84, Supporting Information) and a small
amount of the aglycones. Using chiral-phase chromatography
on a Daicel Chiralpak IG column, the aglycone of 9 was
identified as (2′S)-toddalolactone, and that of 10 as (2′R)-
toddalolactone (Figure S128, Supporting Information).
Enzymatic hydrolysis of 9 and 10 with cellulase was used to
obtain the aglycones in sufficient amounts for ECD and
specific rotation (SR) analysis (Figures S123−S126, Support-
ing Information). ECD identified the aglycone of 9 as the
(2′S) enantiomer, and the one from 10 as the (2′R)-
enantiomer (Figure S8, Supporting Information). Collectively,
compound 9 was identified as (2′S)-toddalolactone 3′-O-β-D-
glucopyranoside and compound 10 as (2′R)-toddalolactone
3′-O-β-D-glucopyranoside. Coumarin 10 has been recently
reported, but the assignment of its absolute configuration was
solely based on OR data and a questionable correlation with
previously known glucoside 9.26
Compound 11 had a molecular formula of C22H30O11
(HRESIMS data m/z 493.1672 [M + Na]+, calcd for
C22H30O11Na
+, 493.1680), and 1D and 2D NMR data
(Table 3) identified it as toddalolactone 2′-O-β-D-glucopyrano-
side.26 As the absolute configuration of 11 was hitherto only
based on SR data, an ECD spectrum was recorded and
compared to calculated spectra of both possible epimers
(Figure S9, Supporting Information). However, the calculated
spectra were highly similar; thus the analysis was inconclusive.
Acidic hydrolysis of 11 afforded the aglycone together with the
respective ketone and aldehyde (Figure S18, Supporting
Information). The aglycone was identified via chiral-phase
HPLC as (2′S)-toddalolactone (Figure S128, Supporting
Information), and compound 11 was conclusively identified
as (2′S)-toddalolactone 2′-O-β-D-glucopyranoside.
A molecular formula of C39H48O17 was determined for
compound 12 (HRESIMS data m/z 811.2758 [M + Na]+,
calcd for C39H48O17Na
+, 811.2784). Using 1D and 2D NMR
data, compound 12 was identified as hazaleanin B (Table S7,
Supporting Information), which was previously reported from
Fagara rhetza (Rutaceae)27 and Zhuyeqing Liquor.28 ECD
analysis corroborated the published absolute configuration as
(2R,3R,4S)-hazaleanin B (Figure S11, Supporting Informa-
tion).
Compound 13 had a molecular formula of C39H50O17
(HRESIMS data m/z 813.2916 [M + Na]+, calcd for
C39H50O17Na
+, 813.2940). By 1D and 2D NMR analysis 13
was identified as hazaleanin A.27 ECD data analysis was used to
independently confirm the absolute configuration. Owing to
the high conformational flexibility of 13, the conformational
analysis was performed not in bulk but in explicit MeOH by
means of molecular dynamics simulations. A comparison of the
experimental and calculated spectra (spectra in Figure S13,
selected conformers in Figures S19−S22, Supporting Informa-
tion) resulted in the assignment of 13 as (2S,3S)-hazaleanin in
accordance with the findings of Shibuya et al.27 This is the first
report of the presence of hazaleanins A and B in T. asiatica.
Compound 14 was identified by 1D and 2D NMR data as p-
coumaroyltyramine (Table S8, Supporting Information).29
Compound 15 had a molecular formula of C16H20O6
(HRESIMS data m/z 309.1329 [M + Na]+, calcd for
C16H20O6Na
+, 309.1333), and 1D and 2D NMR data (Table
S9, Supporting Information) identified the compound as
Table 3. 1H and 13C NMR Spectroscopic Data (500 MHz, Methanol-d4) for Compounds 9, 10, and 11
9 10 11
pos. δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz)
2 163.5, C 163.5, C 163.7, C
3 112.7, CH 6.22, d (9.8) 112.7, CH 6.20, d (9.6) 112.6, CH 6.21, d (9.5)
4 141.3, CH 8.00, d (9.8) 141.4, CH 7.97, d (9.6) 141.6, CH 7.98, d (9.5)
4a 108.5, C 108.5, C 108.5, C
5 157.7, C 157.8, C 157.9, C
6 120.3, C 120.4, C 120.0, C
7 163.7, C 163.9, C 164.1, C
8 96.4, CH 6.72, s 96.4, CH 6.69, s 96.3, CH 6.71, s
8a 156.2, C 156.3, C 156.4, C
9 64.0, CH3 3.90, s
a 64.0, CH3 3.88, s
a 64.2, CH33 3.90, s
a
10 56.9, CH3 3.91, s
a 56.9, CH3 3.88, s
a 56.9, CH 3.90, sa
1′ 27.2, CH2 2.90, dd (13.6, 10.1) 27.2, CH2 2.89, dd (13.7, 9.8) 27.0, CH2 2.98, dd (13.7, 10.0)
1′ 2.79, dd (13.6, 2.0) 2.76, dd (13.7, 2.4) 2.72, d (13.7)
2′ 77.6, CH 3.81a 77.2, CH 3.79a 88.1, CH 3.87a
3′ 82.0, C 81.6, C 75.1, C
4′ 21.9, CH3 1.36, sa 23.0, CH3 1.34, sa 24.3, CH3 1.30, s
5′ 24.0, CH3 1.35, sa 23.4, CH3 1.35, sa 26.6, CH3 1.25, s
1″ 98.7, CH 4.57, d (7.6)a 98.3, CH 4.55, d (7.6)a 106.1, CH 4.20, d (7.0)
2″ 75.3, CH 3.22, dd (8.4, 7.6) 75.5, CH 3.19, dd (9.5, 7.6) 76, CH 3.06a
3″ 78.1, CH 3.4, dd (8.4, 8.4) 78.3, CH 3.38, dd (9.5, 7.9) 78.1, CH 3.23a
4″ 71.7, CH 3.32a 71.8, CH 3.31a 71.7, CH 3.06a
5″ 77.8, CH 3.29a 77.9, CH 3.28a 77.3, CH 2.90, m
6″ 62.8, CH2 3.65, dd (11.7, 5.0) 62.9, CH2 3.66, dd (11.7, 4.7) 62.9, CH2 3.22a
6″ 3.82, ma 3.82a 3.26a
aOverlapping signals.
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toddalolactone.25,30 The negative sign of the specific rotation
suggested (2′S)-toddalolactone (15a).25 This was supported
by the ECD spectrum, which was compared to the calculated
spectra of both enantiomers 15a and 15b (Figure S15,
Supporting Information). The SR of 15 ([α]D
25 −10) compared
to (2′S)-toddalolactone (15a) obtained by enzymatic hydrol-
ysis of 9 ([α]D
25 −51) indicated the enantiomeric excess of 15a
as 20%. This analysis was corroborated by a 1H NMR
experiment in the presence of the shift reagent Eu(hfc)3
31
(29% enantiomeric excess of 15a) and chiral-phase HPLC on a
Daicel Chiralpak IG column (25% enantiomeric excess of
15a).
In conclusion, a total of 15 compounds were isolated from
the MeOH extract of T. asiatica, of which toddalic acid (6) and
toddanolic acid (7) were new natural products. Although
compound 10, the 2′-epimer of 9, was reported recently, we
provide here the first full structural assignment and
spectroscopic data. The co-occurrence of 9 and 10 indicates
that both enantiomers of toddalolactone are naturally present
in the plant.32 The carboxylic moiety at C-6 in coumarin 6 is
unusual from a biosynthetic perspective, and only one similar
naturally occurring coumarin has been reported so far.22
Toddanolic acid (7) is structurally related to toddalolactone
(15). An artifactual formation of 7 can be ruled out given that
an opening of the lactone ring and reduction of the double
bond would require conditions (e.g., basic pH, metal catalyst,
and NaBH4) far from the ones used during the isolation.
33,34
Compounds 1−15 were tested for their ability to suppress
the proliferation of stimulated human primary T lymphocytes
in vitro. Compounds 1−3 and 6−15 showed slight inhibition
of T cell proliferation at the highest test concentration of 30
μM. Compounds 4 and 5 concentration-dependently inhibited
T cell proliferation with IC50’s of 0.4 μM (R
2 = 0.7) and 6.7
μM (R2 = 0.9), respectively (Figure 3). Cytotoxic effects were
detected only at 10 and 30 μM concentrations for compound 4
and at 30 μM concentration for 5. Nitidine chloride (4) has
been previously found to modulate reactive microgliosis after
traumatic brain injury at 0.1 μM, and inhibition of the ERK
and NF-κB signaling pathways in microglia cells was
reported.35 Inhibition of T cell proliferation by nitidine
chloride (4) observed in our study could thus be caused by
inhibition of these pathways. Nitidine chloride reportedly also
induces apoptosis in HCT116 human colorectal cancer cells
via inhibition of ERK.36 In conclusion, nitidine chloride (4) is
a potential lead, with inhibition of T cell proliferation at sub-
micromolar concentrations and an apparent cytotoxicity only
at a 25-fold higher concentration. This possibility was also
corroborated by a patent (CN102008474B) filed for the use of
nitidine in the treatment of autoimmune diseases and resisting
transplant rejection.37 The related dihydronitidine (5) has
been reported to selectively induce apoptosis in various tumor
cell lines when tested at low micromolar concentrations.38
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured at concentrations between 0.4 and 1 mg/mL in MeOH
on a PerkinElmer 341 polarimeter with a 10 cm microcell. UV and
ECD spectra were recorded in MeOH (50−150 μg/mL) on a
Chirascan CD spectrometer using 1 mm path precision cells (110 QS,
Hellma Analytics). NMR data were recorded on a Bruker Avance III
NMR spectrometer operating at 500.13 MHz for 1H and 125.77 MHz
for 13C nuclei. 1H NMR, COSY, HSQC, HMBC, and NOESY spectra
were measured at 23 °C in a 1 mm TXI probe with a z-gradient. 13C
NMR/DEPTQ spectra were recorded at 23 °C in 3 mm tubes using a
5 mm BBI probe. For compound 2, 1H, COSY, HSQC, and HMBC
spectra were also recorded at 60 °C. All spectra were analyzed using
Bruker TopSpin 3.5 and ACDLabs NMR Workbook software suites.
NMR spectra were recorded in CDCl3 (Sigma-Aldrich), methanol-d4,
DMSO-d6, or TFA (all Armar Chemicals). HPLC-PDA-ELSD-ESIMS
Figure 3. Inhibitory effects of compounds 1−15 on the proliferation of human T lymphocytes. Human PBMCs (2 × 105) were stained with CFSE
and stimulated with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs, 100 ng/mL each). Unstimulated cells served as a negative control
(NC). Afterward, cells were incubated for 72 h in the presence of medium (PC), cyclosporin A (CsA; 4.16 μM), camptothecin (CPT; 300 μM), or
compounds 1−15 at concentrations between 0.3 and 30 μM. Cell division was analyzed by flow cytometry. The percentage of proliferating cells
was normalized to the stimulated control and depicted as mean ± standard deviation. n = 3. *p < 0.05.
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data were recorded in the positive and negative mode on a Shimadzu
LC-MS/MS 8030 triple quadrupole ESIMS system connected via a T-
splitter (1:10) to a Shimadzu HPLC system consisting of a degasser,
binary high-pressure mixing pump, autosampler, column oven, and
diode array detector, and via a T-split to an Alltech 3300 ELSD
detector. Data were acquired and processed with the LabSolution
software suite. Semipreparative HPLC separations were carried out
with an Agilent HP 1100 Series system consisting of a quaternary
pump, autosampler, column oven, and a diode array detector
(G1315B). Preparative HPLC separations were carried out using
Agilent 1290 Infinity II preparative binary pumps and an Agilent 1100
DAD detector in line with an Agilent 6120 Quadropole LC/MS
detector. The column effluent was collected via an active split (100:1)
between HPLC columns and detectors. Chemstation software was
used for data acquisition and processing. Waters SunFire C18 (3.5 μm,
3.0 × 150 mm i.d., equipped with a guard column 10 × 3.0 mm i.d.),
SunFire Prep C18 (5 μm, 10 × 150 mm i.d., equipped with a guard
column 10 × 10 mm i.d.), and SunFire Prep C18 OBD (5 μm, 30 ×
150 mm i.d., equipped with a guard column 10 × 20 mm i.d.)
columns were used for reverse-phase analytical, semipreparative, and
preparative separations, respectively. Chiral-phase HPLC separations
were performed at a flow rate of 1 mL/min on either a Daicel
Chiralpak IG column (5 μm, 250 × 4.6 mm) eluted with 20%
CH3CN in H2O for 10 min or a Daicel Chiralpak IF column (5 μm,
250 × 4.6 mm) eluted with 20% CH3CN in H2O, both containing
0.1% formic acid (FA), for 10 min. HPLC-grade MeOH, CH3CN
(Scharlau Chemie), and water from a Milli-Q water purification
system (Merck Millipore) were used for HPLC separations. The
mobile phase used for analytical HPLC contained 0.1% FA.
Technical-grade solvents purified by distillation were used for
extraction, open column chromatography, and CPC separations.
Silica gel (15−40 μm, Merck) and C18 modified silica (RP-18
LiChroprep 25−40 μm) were used for open column chromatography.
HRESIMS data were measured on an LQT XL Orbitrap mass
spectrometer (Thermo Scientific) coupled to a Shimadzu LC-MS
system equipped with a Waters SunFire C18 column (3.5 μm, 3.0 ×
150 mm i.d., equipped with a guard column 10 × 3.0 mm i.d.).
Trimethylsilyldiazomethane was purchased from Tokio Chemical
Industry, and Lewatit MonoPlus SP 112 (Na+ form), Eu(hfc)3, and
cellulase enzyme blend were from Sigma-Aldrich, Germany.
Plant Material. T. asiatica roots were purchased from Bozhou
Swanf Commerce and Trade Co., Ltd. (Bozhou, China) in January
2018. A voucher specimen (number 0 1026) has been deposited at
the Division of Pharmaceutical Biology, University of Basel,
Switzerland.
Microfractionation. Microfractionation of T. asiatica MeOH
extract was carried out by analytical RP-HPLC on an LC-MS 8030
system (Shimadzu) connected with an FC 204 fraction collector
(Gilson). A solution of 10 mg/mL extract in DMSO was prepared,
and three injections were performed: 2 × 30 μL for microfraction,
using only the PDA (0.6 mg of extract in total), and 1 × 10 μL with
PDA-ELSD-ESIMS detectors without microfractionation. Water
containing 0.1% FA (solvent A) and CH3CN with 0.1% FA (B)
were used as a mobile phase. A linear gradient from 5 to 60% B in 30
min was followed by 5 min at 100% B. Microfractions of 1 min each
were collected from the beginning of minute 2 to the end of minute
34. Corresponding microfractions of two successive injections were
collected into the same wells of a 96-deep-well plate. The plates were
dried in a Genevac EZ-2 evaporator.
Extraction and Isolation. T. asiatica roots were ground with a
Retsch ZM1 centrifugal mill. A 740 g amount of the powdered roots
was extracted with 4 × 2.2 L of DCM over 24 h. The remaining plant
material was extracted with 3 × 2.2 L of MeOH over 24 h. The
combined MeOH extracts were dried in vacuo and freeze-dried to
afford 38.7 g of dry residue. A 35.7 g amount of MeOH extract was
subjected to liquid−liquid partitioning using a two-phase system
containing 928 mL of CHCl3, 500 mL of MeOH, and 570 mL of
H2O. After removal of the organic phase, the aqueous phase was
successively extracted with a mixture of 800 mL of CHCl3 and 200
mL of MeOH, a mixture of 500 mL of CHCl3 and 500 mL of MeOH,
and a mixture of 1500 mL of CHCl3 and 500 mL of MeOH. The
organic layers were combined and dried in vacuo, yielding 17.3 g of an
enriched fraction. A precipitate at the interface of the aqueous and the
organic layers was collected separately, filtered, and washed with cold
CHCl3 and MeOH to give 548 mg of 8. Aliquots of the enriched
fraction (1.9 to 3.0 g per run) were subjected to centrifugal partition
chromatography (CPC) using CHCl3/MeOH/H2O (25:30:20) at a
flow rate of 5 mL/min in descending mode. Six fractions (A−F) were
collected, and a switch to ascending mode gave four additional
fractions (G−K). Fraction E (559 mg) was separated on a C18 column
(25−40 μm, 5 × 47 cm) connected to an Interchim Puriflash 4100
system [water + 0.1% FA (A), CH3CN + 0.1% FA (B); 27% B (0−5
min) 27 → 44% B (5−202 min), 44 → 100% (202−220 min), 100%
(220−245 min); flow rate 22 mL/min; sample dissolved in 1.3 mL of
MeOH], and fractions E1−E16 were obtained. E6 (6 mg) was purified
by semipreparative RP HPLC [CH3CN + 0.1% FA (A), H2O + 0.1%
FA (B); 18% B (0−20 min) 18 → 20% B (20−22 min), 20 → 100%
(22−26 min), 100% (26−31 min); flow rate 4 mL/min;
concentration 50 mg/mL in MeOH, injection volume 10−40 μL]
to yield dihydronitidine (5, 0.6 mg). The rest of fraction E (600 mg)
was chromatographed on a silica gel column (15−40 μm; 3.5 × 35
cm) connected to an Interchim Puriflash 4100 system [CHCl3 (A),
MeOH (B); 100% A (0−5 min) 0 → 2% B (5−10 min), 2 → 5%
(10−20 min), 5 → 30% (20−110 min), 30 → 50% (110−175 min),
50 → 55% (175−190 min), 55 → 57% (190−191 min), 57 → 100%
(191−205 min), 100% (205−260 min); flow rate 20 mL/min; solid
state introduction, with the sample adsorbed on 3 g of silica gel (63−
200 μm, Merck)], and 24 fractions (EA−EX) were obtained. Fraction
EL (36 mg) was separated by preparative RP HPLC [CH3CN + 0.1%
FA (A), H2O + 0.1% FA (B); 15% B (0−24 min) 15 → 25% B (24−
35 min), 25 → 35% B (35−40 min), 35 → 60% B (40−45 min), 60
→ 100% B (45−47 min), flow rate 25 mL/min; concentration 90
mg/mL in MeOH, injection volume 390 μL] to afford a mixture of 3a
and 3b (3.5 mg). Fraction EN (9.3 mg) was recrystallized from
MeOH/H2O (1:2) to obtain syringic acid (1, 4.5 mg). Fraction EP
(22 mg) was separated by preparative RP HPLC [CH3CN + 0.1% FA
(A), H2O + 0.1% FA (B); 15% B (0−3 min) 30 → 35% B (3−16
min), 35 → 100% (16−20 min); flow rate 20 mL/min; concentration
55 mg/mL in MeOH/H2O (1:3); injection volume 400 μL], and
fractions EP1−EP4 were collected. EP3 (5.8 mg) was purified by
semipreparative RP HPLC [CH3CN + 0.1% FA (A), H2O + 0.1% FA
(B); 24% B (0−20 min) 24 → 100% B (20−22 min), 100% B (22−
27 min), flow rate 4 mL/min; concentration 2.5 mg/mL MeOH/H2O
(1:1), 3 injections with injection volumes 40−70 μL] to afford 12
(3.6 mg) and 13 (1.5 mg). Fraction EQ (60 mg) was separated by
preparative RP HPLC [CH3CN + 0.1% FA (A), H2O + 0.1% FA (B);
23% B (0−30 min) 23 → 100% B (30−31 min), 100% B (31−36
min); flow rate 20 mL/min; concentration 83 mg/mL in MeOH/
H2O (1:3); 2 injections of 300−400 μL] to afford 9 (20 mg), 10 (11
mg), and 11 (5.1 mg). Fraction ET (55 mg) was dissolved in 700 μL
MeOH/H2O (3:1), and the supernatant was subjected to preparative
HPLC [CH3CN + 0.1% FA (A), H2O + 0.1% FA (B); 13% B (0−2
min), 13 → 25% B (2−32 min), 25 → 29% (32−42 min), 29 → 60%
(42−50 min), 60% (50−52 min), 60 → 100% B (52−55 min), flow
rate 20 mL/min; concentration 75 mg/mL in MeOH/H2O (3:1);
injection volume 700 μL] to yield 2 (1.6 mg). Fraction EV (22 mg)
was separated by preparative RP HPLC [CH3CN + 0.1% FA (A),
H2O + 0.1% FA (B); 21% B (0−3 min) 21 → 29% B (3−24 min), 29
→ 100% (24−30 min), flow rate 20 mL/min; concentration 55 mg/
mL in MeOH/H2O (1:1); injection volume 400 μL] to afford
fractions EV1−EV5. Fraction EV1 (5.8 mg) was purified by
semipreparative RP HPLC [CH3CN + 0.1% FA (A), H2O + 0.1%
FA (B); 11% B (0−30 min) 11 → 100% B (30−32 min), 100% B
(32−38 min), flow rate 4 mL/min; concentration 33 mg/mL in
MeOH/H2O (1:2), 2 injections of 60 μL], to afford 6 (1.0 mg) and 7
(1.5 mg). As compound 7 was obtained as a scalemic mixture of both
enantiomers, the enantiomers 7a and 7b were separated via chiral-
phase HPLC on a Daicel Chiralpak IF column [CH3CN + 0.1% FA
(A), H2O + 0.1% FA (B); 20% B (0−10 min), flow rate 1 mL/min;
concentration of 5 mg/mL; 8 injections with 10 μL]. Compound 7b
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eluted at 7.3 min, and compound 7a at 8.4 min. Fraction EW (58 mg)
was dissolved in 580 μL MeOH and 10 μL of FA and subjected to
preparative RP HPLC [CH3CN (A), H2O (B); 16% B (0−48 min),
16 → 100% B (48−53 min); flow rate 25 mL/min; concentration of
90 mg/mL; injection volume 550 μL], to afford 4 (10.1 mg). The
hydrochloride of 4 was prepared via filtration over Lewatit MonoPlus
SP 112 resin.
Syringic acid (1): white solid; 1H and 13C NMR, see Table S1,
Supporting Information; HRESIMS m/z 181.0489 [M + H − H2O]+
(calcd for C9H9O4
+, 181.0495).
Allocryptopine (2): colorless solid; 1H and 13C NMR, see Table S2,
Supporting Information; HRESIMS m/z 370.1646 [M + H]+ (calcd
for C21H24NO5
+, 370.1649).
Fagaridine and dihydrofagaridine (3b and 3a): red solid; 1H and
13C NMR, see Table S3, Supporting Information; HRESIMS m/z
334.1059 [M]+ (calcd for C20H16NO4
+, 334.1074).
Compound 3b: 1H and 13C NMR, see Table S3, Supporting
Information.
Nitidine chloride (4): yellow solid; 1H and 13C NMR, see Table S4,
Supporting Information; HRESIMS m/z 338.1223 [M]+ (calcd for
C21H18NO4
+, 338.1230).
Dihydronitidine (5): light yellow solid; 1H and 13C NMR, see
Table S4, Supporting Information; HRESIMS m/z 348.1220 [M −
H]+ (calcd for C21H18NO4
+, 348.1230) and m/z 334.1064 [M −
CH3]+ (calcd for C20H16NO4
+, 334.1074).
Toddalic acid (6): colorless solid; UV λmax (MeOH) (log ε) 206
(4.4) nm, 323 (3.9) nm; 1H and 13C NMR, see Table 1; HRESIMS
m/z 251.0542 [M + H]+ (calcd for C12H11O6
+, 251.0550).
Compound 6a: colorless solid; 1H and 13C NMR, see Table 1;
HRESIMS m/z 265.0706 [M + H]+ (calcd for C13H13O6
+, 265.0707).
Toddanolic acid (7): colorless solid; [α]D
25 −12 (c 0.07 g/100 mL,
MeOH); UV λmax (MeOH) (log ε) 204 (4.1), 281 (3.0) nm; ECD
(MeOH, c 0.97 mM, 0.1 cm); Δε +1.49 (204 nm), −0.8 (230 nm);
1H and 13C NMR, see Table 2, Supporting Information; HRESIMS
m/z 327.1437 [M − H]− (calcd for C16H23O7−, 327.1449).
(−)-(2′S)-Toddanolic acid (7a): colorless solid; [α]D25 −20 (c 0.03
g/100 mL, MeOH); UV λmax (MeOH) (log ε) 204 (4.5), 281 (3.3)
nm; ECD (MeOH, c 0.48 mM, 0.1 cm); Δε −3.4 (205 nm), −1.2
(231 nm), −0.5 (273 nm).
(+)-(2′R)-Toddanolic acid (7b): colorless solid; [α]D25 32 (c 0.02 g/
100 mL, MeOH); UV λmax (MeOH) (log ε) 204 (4.5), 282 (3.4) nm;
ECD (MeOH, c 0.32 mM, 0.1 cm); Δε +8.0 (205 nm), +2.6 (232
nm), +1.1 (275 nm).
(2′S)-Hesperidin (8): pale yellow solid; UV λmax (MeOH) (log ε)
200 (4.8), 224 (4.5), 283 (4.3), 331 (3.6) nm; ECD (MeOH, c 0.32
mM, 0.1 cm); Δε +20.2(200 nm) +11.0 (223 nm), −10.4 (289 nm),
+2.5 (334 nm); 1H and 13C NMR, see Table S5, Supporting
Information; HRESIMS m/z 633.1778 [M + Na]+ (calcd for
C28H34NaO15
+, 633.1790) (m/z 633.1778 [M + Na]+, calcd for
C28H34NaO15
+, 633.1790).
(2′S)-Toddalolactone 3′-O-β-D-glycopyranoside (9): yellow solid;
[α]D
25 −45 (c 0.14 g/100 mL, MeOH); UV λmax (MeOH) (log ε) 205
(4.6), 226 (4.1), 330 (4.1) nm; ECD (MeOH, c 0.32 mM, 0.1 cm);
Δε +10.8 (203 nm), −4.6 (227 nm), −1.7 (248 nm), −1.1 (332 nm);
1H and 13C NMR, see Table 3; HRESIMS m/z 493.1669 [M + Na]+
(calcd for C22H30O11Na
+, 493.1680).
Compounds 9a and 9b. 1H and 13C NMR, see Table S6,
Supporting Information.
(2′R)-Toddalolactone 3′-O-β-D-glycopyranoside (10): yellow
solid; [α]D
25 −2.5 (c 0.12 g/100 mL, MeOH); UV λmax (MeOH)
(log ε) 205 (4.6), 225 (4.2), 328 (4.0) nm; ECD (MeOH, c 0.21 mM,
0.1 cm); Δε −2.2 (202 nm), +2.6 (226 nm), +1.0 (251 nm), +0.9
(334 nm); 1H and 13C NMR, see Table 3; HRESIMS m/z 493.1670
[M + Na]+ (calcd for C22H30O11Na
+, 493.1680).
(2′S)-Toddalolactone 2′-O-β-D-glycopyranoside (11): yellow
solid; [α]D
25 −46 (c 0.08 g/100 mL, MeOH); UV λmax (MeOH)
(log ε) 204 (4.5), 224 (4.1), 329 (3.9) nm; ECD (MeOH, c 0.32 mM,
0.1 cm); Δε +12.9 (204 nm), −5.2 (227 nm), −1.9 (248 nm), −1.5
(332 nm); 1H and 13C NMR, see Table 3; HRESIMS m/z 493.1672
[M + Na]+ (calcd for C22H30O11Na, 493.1680).
Hazaleanin B (12): yellow solid; [α]D
25 +14 (c 0.09 g/100 mL,
MeOH); UV λmax (MeOH) (log ε) 205 (5.0), 328 (4.3) nm; ECD
(MeOH, c 0.13 mM, 0.1 cm); Δε +43.7 (203 nm), −18.5 (218 nm),
+14.5 (244 nm), +4.3 (272 nm), −1.9 (287 nm); 1H and 13C NMR,
see Table S7, Supporting Information; HRESIMS m/z 811.2758 [M
+ Na]+ (calcd for C39H48O17Na, 811.2784).
Hazaleanin A (13): white solid; [α]D
25 −9 (c 0.05 g/100 mL,
MeOH); UV λmax (MeOH) (log ε) 205 (4.9), 329 (4.2) nm; ECD
(MeOH, c 0.13 mM, 0.1 cm); Δε +20.5 (208 nm), −7.3 (217 nm),
+1.4 (239 nm); 1H and 13C NMR, see Table S7, Supporting
Information; HRESIMS m/z 813.2916 [M + Na]+ (calcd for
C39H50O17Na, 813.2940).
N-p-Coumaroyltyramine (14): yellowish solid; 1H and 13C NMR,
see Table S8, Supporting Information; HRESIMS m/z 284.1274 [M
+ H]+ (calcd for C17H18NO3, 284.1281).
Toddalolactone (15): white solid; [α]D
25 −10 (c 0.07 g/100 mL,
MeOH); UV λmax (MeOH) (log ε) 205 (4.5), 225 (4.1), 330 (4.0)
nm; ECD (MeOH, c 0.21 mM, 0.1 cm); Δε +3.1 (203 nm), −1.0
(229 nm); 1H and 13C NMR, see Table S9, Supporting Information;
HRESIMS m/z 309.1329 [M + Na]+ (calcd for C16H20O6Na,
309.1333).
(2′S)-Toddalolactone (15a): colorless solid; [α]D25 −51 (c 0.04 g/
100 mL, MeOH); UV λmax (MeOH) (log ε) 196 (4.8), 205 (4.7), 226
(4.4), 330 (4.1) nm; ECD (MeOH, c 0.21 mM, 0.1 cm); Δε +8.8
(203 nm), −6.3 (229 nm), −1.8 (256 nm), −1.7 (327 nm).
(2′R)-Toddalolactone (15b): colorless solid; [α]D25 50 (c 0.06 g/
100 mL, MeOH); UV λmax (MeOH) (log ε) 197 (4.7), 205 (4.6), 225
(4.3), 330 (4.0) nm; ECD (MeOH, c 0.21 mM, 0.1 cm); Δε +5.8
(225 nm), +2.7 (253 nm), +1.0 (329 nm).
Ion Exchange. The resin (Lewatit MonoPlus SP 112 (Na+ form),
500 mg) was placed in a 3 mL glass vial with a magnetic stirrer. The
resin was washed twice with 10 mL of HPLC grade MeOH while
slowly stirring. Compound 2 or 4, respectively, was dissolved in
MeOH at a concentration of 1.7 mg/mL, added to the washed resin,
and stirred until the color of the supernatant had faded. The
supernatant was discarded, and the resin was washed twice with 10
mL of MeOH. Then, 1 mL of a 10% NaCl solution in H2O/MeOH
(1:1) was added while stirring, followed by 5 mL of MeOH. The
supernatant was collected, and the step was repeated once again. The
combined supernatants were dried under a flow of N2, suspended in
1.5 mL of HPLC grade water, and centrifuged at 13 200 rpm for 8
min. The supernatant was discarded, and the precipitate was washed
twice more with 1 mL of H2O, yielding the respective chloride.
Preparation of 6a. Compound 6 (0.1 mg, 0.4 μmol) was
dissolved in 75 μL of DCM and 25 μL of MeOH in a vial under an
argon atmosphere, and 5 μL of trimethylsilyl diazomethane (0.6 M in
n-hexane, 3 μmol) was added. The mixture was vortexed and allowed
to stand at room temperature for 1 h. The reaction was stopped by
the addition of 3.4 μL of 1.7 M acetic acid in H2O. The reaction
mixture was dried in a flow of N2 to yield 6a.
Enantiomeric Excess Determination of Toddalolactone
(15). Eu(hfc)3 (0.7 mg) was dissolved under argon in CDCl3 at a
concentration of 1.5 equiv of 15 per 120 μL, and the solution was
transferred under argon to the mixture of 15a and 15b. The resulting
solution was transferred into a 3 mm NMR tube under argon, and 1H
NMR spectra were recorded.
Acid Hydrolysis of 9, 10, and 11. Analogous to acid hydrolysis
for GCMS sugar analysis,24 approximately 1 mg of 9, 10, or 11,
respectively, was dissolved in 1 mL of 2 N aqueous HCl in a 4 mL
sealable vial. The vial was placed in an oven at 105 °C for 105 min.
After cooling, the mixture was extracted with EtOAc (3 × 1 mL). The
organic layers were combined and dried under N2. The aglycones 15a
and 15b, respectively, were identified as minor compounds via chiral-
phase HPLC on a Daicel Chiralpak IG column eluting with 20%
CH3CN. (2′R)-Toddalolactone (15b) eluted at 4.74 min, and (2′S)-
toddalolactone (15a) at 4.93 min, respectively (Figure S128,
Supporting Information). The major compounds recovered after
hydrolysis of 9, 10̧, and 11, respectively, were the ketone 9a and the
aldehyde 9b (Figure S18, Supporting Information).
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Enzymatic Hydrolysis of 9, 10, and 11. Approximately 1 mg of
9, 10, or 11 was dissolved in 100 μL of cellulase blend (Sigma-
Aldrich, Cellulase, enzyme blend, SAE0020) diluted 1:1 with purified
water. The mixture was stirred at 37 °C for 22.5 h. Afterward, the
reaction mixture was diluted with 900 μL of H2O and extracted with
EtOAc (3 × 1 mL). The organic layers were combined and dried
under N2. Compounds 9 and 10 afforded their respective aglycone,
while 11 was recovered unreacted.
Computational Methods. Conformational analysis was per-
formed with Schrödinger MacroModel 11.0 (Schrödinger, LLC, New
York) employing the OPLS2005 (optimized potential for liquid
simulations) force field in H2O for geometrical optimization in two
steps. In the first step, a global minimum was searched using 20 000 or
30 000 steps, depending on the size of the molecule. In the second
step, the global minimum was used for a conformational search (4000
steps) choosing the five conformers to be subjected to geometrical
optimization and energy calculation applying DFT with Becke’s
nonlocal three-parameter exchange and correlation functional and the
Lee−Yang−Parr correlation functional level (B3LYP), using the
B3LYP/6-31G** basis set, the SCRF method, and the CPMC model
for solvation (MeOH for ECD calculations) with the Gaussian 09
program package.39 Excitation energy (denoted by wavelength in
nm), rotator strength (Rstr), dipole velocity (Rvel), and dipole length
(Rlen) were calculated in MeOH by TD-DFT/B3LYP/6-31G(d,p).
ECD curves were obtained on the basis of rotator strengths with a
half-band of 0.25 eV using SpecDis v1.71.40
Conformational Search for 13. The conformational flexibility
and relative structural complexity of 13 required a more sophisticated
conformational analysis. The 3D structures of all four stereoisomers
were built in the Maestro modeling environment.41 First, a
conformational search was performed to obtain a reasonable starting
conformation by sampling a total of 30 000 conformers using a mixed
torsional/low-mode sampling method, extended torsional sampling,
OPLS 2005 force field, and the implicit water solvent model in
MacroModel.42 The water solvent model was selected from the list of
available implicit models (water, CHCl3, octanol), because it offers
properties closest to MeOH. Next, a periodic boundary system was
created by placing the global minimum structure identified in the
conformational search into a cubic system (edge length 50 Å) of
preorganized MeOH molecules. The whole periodic boundary system
was fully optimized using the default relaxation protocol implemented
in Desmond,43−45 composed of seven stages allowing the solvent
molecules to optimally arrange with respect to the solute. The last
frame of the equilibration stage was used as input for the production
simulation in the total duration of 0.48 ms (NPT ensemble and
standard conditions T = 300 K, p = 101.325 kPa) with frames being
sampled every 480 ps (in total 1000 frames were saved per
simulation). All MD simulations were done using Desmond software.
The MD trajectories were postprocessed using the default clustering
analysis of Desmond. Representative solute structures of the 10 most
significant clusters were used as input for Gaussian 09 calculations as
described earlier.
Ethics Statement. Patients gave their written consent to donate
blood for scientific research. All experiments conducted on human
material were approved by the Ethics Committee of the University of
Freiburg (55/14; 11.02.2014), and all methods used were compliant
with the regulations of the Ethics Committee.
Preparation and Cultivation of Human Peripheral Lympho-
cytes. Peripheral blood mononuclear cells (PBMCs) were isolated
from the blood of healthy adult donors obtained from the Blood
Transfusion Centre (University Medical Center, Freiburg, Germany).
Venous blood was centrifuged on a LymphoPrep gradient (density:
1.077 g/cm3, 20 min, 500g, 20 °C; Progen). After centrifugation, cells
were washed twice with PBS and subsequently cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf serum (GE
Healthcare Life Sciences), 2 mM L-glutamine, 100 U/mL penicillin,
and 100 U/mL streptomycin (all from Life Technologies). The cells
were cultured at 37 °C in a humidified incubator with a 5% CO2/
95% air atmosphere.
T Cell Proliferation Assay. Lymphocytes were isolated, washed
twice in cold PBS, and resuspended in PBS at a concentration of 5 ×
106 cells/mL. Cells were stained for 10 min at 37 °C with
carboxyfluorescein diacetate succinimidyl ester (CFSE; 5 μM:
Sigma-Aldrich, St. Louis, MO, USA). The staining was stopped by
washing twice with complete medium. Stained lymphocytes (2 × 106
cells/mL) were stimulated with anti-human CD3 (clone OKT3) and
anti-human CD28 (clone 28.2) mAbs (each 100 ng/mL; eBioscience)
in the presence of either medium, CsA (4.16 μM; Novartis Pharma),
CPT (300 μM; Tocris), or plant extracts/single compounds
(concentration range 0.3−30 μM) and incubated for 72 h. The
negative control remained unstimulated. Flow cytometric analysis of
the cell division was performed using a FACSCalibur instrument (BD
Biosciences).
Determination of Apoptosis and Necrosis of T Cells.
Lymphocytes were isolated, washed twice in cold PBS, and
resuspended in medium at a concentration of 2 × 106 cells/mL.
Cells were stimulated with anti-human CD3 (clone OKT3) and anti-
human CD28 (clone 28.2) mAbs (each 100 ng/mL; eBioscience) in
the presence of either medium, CPT (300 μM; Tocris), 0.5% Triton-
X 100, or plant extracts and cultivated for 48 h. The negative control
remained unstimulated. Cultured cells were washed with PBS and
stained with annexin V-FITC using the apoptosis detection kit
(eBioscience) according to the manufacturer’s instructions. Propi-
dium iodide (eBioscience) was added and cells were stained for 15
min at room temperature in the dark. Apoptosis and necrosis rates
were determined by flow cytometric analysis using a FACSCalibur
instrument (BD Biosciences).
Testing of Microfractions. The dried microfractions in 96-deep-
well plates were dissolved in 25 μL of DMSO by sonication and
mixing with a pipet. Of these stock solutions, dilutions of 1/1, 1/3, 1/
10, and 1/30 were prepared and tested in duplicates for T lymphocyte
proliferation inhibition as described above. Assuming an equal
distribution of 200 ng substance in each of the microfractions,
theoretical IC50 values were calculated as a relative measure of activity.
They were normalized to 100%, with the highest value representing
100%.
Analysis of Data. For statistical analysis, data were processed with
Microsoft Excel and SPSS software (IBM, version 22.0, Armonk,
USA). Statistical significance was determined with the SPSS software.
Statistical significance was determined with the SPSS software by a
one-way ANOVA, followed by Dunnett’s post hoc pairwise
comparisons. Values are presented as mean ± SD for the indicated
number of independent experiments. The asterisks represent
significant differences from controls (*p < 0.05).
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Martin Smiesǩo − Pharmacenter, University of Basel, 4056
Basel, Switzerland; orcid.org/0000-0003-2758-2680
Carsten Gründemann − Pharmacenter, University of Basel,
4056 Basel, Switzerland
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.jnatprod.0c00564
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
C.G. is supported by PRIAM-BS (Verein Stiftungsprofessur für
Integrative and Anthroposophische Medizin an der Universitaẗ
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Table S3. 1H and 13C NMR Spectroscopic Data (500 MHz, DMSO-d6/TFA ratio 10:1) for Compounds 3a, 3b, and 3c (in methanol-d4). 
Spectra of 3a and 3b were recorded in a mixture (molar ratio 4:1). 
 3a  3b  3c 
position C, typea  H (J in Hz)  C, typea  H (J in Hz)  C, typea  H (J in Hz) 
1 104.9, CH  7.27b  104.5, CH  8.15, s  105.3, CH  7.13, s 
2 149.2, C    149.0, C    149.4, C   
3 148.0, C    149.0, C    148.6, C   
4 98.6, CH  7.56, s  106.1, CH  7.53, s  101.0, CH  7.65, s 
4a 123.5, C    120.4, C    128.0, C   
4b 134.4, C    131.7, C    138.9, C   
6 49.7, CH2  4.46, s  150.1, CH  9.88, s  87.6, CH  5.53, s 
6a 122.0, C    120.0, C    126.2, C   
7 145.3, C    143.7, C    146.7, C   
8 151.1, C    149.4, C    150.8, C   
9 117.3, CH  6.99, d (8.5)  130.8, CH  7.92, d (8.9)  118.4, CH  7.02, d (8.5) 
10 120.2, CH  7.50, d (8.5)  119.3, CH  8.49b  120.1, CH  7.56, d (8.5) 
10a 122.3, C    128.0, C    125.1, C   
10b 124.7, C    125.8, C    124.5, C   
11 120.4, CH  7.74, d (8.5)  118.7, CH  8.5b  124.5, CH  7.48, d (8.5) 
12 127.3, CH  7.67, d (8.5)  131.2, CH  8.09b  120.6, CH  7.77, d (8.5) 
12a 130.9, C    132.4, C    132.3, C   
13 102.0, CH2  6.12, s  102.9, CH2  6.26, s  102.3, CH2  6.04, s 
14 41.6, CH3  2.75, s  52.4, CH3  4.93, s  40.7, CH3  2.74, s 
15 60.7, CH3  3.81, s  61.9, CH3  4.15, s  61.9, CH3  3.94, s 
16         53.1, CD3  c 
a 13C extracted from 1 13C 2D inverse-detected experiments. b Overlapping signals. c Signal not found. 
 5 
Table S4. 1H and 13C NMR Spectroscopic Data (500 MHz, DMSO-d6) for Compounds 4 and 5. Compound 4 in its crude form was 
measured in DMSO-d6 + TFA ratio 2:1. 
 4  Crude 4 in DMSO-d6 and TFA  5 
position H (J in Hz)  C, typea  H (J in Hz)  C, typea  H (J in Hz) 
1 7.77, s  106, CH  7.53, s  103.9, CH  7.28, s 
2   148.9, C    146.9, C   
3   149.2, C    147.6, C   
4 8.37, s  104.7, CH  8.15, s  99.5, CH  7.51, s 
4a   120, C    125.5, C   
4b   132.7, C    142, C   
6 9.91, s  151.3, CH  9.70, s  53.7, CH2  4.08, s 
6a   119.7, C    124.2, C   
7 7.94, s  109, CH  7.74, s  110.7, CH  6.96, s 
8   152, C    148.6, C   
9   158.7, C    148.2, C   
10 8.31, s  103.4, CH  8.1, m  106.9, CH  7.42, s 
10a   132.2, C    123.9, C   
10b   124.2, C    123.9, C   
11 8.90, d (9.2)  119.2, CH  8.60, d (8.9)  120, CH  7.83, d (8.9) 
12 8.29, d (9.2)  130.3, CH  8.06, d (8.9)  123.4, CH  7.55, d (8.9) 
12a   132.7, C    130.2, C   
13 6.34, s  103, CH2  6.28, s  100.9, CH2  6.11, s 
14 4.91, s  51.8, CH3  4.83, s  40.5, CH3  2.50b 
15 4.24, s  56.5, CH3  4.01, s  55.5, CH3  3.81, s 
16 4.05, s  57.4, CH3  4.17, s  55.7, CH3  3.87, s 
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Figure S25. 1H-1H COSY Spectrum of Compound 1 (500 MHz, DMSO-d6).  
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Figure S26. HSQC-DEPT Spectrum of Compound 1 (500 MHz, DMSO-d6).  
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Figure S27. HMBC Spectrum of Compound 1 (500 MHz, DMSO-d6, 23°C).  
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Figure S29. 1H-1H COSY Spectrum of Compound 2 (500 MHz, DMSO-d6, 23°C).  
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Figure S30. HSQC-DEPT Spectrum of Compound 2 (500 MHz, DMSO-d6, 23°C).  
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Figure S31. HMBC Spectrum of Compound 2 (500 MHz, DMSO-d6, 23°C).  
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Figure S32. 1H-1H NOESY Spectrum of Compound 2 (500 MHz, DMSO-d6, 23°C).  
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Figure S34. . 1H-1H COSY Spectrum of Compound 2 (500 MHz, DMSO-d6, 60°C).  
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Figure S35. HSQC-DEPT Spectrum of Compound 2 (500 MHz, DMSO-d6, 60°C).  
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Figure S36. HMBC Spectrum of Compound 2 (500 MHz, DMSO-d6, 60°C).  
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Figure S37. 1H NMR Spectrum of Compound 3a (blue) with 3b (green, molar ratio 4:1, 500 MHz, DMSO-d6 + TFA 10:1). Integrals 
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Figure S38. 1H-1H COSY Spectrum of Compound 3a (blue) with 3b (green, molar ratio 4:1, 500 MHz, DMSO-d6 + TFA 10:1).  
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Figure S39. HSQC-DEPT Spectrum of Compound 3a (blue) with 3b (green, molar ratio 4:1, 500 MHz, DMSO-d6 + TFA 10:1).  
 39 
(14, 6)( , )
(15, 7)( , )
(14, 4b)( , )
(13, 2)(13, 3)( , )( , )(1, 3)( , )
(4, 2)( , )
(14, 4b)( , )
(15, 7)( , )
(9, 10a)( , )
(6, 10a)( , )
(6, 7)( , )
(6, 14)( , )
(1, 12a)( , )
(14, 6)( , )
(4, 4a)( , )
(6, 6a)( , )
(?, 1)(14, ?)( , )( , )
(4, 12)( , )
(6, 4b)( , )
(6, 6a)( , )
(6, 4b)( , )
(6, 14)( , )
(11, 10a)( , )
(4, 2)( , )(10, 8)( , )
(10, 8)( , )
(12, 10b)( , )
(13, 2)( , )(13, 3)( , )
(9, 7)( , )
(6, 7)( , )
(12, 4)( , )
(1, 3)( , )
(12, 4a)( , )
(9, 10a)( , )
(9, 8)( , )
(1, 4a)( , )
(9, 7)( , )
(9, 8)( , )
(12, 1)( , )



















Figure S40. HMBC Spectrum of Compound 3a (blue) with 3b (green, molar ratio 4:1, 500 MHz, DMSO-d6 + TFA 10:1).  
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Figure S42. 1H-1H COSY Spectrum of Compound 3c (500 MHz, methanol-d4).  
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Figure S43. HSQC-DEPT Spectrum of Compound 3c (500 MHz, methanol-d4).  
 43 
(14, 4b)( , )
(15, 7)( , )
(14, 6)( , )
(13, 2)( , )
(13, 3)( , )
(6, 6a)( , )
(6, 14)( , )
(6, 7)( , )
(10, 8)( , )
(6, 16)( , )
(12, 12a)( , )
(9, 10a)( , )
(4, 4b)( , )
(1, 3)( , )
(10, 6a)( , )
(4, 2)( , )
(6, 10a)( , )
(1, 4a)( , )
(4, 12a)( , )
(12, 4b)( , ) (6, 4b)( , )
(1, 2)( , )























Figure S44. HMBC Spectrum of Compound 3c (500 MHz, methanol-d4).  
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Figure S47. 1H-1H COSY Spectrum of Compound 4 (500 MHz, DMSO-d6 + TFA ratio 2:1).  
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Figure S48. HSQC-DEPT Spectrum of Compound 4 (500 MHz, DMSO-d6 + TFA ratio 2:1).  
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Figure S49. HMBC Spectrum of Compound 4 (500 MHz, DMSO-d6 + TFA ratio 2:1).  
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Figure S51. 1H-1H COSY Spectrum of Compound 5 (500 MHz, DMSO-d6).  
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Figure S52. HSQC-DEPT Spectrum of Compound 5 (500 MHz, DMSO-d6).  
 52 
(14, 4b)( , )
(15, 8)( , )
(16, 9)( , )
(6, 10a)( , )(6, 10a)( , )
(14, 6)( , )
(6, 4b)( , )(6, 6a)( , )
(10, 10a)( , )
(13, 3)( , )
(13, 2)( , )
(6, 7)( , )
(1, 2)( , )
(10, 9)( , )
(4, 3)( , )
(4, 4b)( , )
(11, 12a)( , )
(7, 8)( , )
(6, 14)( , )
(1, 4a)( , )
(1, 12)( , )
(7, 10a)( , )
(7, 6)( , )
(10, 8)( , )
(11, 4b)( , )
(12, 1)( , )























Figure S53. HMBC Spectrum of Compound 5 (500 MHz, DMSO-d6).  
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Figure S56. 1H-1H COSY Spectrum of Compound 6 (500 MHz, methanol-d4).  
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Figure S57. HSQC-DEPT Spectrum of Compound 6 (500 MHz, methanol-d4).  
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Figure S58. HMBC Spectrum of Compound 6 (500 MHz, methanol-d4).  
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Figure S59. 1H-1H ROESY Spectrum of Compound 6 (500 MHz, methanol-d4).  
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Figure S61. 1H-1H COSY Spectrum of Compound 6a (500 MHz, methanol-d4).  
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Figure S62. HSQC-DEPT Spectrum of Compound 6a (500 MHz, methanol-d4).  
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Figure S63. HMBC Spectrum of Compound 6a (500 MHz, methanol-d4).  
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Figure S66. 1H-1H COSY Spectrum of Compound 7 with an impurity (ca. 10%) of 6 (500 MHz, methanol-d4).  
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Figure S67. HSQC-DEPT Spectrum of Compound 7 with an impurity (ca. 10%) of 6 (500 MHz, methanol-d4).  
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Figure S68. HMBC Spectrum of Compound 7 with an impurity (ca. 10%) of 6 (500 MHz, methanol-d4).  
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Figure S69. 1H-1H ROESY Spectrum of Compound 7 with an impurity (ca. 10%) of 6 (500 MHz, methanol-d4).  
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Figure S71. 1H-1H COSY Spectrum of Compound 8 (500 MHz, DMSO-d6).  
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Figure S72. HSQC-DEPT Spectrum of Compound 8 (500 MHz, DMSO-d6).  
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Figure S73. HMBC Spectrum of Compound 8 (500 MHz, DMSO-d6).  
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Figure S74. 1H-1H ROESY Spectrum of Compound 8 (500 MHz, DMSO-d6).  
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Figure S77. 1H-1H COSY Spectrum of Compound 9 (500 MHz, methanol-d4).  
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Figure S78. HSQC-DEPT Spectrum of Compound 9 (500 MHz, methanol-d4).  
 78 
(5', 3')' '' '( , )' '
(4', 2')' '' '( , )' '
(12, 7)( , )
(11, 5)( , )
(4', 5')' '' '( , )' ' (5', 4')' '' '( , )' '
(8, 8a)( , )
(8, 4a)( , )
(8, 6)( , )
(8, 7)( , ) (3, 2)( , )
(4, 2)( , )
(4, 8a)( , )
(4'', 5'')'' '''' ''( , )' '
(1'', 3')'' ''' '( , )' '
(3'', 4'')'' '''' ''( , )' '
(1', 6)''( , )'
(4, 5)( , ) (1', 5)''( , )'
(1', 6)''( , )'
(3, 4a)( , )
(1', 7)''( , )'
(1', 3')' '' '( , )' '
(2'', 3'')'' '''' ''( , )' '
(1', 2')' '' '( , )' '
(2'', 1'')'' '''' ''( , )' '
(1', 7)''( , )'
(1'', 3'')'' '''' ''( , )' '
(1', 5)''( , )'
(2', 1')' '' '( , )' '
(2', 6)''( , )'
(2', 4')' '' '( , )' '
(4'', 6'')'' '''' ''( , )' '
(6'', 4'')'' '''' ''( , )' '
(6'', 5'')'' '''' ''( , )' '























Figure S79. HMBC Spectrum of Compound 9 (500 MHz, methanol-d4).  
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Figure S80. 1H-1H ROESY Spectrum of Compound 9 (500 MHz, methanol-d4).  
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Figure S82. 1H-1H COSY Spectrum of Compounds 9a (blue) and 9b (red, molar ratio 3:1) after acid hydrolysis (500 MHz, methanol-
d4).  
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Figure S83. HSQC-DEPT spectrum of 9a (blue) and 9b (red, molar ratio 3:1) after acid hydrolysis (500 MHz, methanol-d4). The signal 
for the aldehyde carbon was “wrapped” and is seen at 24 ppm.  
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Figure S84. HMBC spectrum of 9a (blue) and 9b (red, molar ratio 3:1) after acid hydrolysis (500 MHz, methanol-d4).  
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Figure S87. 1H-1H COSY Spectrum of Compound 10 (500 MHz, methanol-d4).  
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Figure S88 HSQC-DEPT Spectrum of Compound 10 (500 MHz, methanol-d4).  
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Figure S89. HMBC Spectrum of Compound 10 (500 MHz, methanol-d4).  
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Figure S90. 1H-1H ROESY Spectrum of Compound 10 (500 MHz, methanol-d4).  
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Figure S91. 1H NMR Spectrum of Compounds 10a and 10b (molar ratio 1:0.2) after acid hydrolysis (500 MHz, methanol-d4). 
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Figure S94. 1H-1H COSY Spectrum of Compound 11 (500 MHz, methanol-d4).  
 94 
(5', 5')' '' '( , )' '
(11, 11)( , )
(12, 12)( , )
(4', 4')' '' '( , )' '
(8, 8)( , )
(3'', 3'')'' '''' ''( , )' '
(1'', 1'')'' '''' ''( , )' '
(6'', 6'')'' '''' ''( , )' '
(2'', 2'')'' '''' ''( , )' '
(6'', 6'')'' '''' ''( , )' '
(3, 3)( , )
(1', 1')' '' '( , )' '
(4, 4)( , )
(4'', 4'')'' '''' ''( , )' '
(1', 1')' '' '( , )' '
(2', 2')' '' '( , )' '























Figure S95. HSQC-DEPT Spectrum of Compound 11 (500 MHz, methanol-d4).  
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Figure S96. HMBC Spectrum of Compound 11 (500 MHz, methanol-d4).  
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Figure S97. 1H-1H ROESY Spectrum of Compound 11 (500 MHz, methanol-d4).  
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Figure S98. 1H NMR Spectrum of Compounds 11c and 11d (molar ratio 1:0.2) after acid hydrolysis (500 MHz, methanol-d4). 
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Figure S101. 1H-1H COSY Spectrum of Compound 12 (500 MHz, methanol-d4).  
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Figure S102. HSQC-DEPT Spectrum of Compound 12 (500 MHz, methanol-d4).  
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Figure S103. HMBC Spectrum of Compound 12 (500 MHz, methanol-d4).  
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Figure S104. 1H-1H ROESY Spectrum of Compound 12 (500 MHz, methanol-d4).  
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Figure S107. 1H-1H COSY Spectrum of Compound 13 (500 MHz, methanol-d4).  
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Figure S108. HSQC-DEPT Spectrum of Compound 13 (500 MHz, methanol-d4).  
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Figure S109. HMBC Spectrum of Compound 13 (500 MHz, CD3OD).  
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Figure S110. 1H-1H ROESY Spectrum of Compound 13 (500 MHz, methanol-d4).  
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Figure S112. 1H-1H COSY Spectrum of Compound 14 (500 MHz, DMSO-d6).  
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Figure S113. HSQC-DEPT Spectrum of Compound 14 (500 MHz, DMSO-d6).  
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Figure S114. HMBC Spectrum of Compound 14 (500 MHz, DMSO-d6).  
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Figure S115. 1H-1H NOESY Spectrum of Compound 14 (500 MHz, DMSO-d6).  
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Figure S118. 1H-1H COSY Spectrum of Compound 15 (500 MHz, CDCl3).  
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Figure S119. HSQC-DEPT Spectrum of Compound 15 (500 MHz, CDCl3).  
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Figure S120. HMBC Spectrum of Compound 15 (500 MHz, CDCl3).  
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Figure S121. 1H-1H NOESY Spectrum of Compound 15 (500 MHz, CDCl3).  
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Figure S123. 1H NMR Spectrum of Compound 15a from enzymatic hydrolysis of 9 with an impurity (molar ratio 1:0.87) of benzoic 
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Figure S124. 1H-1H COSY Spectrum of Compound 15a from enzymatic hydrolysis of 9 with an impurity (molar ratio 1:0.87) of benzoic 
acid (500 MHz, CDCl3).  
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Figure S125. HSQC-DEPT Spectrum of Compound 15a from enzymatic hydrolysis of 9 with an impurity (molar ratio 1:0.87) of benzoic 
acid (500 MHz, CDCl3).  
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Figure S126. HMBC Spectrum of Compound 15a from enzymatic hydrolysis of 9 with an impurity (molar ratio 1:0.87) of benzoic acid 
(500 MHz, CDCl3).  
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Figure S127. 1H NMR Spectrum of Compound 15b from enzymatic hydrolysis of 10 with an impurity (molar ratio 1:0.67) of benzoic 





















Figure S128. HPLC chromatogram (Daicel Chiralpak IG, 5 μm, 250 x 4.6 mm, 20% CH3CN in H2O isocratic flow, detection at 330 nm) 
for compound 15 (A) and the products from acid hydrolysis of compounds 9 (B), 10 (C), and 11 (D). For each run, the full chromatogram 














Autoimmune diseases are a rising burden in industrialized countries and will continue to affect 
more and more people as the standard of living keeps increasing throughout the world. In this 
work, we investigated possible lead compounds from different plant extracts. This contributes to 
the search for urgently needed small molecule drugs for the treatment of autoimmune diseases. 
The initial search among extracts from plants used in Traditional Chinese Medicine led to a 
number of extracts with significant inhibition of T cell proliferation. From these, the ethyl acetate 
extract of the herb Artemisia argyi and the MeOH extract of the roots of Toddalia asiatica were 
investigated in detail. Compounds from the active regions in the chromatograms were isolated 
based on the HPLC activity profile. This resulted in the publication of a total of 33 compounds, 
including flavonoids, sesquiterpene lactones, sesquiterpene lactone dimers, alkaloids, coumarins, 
lignans, and small phenolics. Of those, seven compounds were new natural products. Significant 
T cell inhibition in vitro was observed for the alkaloid nitidine as well as for several sesquiterpene 
lactones. Most prominently, seco-tanapartholides A and B, and guaianolide sesquiterpene 
lactones related to canin showed remarkable activity (IC50 1.0-3.7 µM), which could be exploited 
in the future.  
Furthermore, the modes of action of the active constituents isolated from A. argyi extract were 
investigated. An inhibition of the NFAT as well as the NF-κB pathway was observed for both the 
extract and isolated sesquiterpene lactones. Upon further investigating the NFAT pathway, we 
observed differential effects on Ca2+ signaling from the extract and the sesquiterpene lactones 
isolated from it. The extract inhibited the ion flux from the ER as well as from the extracellular 
lumen, while the tested sesquiterpene lactones and a mixture of them only inhibited the Ca2+ flux 
from the extracellular space. This could hint at an inhibition of the CRAC or other Ca2+ channels 
by the tested sesquiterpene lactones. As the extract shows additional inhibition of the ER calcium 
flux, it likely has an additional mode of action. This could be caused by unidentified compounds, 
synergies between compounds, effects from identified compounds at the concentrations present 
in the extract, or a combination of these factors. As the in vitro immunosuppressant activity of one 
extract through at least three different modes of action is a highly unusual finding, further 
investigation is warranted.  
A possible path could be the use of HPLC activity profiling in combination with measuring the 
intracellular calcium flux. If this would be successful, synergy and concentration effects could be, 
at least in part, excluded. It would also enable the isolation of compounds responsible for the 
activity of the A. argyi extract. This would give lead structures from A. argyi for the targeted 
inhibition of different points in the NFAT pathway, which could be used to design experiments, but 
also for the development of new small molecule drugs based on these structures.  
Sesquiterpene lactones are a class of highly interesting compounds, particularly through their 
possible complexity from variable scaffolds, configurations and substitution patterns. The 
sesquiterpene lactone ring can form covalent bonds with proteins as a kind of “covalent warhead”. 
As this recognition is dependent on their three-dimensional structure, their exact and reliable 
stereochemical characterization is strictly necessary for further development. Thus, the absolute 
configurations reported in this work for the isolated compounds enable the further development of 
these compounds.  
NMR was the primary means to establish the relative configuration. After careful evaluation of 
NOE information, 13C chemical shifts, and JHH coupling constants, possible relative configurations 
were compiled. Afterwards, ECD was used as a standard technique for all compounds of which a 
spectrum could be expected. If a spectrum was obtained, this was compared to ab initio calculated 
spectra of all possible configurations. To overcome limitations in case of more than one possible 
relative configuration, VCD was used. This proved to be especially helpful in the case of seco-
tanapartholides A and B, which have almost enantiomeric ECD spectra, but have easily 
distinguishable VCD spectra. Due to the complexity of the spectra in comparison to ECD, VCD is 
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less straightforward to apply in practice. Thus, its evaluation was aided by computational 
comparisons. As only the maximal spectrum overlap is considered and no bands are assigned, 
this can lead to false attributions in some cases. For this reason, the necessity of a visual control 
cannot be stressed enough in order to avoid false attributions. When this is done, VCD is a very 
potent technique with respect to assigning absolute configurations absolutely inaccessible by 
ECD.  
An approach combining several methods was used when investigating the compounds isolated 
from T. asiatica root extract. Here, different compounds needed different approaches to determine 
their configurations. A series of glycosylated coumarins with enantiomeric aglycones and different 
glycosylation positions was found. After acid hydrolysis, the sugar was determined as D-glucose, 
but most of the aglycone had lost its chirality due to dehydration of the formed 1,2-diol. The 
remnants, however, could be analyzed using enantioselective HPLC. Two compounds were 
confirmed by enzymatic hydrolysis and ECD. These examples show the necessity for the use of 
a wide variety of methods. 
In any case, when assigning absolute configurations, the use of different techniques gives different 
perspectives on a stereochemical problem, thus contributing significantly to the quality of the work. 
This also significantly increases the value for any biological testing, as each assay ultimately 















Curiculum vitae        October 23, 2020 
Name Jakob Reinhardt 








PhD Thesis in the Lab of Prof. Dr. Matthias Hamburger in Basel, Switzerland 
Topic: “Activity-guided isolation of natural products with immunosuppressive 
activity” 
03.2016 Master thesis: „Studies on the biomass-composition of selected microalgae 
under the influence of exogenous factors“ in the research group of 
Prof. Dr. Ulrike Lindequist (Pharmaceutical Biology, Greifswald, Germany) 
2013 - 2016 “Master of Science” in Biochemistry, University Greifswald, Germany 
10.2013 Bachelor thesis: “Development of a new kind of fluorescence sensors by 
combining dithiolene ligands with electron deficient fluorophores” in the 
research group of Prof. Dr. Carola Schulzke (Bioinorganic chemistry, 
Greifswald, Germany) 




2020 Supervision of Master students in their practical education for isolation of 
natural products and structure elucidation 
2016 - 2019 Supervision of bachelor students in their practical education in Pharmaceutical 
Biology and Systematics courses 










08.2020 Reinhardt JK, Zimmermann-Klemd AM, Danton O, Smieško M, Huber R, 
Gründemann C, Hamburger M. Isolated compounds from Toddalia asiatica: 





07.2020 Zimmermann-Klemd AM*, Reinhardt JK*, Nilsu T, Morath A, Falanga CM, 
Schamel WW, Huber R, Hamburger M, Gründemann C. Boswellia carteri 
extract and 3-O-acetyl-alpha-boswellic acid suppress T cell function. 
Fitoterapia 2020, DOI: 10.1016/j.fitote.2020.104694: 104694 
01.2020 Gründemann C, Reinhardt JK, Lindequist U. European medicinal 
mushrooms: Do they have potential for modern medicine? – An update. 
Phytomedicine 2020; 66: 153131 
04.2020 Zimmermann-Klemd AM*, Reinhardt JK*, Morath A, Schamel WW, 
Steinberger P, Leitner J, Huber R, Hamburger M, Gründemann C. 
Immunosuppressive Activity of Artemisia argyi Extract and Isolated 
Compounds. Front. Pharmacol. 2020; 11: 402 
06.2019 Reinhardt JK*, Klemd AM*, Danton O, De Mieri M, Smiesko M, Huber R, 
Burgi T, Grundemann C, Hamburger M. Sesquiterpene lactones from 
Artemisia argyi: Absolute configuration and immunosuppressant activity. J. 
Nat. Prod. 2019; 82: 1424-1433  
06.2016 Schulze C, Reinhardt J, Wurster M, Ortiz-Tena JG, Sieber V, Mundt S. A 
one-stage cultivation process for lipid- and carbohydrate-rich biomass of 
Scenedesmus obtusiusculus based on artificial and natural water sources. 
Bioresour. Technol. 2016; 218: 498-504. 
02.2016 Schulze, C., Wetzel, M., Reinhardt, J., Schmidt, M., Felten, L., Mundt, S., 
2016. Screening of microalgae for primary metabolites including β-glucans 
and the influence of nitrate starvation and irradiance on β-glucan production. 
J. Appl. Phycol. 28(5), 2719-2725. 
07.2014 Ghosh AC, Reinhardt JK, Kindermann MK, Schulzke C. The ring opening 
reaction of 1,3-dithiol-2-one systems is fully reversible. Chem. Commun. 
(Camb) 2014; 50: 10102-10104. 




09.2019 Reinhardt JK, Baburin I, Andranovits S, Hering S, Hamburger M. High affinity 
HERG and low affinity Cav1.2 Blockers Dehydroevodiamine and Hortiamine in 
Decoctions of the TCM drug Evodiae fructus, poster presented at 67th 
International Congress of the Society for Medicinal Plant and Natural Product 
Research (GA) 2019 in Innsbruck, Austria. 
09.2019 Reinhardt JK, Klemd AM, Danton O, De Mieri M, Smieško M, Huber R, Bürgi 
T, Gründemann C, Hamburger M. Absolute configuration of sesquiterpene 
lactones with potent immunosuppressant activity, poster presented at 67th 
International Congress of the Society for Medicinal Plant and Natural Product 
Research (GA) 2019 in Innsbruck, Austria.  
02.2019 Reinhardt JK, Klemd AM, Danton O, De Mieri M, Smieško M, Huber R, Bürgi 
T, Gründemann C, Hamburger M. Activity-guided isolation of natural products 
with immunosuppressive activity, oral presentation at Annual Research 




06.2018 Reinhardt JK, Klemd AM, Danton O, De Mieri M, Smieško M, Huber R, Bürgi 
T, Gründemann C, Hamburger M. Sesquiterpene lactones from Artemisia 
argyi - determination of absolute configurations and immunosuppressive 
activity, oral presentation at Phytopharm 2018 in Horgen, Switzerland. 
09.2017 Reinhardt JK, Klemd AM, De Mieri M, Smieško M, Bürgi T, Gründemann C, 
Hamburger M. Absolute configuration of sesquiterpene lactones with potent 
immunosuppressive activity, Poster presented at 65th International Congress 





2019 Travel Grant for the 67th International Congress of the Society for Medicinal 




English Good knowledge 
German Native proficiency 




I spend most of my free time with different sport activities. To move on water, I am in a dragon 
boat team, paddling in sync to keep the flow. On land, I can free my mind when riding my bike, 
be it a short trip to work or a longer one to Venice. Moving vertically, I enjoy the mental and 
physical challenges of bouldering and climbing. And to inspire the movement of the mind, I read 
books, always in pursuit of new ideas and knowledge. 
 
 
Basel, October 23, 2020 
